Fused tricyclic derivatives as SRC homolog-2 phosphatase inhibitors
By developing SHP2 inhibitors, drug resistance to targeting RAS-MAPK pathway and the oncogenic effect of SHP2 in a variety of diseases have been solved, and effective treatment of KRAS-driven cancer and immune diseases have been achieved.
Patent Information
- Application Number
- CN201980074211.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-08-06
- Filing Date
- 2019-09-17
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-09-17
AI Technical Summary
The existing drug targeting RAS-MAPK pathway drug resistance problem, especially the activation of RTKs leads to the reactivated MAPK signaling, making it difficult to effectively treat KRAS-driven cancer in the long term, and SHP2 plays a role in carcinogenic and immune diseases in a variety of diseases. , lack of effective inhibitors.
A class of Src homologous-2 phosphatase (SHP2) inhibitors have been developed to inhibit the activity of SHP2 to prevent drug resistance and treat a variety of diseases by providing specific compound structures and drug combinations.
By inhibiting SHP2, resistance to targeting the MAPK pathway is effectively overcome, providing a potential treatment plan for KRAS-driven cancer, and potentially improving immune function and enhancing the therapeutic effect on a variety of diseases.
Smart Images

Figure FDA0004857579910000011 
Figure FDA0004857579910000012 
Figure FDA0004857579910000013
Abstract
Description
[0001] CROSS REFERENCE TO RELATED APPLICATIONS
[0002] This application is an international application, claiming the benefit of U.S. Provisional Application No. 62 / 733,061 filed on September 18, 2018, U.S. Provisional Application No. 62 / 749,655 filed on October 23, 2018, U.S. Provisional Application No. 62 / 810,911 filed on February 26, 2019, U.S. Provisional Application No. 62 / 883,120 filed on August 6, 2019, and U.S. Provisional Application No. 62 / 883,121 filed on August 6, 2019; the entire contents of the above applications are incorporated herein by reference. Field of the Invention
[0003] The present disclosure provides certain fused tricyclic derivatives that are inhibitors of Src homology-2 phosphatase (SHP2) and are therefore useful in treating diseases treatable by inhibiting SHP2. Pharmaceutical compositions containing such compounds and methods for preparing such compounds are also provided. Background of the Invention
[0005] SHP2 is a non-receptor protein phosphatase ubiquitously expressed in a variety of tissues and cell types (see review: Tajan M et al., Eur J Med Genet 2016 58 (10): 509-25; Grossmann KS et al., Adv Cancer Res 2010106: 53-89). SHP2 consists of two Src homology 2 (N-SH2 and C-SH2) domains at its NH2 terminus, a catalytic PTP (protein-tyrosine phosphatase) domain, and a C-terminal tail with regulatory properties. In the basal state, the intermolecular interaction between the SH2 domain and the PTP domain prevents substrates from entering the catalytic pocket, keeping SHP2 in a closed, autoinhibitory conformation. In response to stimulation, SHP2 activation proteins with phosphotyrosine motifs bind to the SH2 domain, resulting in exposure of the active site and enzymatic activation of SHP2.
[0006] SHP2 plays an important role in basic cell functions including proliferation, differentiation, cell cycle maintenance and migration. By dephosphorylating its related signaling molecules, SHP2 regulates a variety of intracellular signaling pathways in response to a wide range of growth factors, cytokines and hormones. The cell signaling processes involved in SHP2 include the RAS-MAPK (mitogen-activated protein kinase) pathway, the PI3K (phosphoinositide 3-kinase)-AKT pathway and the JAK-STAT pathway.
[0007] The RAS-MAPK signaling pathway is essential for tumor formation and maintenance. Genes encoding various components of this pathway (including RTKs (receptor tyrosine kinases), SHP2, NF1, RAS or RAF) are mutated in cancer, leading to upregulation of MAPK signaling. SHP2 also plays a role in signal enhancement in this pathway, acting downstream of RTKs and upstream of RAS. It has been confirmed that RTK-driven cancer cells rely on SHP2 for survival. Therefore, SHP2 inhibitors have been proposed as an effective treatment for RTK-driven cancers (see Prahallad, A. et al. Cell Reports 12, 1978–1985 (2015); Chen YN, Nature 535, 148-152 (2016)).
[0008] Much effort has been made to develop pharmacological agents that target various nodes on the RAS-MAPK pathway, such as RTK inhibitors, BRAF inhibitors, and MEK inhibitors, for the treatment of cancer. Although these agents show good initial efficacy, resistance to these agents frequently occurs. A common mechanism of resistance involves the activation of RTKs, which stimulates the reactivation of MAPK signaling. Since SHP2 is required for signal transduction downstream of multiple RTKs, SHP2 inhibition may provide a general strategy for preventing resistance to anticancer drugs that target the MAPK pathway. Recent preclinical model studies have shown that SHP2 inhibition overcomes resistance and provides a synergistic therapeutic effect when combined with ALK inhibitors (see Dardaei L et al., Nat Med. 24, 512-17 (2018)), MEK inhibitors (see Mainardi, S. et al., Nat. Med. https: / / doi.org / 10.1038 / s41591-018-0023-9 (2018); Ruess, DA et al., Nat. Med. https: / / doi.org / 10.1038 / s41591-018-0024-8 (2018); Wong, GS et al., Nat. Med. https: / / doi.org / 10.1038 / s41591-018-0022-x (2018); Fedele C et al., Cancer Discov pii:CD-18-0444.doi:10.1158 / 2159-8290.CD-18-0444(2018)) or BRAF inhibitors (see Prahallad, A. et al., Cell Reports 12, 1978–1985(2015)). In particular, it has been determined that combined inhibition of MEK / SHP2 has the potential to treat cancers driven by KRAS, the most common mutated oncogene. Despite years of effort, inhibitors directly targeting KRAS have not been successfully developed for clinical use. Inhibition of MEK, a downstream effector of KRAS, only temporarily inhibits MAPK signaling. The discovery of dual inhibition of MEK / SHP2 has made important progress in the long-term effort to better understand and therapeutically target KRAS-driven cancers.
[0009] Given the essential physiological functions performed by SHP2, targeting SHP2 dysregulation is expected to have broad therapeutic applications. Gain-of-function mutations in PTPN11, the gene encoding SHP2, have been causally linked to several human diseases, including Noonan syndrome, juvenile myelomonocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome, and acute B-lymphoblastic leukemia. SHP2 functions as an oncogene, and its overexpression and / or activating mutations have been reported in a variety of solid tumors, such as neuroblastoma, breast cancer, colon cancer, lung cancer, melanoma, and hepatocellular carcinoma.
[0010] In addition, it is believed that SHP-2 mediates inhibitory immune checkpoint signaling of multiple receptors (e.g., PD-1) by dephosphorylating CD28. In support of this view, dominant negative SHP-2 abolishes the PD-1 signaling pathway and restores the function of cytotoxic CAR T cells. Therefore, SHP-2 inhibitors have the potential to be used in combination therapies with existing targeted and immuno-oncology (IO) agents.
[0011] In addition to human tumors, increased expression or activity of SHP2 has been implicated in the pathogenesis of autoimmune diseases such as systemic lupus erythematosus (Wang J et al., J Clin Invest. 2016 Jun 1; 126(6): 2077-92) and rheumatoid arthritis (see Stanford SM et al., Arthritis Rheum. 2013 May; 65(5): 1171-80; Maeshima K et al., JCI Insight. 2016 May 19; 1(7)). Recently, SHP2 has also been characterized as a molecular checkpoint for TGFβ-induced JAK2 / STAT3 signaling, suggesting that SHP2 inhibition may provide therapeutic benefits for the treatment of fibrosis (see Zehender A et al., Nat Commun. 2018 Aug 14; 9(1): 3259). Therefore, SHP2 represents an attractive target for the development of novel therapeutics for a variety of diseases. Summary of the invention
[0012] In a first aspect, there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof:
[0013]
[0014] in:
[0015] A and E are independently selected from a bond, CH2, O, NH, S and S(O)2;
[0016] Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl and heteroaryl are optionally substituted with one to three halo), -O(alk) y R a 、-O(alk)OR b 、-S(O)R c 、-S(O)2R d 、-NR e C(O)R f 、-NR g S02R h 、-OC(O)NR i R j 、-C(O)NR k R m 、-S(O)2NR n R o 、-NR p R q 、-NR r C(O)C(O)R s or -YM (wherein Y is a bond, O or SO2, and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl or heteroaryl, wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are replaced by -O(alk) y R a 、-O(alk)OR b 、-S(O)R c 、-S(O)2R d 、-NR e C(O)R f 、-NR g S02R h 、-OC(O)NR i R j 、-C(O)NR k R m 、-S(O)2NR n R o 、-NR p R q or -NR r C(O)C(O)R s substituted, and cycloalkyl, heterocyclyl and heteroaryl are optionally further substituted by 1 to 3 halo); wherein each y is 0 or 1, each alk is alkylene, and each R c , R d , R f , R h and R sis independently alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; and each R a , R b , R e , R g , R i , R j , R k , R m , R n , R o , R p , R q , R r and R s R is independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; or, independently of one another, each R i and R j , R k and R m , R n and R o and R p and R q together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl;
[0017] R 1 , R 2 , R 3 and R 4 independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxyalkyl, amino, and aminoalkyl;
[0018] Or, R 1 and R 2 and R 3 and R 4 of which, when attached to the same carbon, combine to form an oxo group, an olefinic group, a 3- to 6-membered cycloalkylene group, or a 4- to 6-membered optionally substituted heterocyclylene group;
[0019] R 5 and R 6 R is independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxyalkyl, amino and aminoalkyl, or R 5 and R 6 is an optionally substituted heterocyclic group, and R 5 and R 6the other of which is selected from the group consisting of hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxyalkyl, amino, and aminoalkyl;
[0020] L is a bond, O, S, S(O), S(O)2 or CR 7 R 8 , where R 7 and R 8 are independently hydrogen or alkyl;
[0021] Z 1 A group of formula (a) or (b):
[0022]
[0023] in:
[0024] R 9 is hydrogen, alkyl, halo, hydroxy, amino or haloalkyl;
[0025] R 10 is hydrogen, alkyl, halo, hydroxy, hydroxyalkyl, -CD2OH, alkylsulfoxide, alkylsulfonyl, amino, aminoalkyl, aminosulfonyl, aminocarbonyl, carboxyl, cyano or alkoxycarbonyl;
[0026] R 13 is hydrogen, alkyl, halo, hydroxy, amino or haloalkyl;
[0027] R 14 is hydrogen, alkyl or haloalkyl;
[0028] R 11 and R 15 Selected from amino and aminoalkyl;
[0029] R 12 and R 16 is selected from the group consisting of hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, wherein alkyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano;
[0030] Or, R 11 and R 12 and R 15 and R 16 Together with the carbon atom to which they are attached, they form a ring of formula (c):
[0031]
[0032] in:
[0033] e is 0, 1, or 2;
[0034] k is 0, 1 or 2, provided that e+k is 1, 2 or 3;
[0035] q is 0, 1, 2 or 3;
[0036] R 17 and R 18 independently selected from hydrogen, alkyl, cycloalkyl and haloalkyl;
[0037] Each R 19 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or
[0038] When two R 19 When the groups are attached to the same carbon atom, the two R 19 The groups, together with the carbon atom to which they are attached, form a cycloalkylene or heterocyclylene group.
[0039] Ring D is absent or present; wherein:
[0040] (i) when ring D is absent, then one of Q and W is CH2, O, S, S(O), S(O)2 or NH; and the other of Q and W is CH2; and
[0041] (ii) when ring D is present, then Q and W are independently N or C, provided that only one of Q and W is N; and ring D is phenyl or a 5- or 6-membered heteroaryl ring containing from one to three heteroatoms independently selected from N, O and S, including Q and W, and ring D is optionally substituted with one or two substituents independently selected from alkyl, cycloalkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxy and optionally substituted heterocyclyl.
[0042] In a second aspect, there is provided a compound of formula (IA) or a pharmaceutically acceptable salt thereof:
[0043]
[0044] in:
[0045] A and E are independently selected from a bond, CH2, O, NH, S and S(O)2;
[0046] Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl and heteroaryl are optionally substituted with one to three halo), -O(alk) y R a、-O(alk)OR b 、-S(O)R c 、-S(O)2R d 、-NR e C(O)R f 、-NR g S02R h 、-OC(O)NR i R j 、-C(O)NR k R m 、-S(O)2NR n R o 、-NR p R q 、-NR r C(O)C(O)R s or -YM (wherein Y is a bond, O or SO2, and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl or heteroaryl, wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are replaced by -O(alk) y R a 、-O(alk)OR b 、-S(O)R c 、-S(O)2R d 、-NR e C(O)R f 、-NR g S02R h 、-OC(O)NR i R j 、-C(O)NR k R m 、-S(O)2NR n R o 、-NR p R q or -NR r C(O)C(O)R s substituted, and cycloalkyl, heterocyclyl and heteroaryl are optionally further substituted by 1 to 3 halo); wherein each y is 0 or 1, each alk is alkylene, and each R c , R d , R f , R h and R s is independently alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; and each R a , R b , R e , R g , R i , Rj, Rk , R m , R n , R o , R p , R q , R r and R s R is independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; or, independently of one another, each R i and R j , R k and R m , R n and R o and R p and R q together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl;
[0047] R 1 , R 2 , R 3 and R 4 independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxyalkyl, amino, and aminoalkyl;
[0048] Or, R 1 and R 2 and R 3 and R 4 of which, when attached to the same carbon, combine to form an oxo group, an olefinic group, a 3- to 6-membered cycloalkylene group, or a 4- to 6-membered optionally substituted heterocyclylene group;
[0049] R 5 and R 6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxyalkyl, amino and aminoalkyl, or wherein R 5 and R 6 is an optionally substituted heterocyclic group, and R 5 and R 6 the other of which is selected from the group consisting of hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxyalkyl, amino, and aminoalkyl;
[0050] L is a bond, O, S, S(O), S(O)2 or CR 7 R 8 , where R 7 and R 8 are independently hydrogen or alkyl;
[0051] Z 1 A group of formula (a) or (b):
[0052]
[0053] in:
[0054] R 9 is hydrogen, alkyl, halo, hydroxy, amino or haloalkyl;
[0055] R 10 is hydrogen, alkyl, halo, hydroxy, hydroxyalkyl, -CD2OH, alkylsulfoxide, alkylsulfonyl, amino, aminoalkyl, aminosulfonyl, aminocarbonyl, carboxyl, cyano or alkoxycarbonyl;
[0056] R 13 is hydrogen, alkyl, halo, hydroxy, amino or haloalkyl;
[0057] R 14 is hydrogen, alkyl or haloalkyl;
[0058] R 11 and R 15 Selected from amino and aminoalkyl;
[0059] R 12 and R 16 is selected from the group consisting of hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, wherein alkyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano;
[0060] Or, R 11 and R 12 and R 15 and R 16 Together with the carbon atom to which they are attached, they form a ring of formula (c):
[0061]
[0062] in:
[0063] e is 0, 1, or 2;
[0064] k is 0, 1 or 2, provided that e+k is 1, 2 or 3;
[0065] q is 0, 1, 2 or 3;
[0066] R 17 and R 18 are independently selected from hydrogen, alkyl, cycloalkyl and haloalkyl,
[0067] Each R 19 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or
[0068] When two R 19 When the groups are attached to the same carbon atom, the two R 19 The groups, together with the carbon atom to which they are attached, form a cycloalkylene or heterocyclylene group.
[0069] Ring D is absent or present; wherein:
[0070] (i) when ring D is absent, then one of Q and W is CH2, O, S, S(O), S(O)2 or H; and the other of Q and W is CH2; and
[0071] (ii) when ring D is present, Q and W are independently N or C, provided that only one of Q and W is N; and ring D is phenyl or a 5- or 6-membered heteroaryl ring containing from one to three heteroatoms independently selected from N, O and S, including Q and W, and ring D is optionally substituted with one or two substituents independently selected from alkyl, cycloalkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxyl and optionally substituted heterocyclyl; provided that when the compound of formula (I) or a pharmaceutically acceptable salt thereof is of formula Compound or a pharmaceutically acceptable salt thereof (wherein R 9 is hydrogen, R 10 is not hydrogen, amino or aminoalkyl, and L, R 11 and R 12 As defined in formula (I); then:
[0072] (i) When R 1 , R 2 , R 3 , R 4 , R 5 and R 6 Four of them are hydrogen, and R 1 , R 2 , R 3 , R 4 , R 5 and R 6 When the other two of are independently selected from hydrogen, alkyl, cycloalkyl, amino, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano and aminoalkyl; then Z is not hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, -OR a (where R ais hydrogen or alkyl), -OC(O)NH2, -O-tetrahydrofuran-3-yl, -O-oxetan-3-yl, cyano, pyrazol-1-yl, -CH2OCH3, -OCH2OCH3, -OCH2cyclopropyl, -O-CH2CH2OCH3 and -SO2CH3,
[0073] (ii) When R 5 and R 6 is hydrogen, and R 1 , R 2 , R 3 and R 4 two of which are hydrogen, and a) R 1 and R 2 and b) R 3 and R 4 One of the groups is hydrogen, and a) R 1 and R 2 and b) R 3 and R 4 When the other group of is attached to the same carbon and combines to form an alkylene, a 3- to 6-membered cycloalkylene, or a 4- to 6-membered heterocyclylene, then Z is not hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, -OR a (where R a is hydrogen or alkyl), -NH2 or -YM (wherein Y is a bond and M is -OR a or -NR p R q Substituted alkyl, wherein each R a is hydrogen or alkyl, and R p and R q are independently hydrogen, alkyl, hydroxyalkyl or alkoxyalkyl, or R p and R q together with the nitrogen atom to which they are attached form an optionally substituted heterocyclyl); and
[0074] (iii) When Z is hydrogen, a) R 1 and R 2 and b) R 3 and R 4 are attached to the same carbon and combined to form a 3- to 6-membered cycloalkylene or a 4- to 6-membered heterocyclylene, and the remaining R 1 , R 2 , R 3 , R 4 , R 5 and R 6 When three of them are hydrogen, then R 1 , R 2 , R 3 , R 4 , R5 and R 6 The remaining one of is not hydrogen, alkyl, cycloalkyl, halo, haloalkyl, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, aminoalkyl or amino.
[0075] In a third aspect, there is provided a compound of formula (IB) or a pharmaceutically acceptable salt thereof:
[0076]
[0077] in:
[0078] A and E are independently selected from a bond, CH2, O, NH, S and S(O)2;
[0079] Z is hydrogen, alkyl, haloalkyl, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl and heteroaryl are optionally substituted by one to three halo), -O(alk) y R a 、-O(alk)OR b 、-S(O)R c 、-S(O)2R d 、-NR e C(O)R f 、-NR g S02R h 、-OC(O)NR i R j 、-C(O)NR k R m 、-S(O)2NR n R o 、-NR p R q 、-NR r C(O)C(O)R s or -YM (wherein Y is a bond, O or SO2 and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl or heteroaryl, wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are replaced by -O(alk) y R a 、-O(alk)OR b 、-S(O)R c 、-S(O)2R d 、-NR e C(O)R f 、-NR g S02R h 、-OC(O)NR i R j 、-C(O)NR k R m 、-S(O)2NR nR o 、-NR p R q or -NR r C(O)C(O)R s substituted, and cycloalkyl, heterocyclyl and heteroaryl are optionally further substituted by 1 to 3 halo); wherein each y is 0 or 1, each alk is alkylene, and each R c , R d , R f , R h and R s is independently alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; and each R a , R b , R e , R g , R i , R j , R k , R m , R n , R o , R p , R q , R r and R s R is independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; or, independently of one another, each R i and R j , R k and R m , R n and R o and R p and R q together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl;
[0080] R 1 , R 2 , R 3 and R 4 independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxyalkyl, amino, and aminoalkyl;
[0081] Or, R 1 and R 2 and R 3 and R 4of which, when attached to the same carbon, combine to form an oxo group, an olefinic group, a 3- to 6-membered cycloalkylene group, or a 4- to 6-membered optionally substituted heterocyclylene group;
[0082] R 5 and R 6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxyalkyl, amino and aminoalkyl, or wherein R 5 and R 6 is an optionally substituted heterocyclic group, and R 5 and R 6 the other of which is selected from the group consisting of hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxyalkyl, amino, and aminoalkyl;
[0083] L is a bond, O, S, S(O), S(O)2 or CR 7 R 8 , where R 7 and R 8 are independently hydrogen or alkyl;
[0084] Z 1 A group of formula (a) or (b):
[0085]
[0086] in:
[0087] R 9 is hydrogen, alkyl, halo, hydroxy, amino or haloalkyl;
[0088] R 10 is hydrogen, alkyl, halo, hydroxy, hydroxyalkyl, -CD2OH, alkylsulfoxide, alkylsulfonyl, amino, aminoalkyl, aminosulfonyl, aminocarbonyl, carboxyl, cyano or alkoxycarbonyl;
[0089] R 13 is hydrogen, alkyl, halo, hydroxy, amino or haloalkyl;
[0090] R 14 is hydrogen, alkyl or haloalkyl;
[0091] R 11 and R 15 Selected from amino and aminoalkyl;
[0092] R 12 and R 16is selected from the group consisting of hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, wherein alkyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano;
[0093] Or, R 11 and R 12 and R 15 and R 16 Together with the carbon atom to which they are attached, they form a ring of formula (c):
[0094]
[0095] in:
[0096] e is 0, 1, or 2;
[0097] k is 0, 1 or 2, provided that e+k is 1, 2 or 3;
[0098] q is 0, 1, 2 or 3;
[0099] R 17 and R 18 are independently selected from hydrogen, alkyl, cycloalkyl and haloalkyl,
[0100] Each R 19 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or
[0101] When two R 19 When the groups are attached to the same carbon atom, the two R 19 The groups, together with the carbon atom to which they are attached, form a cycloalkylene or heterocyclylene group.
[0102] Ring D is absent or present; wherein:
[0103] (i) when ring D is absent, then one of Q and W is CH2, O, S, S(O), S(O)2 or NH; and the other of Q and W is CH2; and
[0104] (ii) when ring D is present, Q and W are independently N or C, provided that only one of Q and W is N; and ring D is phenyl or a 5- or 6-membered heteroaryl ring containing from one to three heteroatoms independently selected from N, O and S, including Q and W, and ring D is optionally substituted with one or two substituents independently selected from alkyl, cycloalkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxyl and optionally substituted heterocyclyl; provided that when the compound of formula (I) or a pharmaceutically acceptable salt thereof is of formula Compound or a pharmaceutically acceptable salt thereof (wherein R 9 is hydrogen, R 10 is not hydrogen, amino or aminoalkyl, and L, R 11 and R 12 As defined in formula (IB); then:
[0105] (i) When R 1 , R 2 , R 3 , R 4 , R 5 and R 6 Four of them are hydrogen, and R 1 , R 2 , R 3 , R 4 , R 5 and R 6 The remaining two of the groups are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino and aminoalkyl; then Z is not hydrogen, halogen, alkyl, haloalkyl, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl and heteroaryl are optionally substituted with one to three halo), -OR a 、-S(O)R c 、-S(O)2R d 、-NR e C(O)R f 、-NR g S02R h 、-OC(O)NR i R j 、-C(O)NR k R m 、-S(O)2NR n R o 、-NR p R q 、-NR r C(O)C(O)R s (where R c , R d , R f , Rh and R s R is independently alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; and R a , R e , R g , R i , Rj, R k , R m , R n , R o , R p , R q and R r R is independently hydrogen, alkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; or, independently of one another, each R i and R j , R k and R m , R n and R o and R p and R q Together with the nitrogen atom to which they are attached, they form an optionally substituted heterocyclic group) or YM (wherein (a) Y is a bond or O, and M is -OR a or -NR p R q Substituted alkyl, wherein R a is hydrogen or alkyl, and R p and R q are independently hydrogen, alkyl, hydroxyalkyl or alkoxyalkyl, or R p and R q Together with the nitrogen atom to which they are attached, they form an optionally substituted heterocyclic group, and (b) Y is SO2, and M is a cycloalkyl group (substituted by -OR a substituted), heteroaryl or heterocyclyl, wherein the heteroaryl or heterocyclyl is independently replaced by -OR a 、-S(O)2R d or -NR p R q Substitution; wherein R a is hydrogen or alkyl, R d is an alkyl group, and R p and R q are independently hydrogen or alkyl, and cycloalkyl is optionally further substituted with one halo, and heterocyclyl and heteroaryl are optionally further substituted with 1 or 2 halo;
[0106] (ii) When R 5and R 6 are each hydrogen, and R 1 , R 2 , R 3 and R 4 two of which are hydrogen, and a) R 1 and R 2 and b) R 3 and R 4 One of the groups is hydrogen, and a) R 1 and R 2 and b) R 3 and R 4 The other group in is attached to the same carbon and combines to form an alkylene, a 3- to 6-membered cycloalkylene, or a 4- to 6-membered heterocyclylene, then Z is not hydrogen, alkyl, halo, haloalkyl, cyano, cycloalkyl, -OR a (where R a is hydrogen or alkyl), -NH2 or -YM (wherein Y is a bond and M is -OR a or -NR p R q Substituted alkyl, wherein each R a is hydrogen or alkyl, and R p and R q are independently hydrogen, alkyl, hydroxyalkyl or alkoxyalkyl, or R p and R q together with the nitrogen atom to which they are attached form an optionally substituted heterocyclyl); and
[0107] (iii) When Z is hydrogen, a) R 1 and R 2 and b) R 3 and R 4 are attached to the same carbon and combined to form a 3- to 6-membered cycloalkylene or a 4- to 6-membered heterocyclylene, and the remaining R 1 , R 2 , R 3 , R 4 , R 5 and R 6 When three of them are hydrogen, then R 1 , R 2 , R 3 , R 4 , R 5 and R 6 The remaining one of is not hydrogen, alkyl, halo, haloalkyl, cyano, cycloalkyl, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, aminoalkyl or amino.
[0108] In a fourth aspect, there is provided a compound of formula (IC) or a pharmaceutically acceptable salt thereof:
[0109]
[0110] in:
[0111] A and E are independently selected from a bond, CH2, O, NH, S and S(O)2;
[0112] Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl and heteroaryl are optionally substituted with one to three halo), -O(alk) y R a 、-O(alk)OR b 、-S(O)R c 、-S(O)2R d 、-NR e C(O)R f 、-NR g S02R h 、-OC(O)NR i R j 、-C(O)NR k R m 、-S(O)2NR n R o 、-NR p R q 、-NR r C(O)C(O)R s or -YM (wherein Y is a bond, O or SO2, and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl or heteroaryl, wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are replaced by -O(alk) y R a 、-O(alk)OR b 、-S(O)R c 、-S(O)2R d 、-NR e C(O)R f 、-NR g S02R h 、-OC(O)NR i R j 、-C(O)NR k R m 、-S(O)2NR n R o 、-NR p R q or -NR r C(O)C(O)R s substituted, and cycloalkyl, heterocyclyl and heteroaryl are optionally further substituted by 1 to 3 halo); wherein each y is 0 or 1, each alk is alkylene, and each R c, R d , R f , R h and R s is independently alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; and each R a , R b , R e , R g , R i , R j , R k , R m , R n , R o , R p , R q , R r and R s R is independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; or, independently of one another, each R i and R j , R k and R m , R n and R o and R p and R q together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl;
[0113] R 1 , R 2 , R 3 and R 4 independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxyalkyl, amino, and aminoalkyl;
[0114] Or, R 1 and R 2 and R 3 and R 4 of which, when attached to the same carbon, combine to form an oxo group, an olefinic group, a 3- to 6-membered cycloalkylene group, or a 4- to 6-membered optionally substituted heterocyclylene group;
[0115] R 5 and R 6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxyalkyl, amino and aminoalkyl, or wherein R 5 and R6 is an optionally substituted heterocyclic group, and R 5 and R 6 the other of which is selected from the group consisting of hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxyalkyl, amino, and aminoalkyl;
[0116] L is a bond, O, S, S(O), S(O)2 or CR 7 R 8 , where R 7 and R 8 are independently hydrogen or alkyl;
[0117] Z 1 A group of formula (a) or (b):
[0118]
[0119] in:
[0120] R 9 is hydrogen, alkyl, halo, hydroxy, amino or haloalkyl;
[0121] R 10 is hydrogen, alkyl, halo, hydroxy, hydroxyalkyl, -CD2OH, alkylsulfoxide, alkylsulfonyl, amino, aminoalkyl, aminosulfonyl, aminocarbonyl, carboxyl, cyano or alkoxycarbonyl;
[0122] R 13 is hydrogen, alkyl, halo, hydroxy, amino or haloalkyl;
[0123] R 14 is hydrogen, alkyl or haloalkyl;
[0124] R 11 and R 15 Selected from amino and aminoalkyl;
[0125] R 12 and R 16 is selected from the group consisting of hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, wherein alkyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano;
[0126] Or, R 11 and R 12 and R 15 and R 16 Together with the carbon atom to which they are attached, they form a ring of formula (c):
[0127]
[0128] in:
[0129] e is 0, 1, or 2;
[0130] k is 0, 1 or 2, provided that e+k is 1, 2 or 3;
[0131] q is 0, 1, 2 or 3;
[0132] R 17 and R 18 independently selected from hydrogen, alkyl, cycloalkyl and haloalkyl;
[0133] Each R 19 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or
[0134] When two R 19 When the groups are attached to the same carbon atom, the two R 19 The groups, together with the carbon atom to which they are attached, form a cycloalkylene or heterocyclylene group.
[0135] Ring D is absent or present; wherein:
[0136] (i) when ring D is absent, then one of Q and W is CH2, O, S, S(O), S(O)2 or NH; and the other of Q and W is CH2; and
[0137] (ii) when ring D is present, then Q and W are independently N or C, provided that only one of Q and W is N; and ring D is phenyl or a 5- or 6-membered heteroaryl ring containing from one to three heteroatoms independently selected from N, O and S, including Q and W, and ring D is optionally substituted with one or two substituents independently selected from alkyl, cycloalkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxyl and optionally substituted heterocyclyl; provided that the compound of formula (IC) is not a compound of any one of Embodiments 37-42 and 45-63 disclosed herein below and the embodiments contained therein, or a pharmaceutically acceptable salt thereof.
[0138] In a fifth aspect, a pharmaceutical composition is provided, comprising a compound of Formula (I), (IA), (IB) or (IC) (or any embodiment thereof described herein) or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
[0139] In a sixth aspect, a method of treating a disease treatable by inhibiting SHP2 in a patient is provided, the method comprising administering to the patient, preferably a patient in need of such treatment, a therapeutically effective amount of a compound of Formula (I), (IA), (IB) or (IC) (or any embodiment thereof as described herein), or administering to the patient, preferably a patient in need of such treatment, a pharmaceutical composition comprising a compound of Formula (I), (IA), (IB) or (IC) (or any embodiment thereof as described herein) and a pharmaceutically acceptable excipient. In one embodiment, the disease is cancer. In another embodiment, the disease is a cancer selected from the group consisting of lung cancer, gastric cancer, liver cancer, colon cancer, kidney cancer, breast cancer, pancreatic cancer, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, and acute myeloid leukemia. In one embodiment, the disease is selected from Noonan syndrome and Leopard syndrome.
[0140] In a seventh aspect, there is provided a compound of Formula (I), (IA), (IB) or (IC) (or any embodiment thereof as described herein), or a pharmaceutically acceptable salt thereof, for use as a medicament.
[0141] In an eighth aspect, provided is the use of a compound of Formula (I), (IA), (IB) or (IC) or a pharmaceutically acceptable salt thereof (and any embodiments thereof disclosed herein) in the preparation of a medicament for treating a disease in a patient in need of such treatment, wherein the activity of SHP2 contributes to the pathology and / or symptoms of the disease.
[0142] In a ninth aspect, a method of inhibiting SHP2 is provided, the method comprising contacting SHP2 with a compound of formula (I), (IA), (IB) or (IC) (or any embodiment thereof as described herein) or a pharmaceutically acceptable salt thereof; or contacting SHP2 with a pharmaceutical composition comprising a compound of the present disclosure (or any embodiment thereof as described herein) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
[0143] In a tenth aspect, there is provided an intermediate of formula (V) or an acceptable salt thereof:
[0144]
[0145] in:
[0146] Q is halogenated or SH;
[0147] A and E are independently selected from a bond, CH2, O, NH, S and S(O)2;
[0148] Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl and heteroaryl are optionally substituted with one to three halo), -O(alk) y R a 、-O(alk)OR b 、-S(O)R c 、-S(O)2R d 、-NR e C(O)R f 、-NR g S02R h 、-OC(O)NR i R j 、-C(O)NR k R m 、-S(O)2NR n R o 、-NR p R q 、-NR r C(O)C(O)R s or -YM (wherein Y is a bond, O or SO2, and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl or heteroaryl, wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are replaced by -O(alk) y R a 、-O(alk) y OR b 、-S(O)R c 、-S(O)2R d 、-NR e C(O)R f 、-NR g S02R h 、-OC(O)NR i R j 、-C(O)NR k R m 、-S(O)2NR n R o 、-NR p R q or -NR r C(O)C(O)R s substituted, and cycloalkyl, heterocyclyl and heteroaryl are optionally further substituted by 1 to 3 halo); wherein each y is 0 or 1, each alk is alkylene, and each R c , R d , R f , R h and R sis independently alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; and each R a , R b , R e , R g , R i , Rj, R k , R m , R n , R o , R p , R q , R r and R s R is independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; or, independently of one another, each R i and R j , R k and R m , R n and R o and R p and R q together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl;
[0149] R 1 , R 2 , R 3 and R 4 independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxyalkyl, amino, and aminoalkyl;
[0150] Or, R 1 and R 2 and R 3 and R 4 of which, when attached to the same carbon, combine to form an oxo group, an olefinic group, a 3- to 6-membered cycloalkylene group, or a 4- to 6-membered optionally substituted heterocyclylene group;
[0151] R 5 and R 6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxyalkyl, amino and aminoalkyl, or wherein R 5 and R 6 is an optionally substituted heterocyclic group, and R 5 and R 6The other of the groups is selected from the group consisting of hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxyalkyl, amino, and aminoalkyl.
[0152] In a first embodiment of the tenth aspect, Q is halo. In a subembodiment of the first embodiment, Q is chloro, bromo or iodo.
[0153] In a second embodiment of the tenth aspect, Q is -S - M + , where M + In a sub-embodiment of the second embodiment, M + Sodium or potassium.
[0154] In a third embodiment of any of the tenth aspect, the first and second embodiments and sub-embodiments contained therein, for
[0155] In a tenth aspect, in a fourth embodiment of any one of the first, second and third embodiments and sub-embodiments contained therein, A, E, Z, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 As defined in the Embodiments section below. DETAILED DESCRIPTION OF THE INVENTION
[0157] Certain structures provided herein are drawn using one or more floating substituents. Unless otherwise specified or otherwise clear from the context, the one or more substituents may be present on any atom in the ring to which they are attached, as long as it is chemically feasible and permitted by the valence rules. For example, in the following structure: R 3 , R 4 The Z substituents may replace any hydrogen on the 6-membered ring containing group A, including one or two hydrogens of the CH2 group when A is CH2, and including the hydrogen of NH when A is NH. In another example, in formula (c): In the ring of, when ring D is absent and Q and / or W is CH2, one or both of these hydrogen atoms are optionally replaced by one or two R 19 Group replacement.
[0158] definition:
[0159] Unless otherwise indicated, the following terms used in the specification and claims are defined for the purposes of this application and have the following meanings:
[0160] "Alkyl" refers to a straight chain saturated monovalent hydrocarbon group having 1 to 6 carbon atoms or a branched chain saturated monovalent hydrocarbon group having 3 to 6 carbon atoms, such as methyl, ethyl, propyl, 2-propyl, butyl, pentyl, etc. Those skilled in the art will recognize that the term "alkyl" may include "alkylene" groups.
[0161] Unless otherwise specified, "alkylene" refers to a straight-chain saturated divalent hydrocarbon group having 1 to 6 carbon atoms or a branched saturated divalent hydrocarbon group having 3 to 6 carbon atoms, for example, methylene, ethylene, propylene, 1-methylpropylene, 2-methylpropylene, butylene, pentylene, etc.
[0162] The "alkenyl" refers to a linear monovalent hydrocarbon group having 2 to 6 carbon atoms or a branched monovalent hydrocarbon group having 3 to 6 carbon atoms containing a double bond, for example, propenyl, butenyl, and the like.
[0163] "Alkyldienyl" is an alkenyl group as defined above attached via a terminal divalent carbon. For example, in the following compound: In the figure, the olefinic group is circled by the arrow.
[0164] "Alkylthio" refers to a -SR group where R is alkyl as defined above, eg, methylthio, ethylthio, and the like.
[0165] "Alkylsulfonyl" means a -SO2R group where R is alkyl as defined above, eg, methylsulfonyl, ethylsulfonyl, and the like.
[0166] "Alkylsulfoxide" refers to a -SOR group where R is alkyl as defined above, eg, methylsulfoxide, ethylsulfoxide, and the like.
[0167] "Amino" refers to -NH2.
[0168] "Alkylamino" refers to a -NHR group where R is alkyl as defined above, eg, methylamino, ethylamino, propylamino, or 2-propylamino, and the like.
[0169] "Acylamino" means a -NHC(O)R group where R is alkyl as defined above, eg, acetylamino, propionylamino, and the like.
[0170] "Aminoalkyl" refers to a straight chain monovalent hydrocarbon radical having 1 to 6 carbon atoms or a branched monovalent hydrocarbon radical having 3 to 6 carbons substituted with -NR'R", wherein R' and R" are independently hydrogen, alkyl, haloalkyl, hydroxyalkyl or alkoxyalkyl, or R' and R" together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic radical, each as defined herein, e.g., aminomethyl, aminoethyl, methylaminomethyl, morpholinylethyl, piperazin-1-ylethyl, and the like.
[0171] "Alkoxy" refers to a -OR group where R is alkyl as defined above, for example, methoxy, ethoxy, propoxy or 2-propoxy, n-butoxy, isobutoxy or tert-butoxy and the like.
[0172] "Alkoxyalkyl" refers to a straight chain monovalent hydrocarbon radical having 1 to 6 carbon atoms or a branched monovalent hydrocarbon radical having 3 to 6 carbon atoms substituted with at least one alkoxy radical as defined above (e.g., one or two alkoxy radicals), for example, 2-methoxyethyl, 1-methoxypropyl, 2-methoxypropyl or 3-methoxypropyl, 2-ethoxyethyl, and the like.
[0173] "Alkoxycarbonyl" refers to a -C(O)OR group where R is alkyl as defined above, eg, methoxycarbonyl, ethoxycarbonyl, and the like.
[0174] "Aryl" refers to a monovalent monocyclic or bicyclic aromatic hydrocarbon group having 6 to 10 ring atoms, for example, phenyl or naphthyl.
[0175] "Aralkyl" refers to an -(alkylene)-R, where R is aryl as defined above, for example, benzyl or phenethyl.
[0176] Unless otherwise specified, "cycloalkyl" refers to a monocyclic saturated monovalent hydrocarbon group having three to ten carbon atoms, optionally substituted by one or two substituents, the substituents being independently selected from alkyl, halo, alkoxy, hydroxyl and cyano. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, etc.
[0177] "Cycloalkylalkyl" refers to a -(alkylene)-R radical where R is cycloalkyl as defined above, eg, cyclopropylmethyl, cyclohexylmethyl, and the like.
[0178] Unless otherwise indicated, "cycloalkylene" refers to a monocyclic saturated divalent hydrocarbon radical having 3 to 6 carbon atoms, optionally substituted by one or two substituents, the substituents being independently selected from alkyl, halo, alkoxy, hydroxyl and cyano (each as defined herein). Examples include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene or cyclohexylene, etc.
[0179] "Carboxy" refers to -C(O)OH.
[0180] "Dialkylamino" refers to a -NRR' group where R and R' are alkyl as defined above, for example, dimethylamino, methylethylamino, and the like.
[0181] "Aminosulfonyl" refers to a -SO2NRR' group where R and R' are independently hydrogen, alkyl, haloalkyl, hydroxyalkyl or alkoxyalkyl (each as defined herein), eg, aminosulfonyl, methylaminosulfonyl, dimethylaminosulfonyl, and the like.
[0182] "Aminocarbonyl" refers to a -CONRR' group where R and R' are independently hydrogen, alkyl, haloalkyl, hydroxyalkyl or alkoxyalkyl (each as defined herein), e.g., aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, ethylmethylaminocarbonyl, and the like.
[0183] "Aminocarboxy" refers to a -C(O)ONRR' radical where R and R' are independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl (each as defined herein), eg, aminocarbonyloxy, methylaminocarbonyloxy, dimethylaminocarbonyloxy, and the like.
[0184] "Halo" refers to fluoro, chloro, bromo or iodo, preferably fluoro or chloro.
[0185] "Haloalkyl" refers to an alkyl group as defined above substituted with one or more halogen atoms (e.g., one to five halogen atoms, such as fluorine or chlorine), including those substituted with different halogens, such as -CH2Cl, -CF3, -CHF2, -CH2CF3, -CF2CF3, -CF(CH3)2, etc. When an alkyl group is substituted only with fluorine, it may be referred to as a fluoroalkyl group in the present application.
[0186] "Haloalkoxy" refers to a -OR group, wherein R is a haloalkyl group as defined above, for example, -OCF3, -OCHF2, etc. When R is a haloalkyl group wherein the alkyl group is substituted only with fluorine, it may be referred to herein as a fluoroalkoxy group.
[0187] "Hydroxyalkyl" refers to a linear monovalent hydrocarbon radical having 1 to 6 carbon atoms or a branched monovalent hydrocarbon radical having 3 to 6 carbon atoms substituted by one or two hydroxyl groups, provided that if two hydroxyl groups are present, they are not on the same carbon atom. Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxy-ethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 1-(hydroxymethyl)-2-hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl, preferably 2-hydroxyethyl, 2,3-dihydroxypropyl and 1-(hydroxymethyl)-2-hydroxyethyl.
[0188] "Heterocyclyl" refers to a saturated or unsaturated monovalent monocyclic or bicyclic ring having 4 to 10 ring atoms, wherein one, two or three of the ring atoms are selected from N, O and S(O). n Heteroatoms, wherein n is an integer from 0 to 2, and the remaining ring atoms are C. In addition, one or two ring carbon atoms in the heterocyclic ring may be optionally replaced by -CO- groups. More specifically, the term heterocyclic includes, but is not limited to, pyrrolidinyl, piperidinyl, homopiperidinyl, 2-oxopyrrolidinyl, 2-oxopiperidinyl, morpholino, piperazinyl, tetrahydro-pyranyl, thiomorpholino, 6,7,8,9-tetrahydro-4H-pyrido [1,2-a] pyrimidine-4-one, 6,7-dihydropyrimido [2,1-c] [1,4] oxazine-4 (9H) -one, etc. When the heterocyclic ring is unsaturated, it may contain one or two ring double bonds, provided that the ring is not aromatic. When the heterocyclic group contains at least one nitrogen atom, it is also referred to as heterocyclic amino in this article and is a subset of the heterocyclic group.
[0189] Unless otherwise indicated, "heterocyclylene" refers to a saturated or unsaturated divalent monocyclic or bicyclic ring having 4 to 6 ring atoms, wherein one, two or three of the ring atoms are selected from N, O and S(O). n wherein n is an integer from 0 to 2 and the remaining ring atoms are C. The heterocyclylene group may be optionally substituted with one or two substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, cyano or hydroxy (each as defined herein).
[0190] Unless otherwise indicated, " heteroaryl " refers to a monovalent monocyclic or bicyclic aromatic group with 5 to 10 ring atoms, wherein one or more (in one embodiment, one, two or three) ring atoms are heteroatoms selected from N, O or S, and the remaining ring atoms are carbon. Representative examples include but are not limited to pyrrolyl, thienyl, thiazolyl, imidazolyl, furyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, benzothiazolyl, benzoxazolyl, quinolyl, isoquinolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl etc. As defined in this article, the terms " heteroaryl " and " aryl " are mutually exclusive. When the heteroaryl ring contains 5 or 6 ring atoms, it is also referred to as 5 yuan or 6 yuan of heteroaryl in this article.
[0191] "Heteroaralkyl" refers to an -(alkylene)-R where R is heteroaryl as defined above, eg, benzyl or phenethyl.
[0192] The term "oxo," as used herein, alone or in combination, refers to =(O).
[0193] When necessary, any definition herein can be used in combination with any other definition to describe a composite structural group. By convention, the trailing element of any such definition is the element attached to the parent moiety. For example, the composite group alkoxyalkyl refers to an alkoxy group attached to the parent molecule via an alkyl group.
[0194] The present disclosure also includes protected derivatives of compounds of formula (I), (IA), (IB) or (IC) or embodiments thereof. For example, when compounds of formula (I), (IA), (IB) or (IC) contain groups such as hydroxyl, carboxyl, sulfhydryl or any group containing nitrogen atoms, these groups may be protected by suitable protecting groups. A comprehensive list of suitable protecting groups can be found in TW Greene, Protective Groups in Organic Synthesis, 5 th Ed., John Wiley & Sons, Inc. (2014), the disclosure of which is incorporated herein by reference in its entirety. Protected derivatives of compounds of formula (I), (IA), (IB) or (IC) can be prepared by methods well known in the art.
[0195] The present disclosure also includes polymorphic forms and deuterated forms of the compounds of Formula (I), (IA), (IB) or (IC). The term "prodrug" refers to a compound that is made to have higher activity in vivo. Certain compounds disclosed herein may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003). Prodrugs of the compounds described herein are structurally modified forms of the compounds that readily undergo chemical changes under physiological conditions to provide active compounds. Prodrugs are often useful because in some cases they may be easier to administer than the compound or parent drug. For example, they may be bioavailable by oral administration, while the parent drug is not. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. A non-limiting example of a prodrug would be a compound that is administered as an ester (the "prodrug") but is subsequently metabolically hydrolyzed to the carboxylic acid (the active entity). Additional examples include peptidyl derivatives of the compounds.
[0196] A "pharmaceutically acceptable salt" of a compound of formula (I), (IA), (IB) or (IC) refers to a salt that is pharmaceutically acceptable and possesses the desired pharmacological activity of the parent compound. Such salts include:
[0197] Acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or acid addition salts formed with organic acids such as formic acid, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, etc.; or
[0198] Salts formed when an acidic proton present in the parent compound is replaced by a metal ion (e.g., an alkali metal ion, an alkaline earth metal ion, or an aluminum ion); or salts formed by coordination with an organic base (e.g., ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, etc.). It should be understood that pharmaceutically acceptable salts are non-toxic. Additional information about suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, which is incorporated herein by reference in its entirety.
[0199] Compounds of formula (I), (IA), (IB) or (IC) may have an asymmetric center. Compounds of formula (I), (IA), (IB) or (IC) containing asymmetrically substituted atoms may be separated in optically active form or racemic form. Individual stereoisomers of a compound may be prepared synthetically from commercially available starting materials containing a chiral center, or by preparing a mixture of enantiomeric products followed by separation (such as conversion into a mixture of diastereoisomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on a chiral chromatographic column, or any other suitable method known in the art). Unless a specific stereochemistry or isomeric form is explicitly indicated, all chiral, diastereoisomer, all mixtures of chiral or diastereomeric forms, and racemic forms are within the scope of the present disclosure. It will also be appreciated by those skilled in the art that when a compound is represented as an (R) stereoisomer, it may contain the corresponding (S) stereoisomer as an impurity, and vice versa.
[0200] Certain compounds of formula (I), (IA), (IB) or (IC) may exist as tautomers and / or geometric isomers. All possible tautomers as well as cis and trans isomers as single forms and mixtures thereof are within the scope of the present disclosure. In addition, as used herein, the term alkyl includes all possible isomeric forms of the alkyl, although only a few examples are listed. In addition, when cyclic groups such as aryl, heteroaryl, heterocyclic groups are substituted, they include all positional isomers, although only a few examples are listed. In addition, all hydrates of compounds of formula (I), (IA), (IB) or (IC) are within the scope of the present disclosure.
[0201] Compounds of Formula (I), (IA), (IB) or (IC) may also contain unnatural amounts of isotopes at one or more atoms that constitute the compound. Unnatural amounts of isotopes may be defined as ranging from the amount found in nature to 100% of the amount of the atom in question, differing only in the presence of one or more isotopically enriched atoms. Exemplary isotopes that may be incorporated into compounds of the invention, such as compounds of Formula (I), (IA), (IB) or (IC) (and any embodiments thereof disclosed herein, including specific compounds), include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine and iodine, respectively, as described in 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 32 P. 33 P. 35 S. 18 F. 36 Cl, 123 I and 125 I. Isotope-labeled compounds (e.g. 3 H and 14 C-labeled) can be used in compound or substrate tissue distribution assays. 3 H) and carbon-14 (i.e., 14 C) isotopes are useful because of their ease of preparation and detectability. In addition, heavier isotopes such as deuterium (i.e., 2 H) substitution may provide certain therapeutic advantages due to greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements). In some embodiments, in the compounds disclosed herein (including in Table 1 below), one or more hydrogen atoms are replaced by 2 H or 3 H replacement, or one or more carbon atoms are enriched 13 C- or 14 C-carbon substitution. Positron emitting isotopes (such as 15 O. 13 N. 11 C and 15 F) can be used in positron emission tomography (PET) studies to examine substrate receptor occupancy.Isotopically labeled compounds can generally be prepared by following procedures analogous to those disclosed in the Schemes or Examples herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
[0202] "Optionally substituted aryl" refers to an aryl group optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, hydroxy, cycloalkyl, carboxy, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, alkylsulfonyl, amino, alkylamino, dialkylamino, halo, haloalkyl, haloalkoxy and cyano.
[0203] "Optionally substituted aralkyl" refers to a -(alkylene)-R group, wherein R is an optionally substituted aryl group as defined above.
[0204] "Optionally substituted heteroaryl" refers to a heteroaryl group as defined above optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, alkylthio, alkylsulfonyl, hydroxy, cycloalkyl, carboxy, alkoxycarbonyl, hydroxy, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino and cyano.
[0205] "Optionally substituted heteroaralkyl" refers to a -(alkylene)-R, where R is an optionally substituted heteroaryl as defined above.
[0206] "Optionally substituted heterocyclyl" refers to a heterocyclyl as defined above optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, alkylthio, alkylsulfonyl, hydroxy, cycloalkyl, carboxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, aminoalkyl, halo, haloalkyl, haloalkoxy and cyano.
[0207] "Optionally substituted heterocyclylalkyl" refers to a -(alkylene)-R wherein R is an optionally substituted heterocyclyl as defined above.
[0208] "Pharmaceutically acceptable carrier or excipient" refers to a carrier or excipient that can be used to prepare a pharmaceutical composition, which is generally safe, non-toxic, and neither biologically nor otherwise undesirable, and includes carriers or excipients that are acceptable for veterinary use as well as human pharmaceutical use. "Pharmaceutically acceptable carrier / excipient" as used in this specification and claims includes one and more than one such excipient.
[0209] As used herein, the term "about" is intended to qualify the numerical value it modifies, indicating that this value is variable within the margin of error. When no specific margin of error (such as the standard deviation of the mean value given in the table) is listed, the term "about" should be understood to mean a range covering ±10%, preferably ±5%, including the listed values and ranges.
[0210] As used herein, the term "disease" is intended to be generally synonymous with and used interchangeably with the terms "disorder," "syndrome," and "condition" (as in medical conditions), as all reflect an abnormal condition of the human or animal body or one of its parts that impairs normal function, which usually manifests itself as distinctive signs and symptoms, and results in a shortened life span or reduced quality of life in a human or animal.
[0211] The term "combination therapy" refers to the administration of two or more therapeutic agents to treat the diseases or disorders described in this disclosure. Such administration encompasses the co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule with a fixed ratio of active ingredients or in multiple separate capsules for each active ingredient. In addition, such administration also encompasses the use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide the beneficial effects of the drug combination in treating the conditions or disorders described herein.
[0212] The term "patient" is generally synonymous with the term "subject" and includes all mammals (including humans). Examples of patients include humans, livestock (such as cattle, goats, sheep, pigs and rabbits) and companion animals (such as dogs, cats, rabbits and horses). Preferably, the patient is a human.
[0213] “Treating” or “treatment” of a disease includes:
[0214] (1) preventing the disease, that is, causing clinical symptoms of the disease to not develop in a mammal that may be susceptible to the disease or is susceptible to the disease but does not yet experience or show symptoms of the disease;
[0215] (2) inhibiting the disease, i.e., preventing or reducing the development of the disease or its clinical symptoms; or
[0216] (3) Alleviating the disease, i.e., causing regression of the disease or its clinical symptoms. In one embodiment, treating or treatment refers to (2) or (3) above.
[0217] A "therapeutically effective amount" refers to an amount of a compound of Formula (I), (IA), (IB) or (IC) or a pharmaceutically acceptable salt thereof that, when administered to a patient for treating a disease, is sufficient to affect such treatment of the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, etc., of the mammal to be treated.
[0218] The terms "inhibit" and "reduce" or any variations of these terms with respect to SHP2 include any measurable decrease or complete inhibition that achieves the desired result. For example, a decrease in SHP2 activity compared to normal can be a decrease of about, up to about, or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more, or any range derivable therein.
[0219] Representative compounds of formula (I) are disclosed in Table (I) below.
[0220] Table 1
[0221]
[0222]
[0223]
[0224]
[0225]
[0226]
[0227]
[0228]
[0229]
[0230]
[0231]
[0232]
[0233]
[0234]
[0235] The compounds of formula (I) considered are disclosed in Table 2 below
[0236]
[0237]
[0238]
[0239]
[0240]
[0241] Implementation plan:
[0242] In the following further embodiments 1-25, the present disclosure comprises:
[0243] 1. In embodiment 1, provided is a compound of formula (I), (IA), (IB) or (IC) as described above in the Summary of the Invention, or a pharmaceutically acceptable salt thereof.
[0244] In a first sub-embodiment of embodiment 1, the compound is a compound of formula (I) or a pharmaceutically acceptable salt thereof. In a second sub-embodiment of embodiment 1, the compound is a compound of formula (IA) or a pharmaceutically acceptable salt thereof. In a third sub-embodiment of embodiment 1, the compound is a compound of formula (IB) or a pharmaceutically acceptable salt thereof. In a fourth sub-embodiment of embodiment 1, the compound is a compound of formula (IC) or a pharmaceutically acceptable salt thereof.
[0245] 2. In embodiment 2, the compound or pharmaceutically acceptable salt thereof as described in any one of embodiment 1 and the sub-embodiments contained in embodiment 1, wherein the compound has the structure of formula (II): (i.e., Z 1 is a group of formula (a)
[0246]
[0247] 3. In embodiment 3, the compound or pharmaceutically acceptable salt thereof as described in any one of embodiments 1 and 2 and the sub-embodiments contained therein, wherein the compound has the structure of formula (IIA):
[0248]
[0249] 4. In embodiment 5, the compound or pharmaceutically acceptable salt thereof as described in any one of embodiment 1 and the sub-embodiments contained in embodiment 1, wherein the compound has the structure of formula (III): (i.e., Z 1 is a group of formula (b)
[0250]
[0251] 5. In embodiment 5, the compound or pharmaceutically acceptable salt thereof as described in any one of embodiments 1 and 4 and the sub-embodiments contained therein, wherein the compound has the structure of formula (IIIA):
[0252]
[0253] 6. In Embodiment 6, a compound or pharmaceutically acceptable salt thereof as described in any one of Embodiments 1 to 5 and sub-embodiments contained therein, wherein E is O and A is CH2 or a bond.
[0254] 7. In Embodiment 7, a compound or pharmaceutically acceptable salt thereof as described in any one of Embodiments 1 to 5 and subembodiments contained therein, wherein E is O and A is a bond.
[0255] 8. In embodiment 8, the compound or pharmaceutically acceptable salt thereof as described in embodiment 3 and the sub-embodiments contained therein has the structure of formula (IIB):
[0256]
[0257] 9. In embodiment 9, the compound or pharmaceutically acceptable salt thereof as described in embodiment 5 and the sub-embodiments contained therein has the structure of formula (IIIB):
[0258]
[0259] 10. In embodiment 10, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 9 and the sub-embodiments contained therein, wherein Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl and heteroaryl are optionally substituted with one to three halo), -O(alk) y R a 、-O(alk)OR b 、-S(O)2R d 、-OC(O)NR i R j 、-S(O)2NR n R o 、-NR p R q or -YM (wherein Y is a bond, O or SO2, and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl or heteroaryl, wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are replaced by -O(alk) y R a 、-O(alk)OR b 、-S(O)2R d or -NR p R q substituted, and the cycloalkyl, heterocyclyl and heteroaryl are optionally further substituted with 1 to 3 halo).
[0260] 11. In embodiment 11, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 9 and the sub-embodiments contained therein, wherein Z is -YM (wherein Y is a bond or O, and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl or heteroaryl, wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are replaced by -O(alk)OR b 、-S(O)2R d 、-NR e C(O)R f 、-NR g S02R h 、-OC(O)NR i R j 、-C(O)NR k R m or -S(O)2NR n R o replace.
[0261] 12. In embodiment 12, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 9 and the sub-embodiments contained therein, wherein Z is -YM (wherein Y is a bond, and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl or heteroaryl, wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are replaced by -OR a Substitution, where R a is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl or optionally substituted heteroaryl.
[0262] 13. In embodiment 13, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 9 and the sub-embodiments contained therein, wherein Z is -YM (wherein Y is a bond, and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl or heteroaryl, wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are replaced by -O(alk)OR a Substitution, where R a is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl or optionally substituted heteroaryl.
[0263] 14. In embodiment 14, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 9 and sub-embodiments contained therein, wherein Z is -OR a , where R a is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl or optionally substituted heteroaryl.
[0264] 15. In embodiment 15, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 9 and sub-embodiments contained therein, wherein Z is -O(alk)OR b , where R b is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl or optionally substituted heteroaryl.
[0265] 16. In embodiment 16, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 9 and the sub-embodiments contained therein, wherein Z is hydrogen, fluoro, cyano, methoxy, hydroxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, oxetan-3-yloxy, methoxymethoxy, methoxyethoxy, methylsulfonyl, aminocarbonyloxy, pyrazol-1-yl, hydroxymethyl, methoxymethyl, ethoxymethyl, methoxymethoxymethyl, ethoxymethoxymethyl, methoxyethoxymethyl, cyclopropylmethoxy or oxetan-3-ylmethoxymethyl.
[0266] 17. In embodiment 17, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 9 and sub-embodiments contained therein, wherein Z is methoxymethoxy, methoxyethoxy, methoxymethyl, methoxymethoxymethyl, ethoxymethoxymethyl, methoxyethoxymethyl, cyclopropylmethoxy or oxetan-3-ylmethoxymethyl.
[0267] 18. In embodiment 18, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 9 and sub-embodiments contained therein, wherein Z is methoxymethyl, methoxymethoxymethyl, ethoxymethoxymethyl, methoxyethoxymethyl, cyclopropylmethoxymethyl or oxetan-3-ylmethoxymethyl.
[0268] 19. In embodiment 18, a compound or pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 9 and subembodiments contained therein, wherein Z is fluoro.
[0269] 20. In embodiment 20, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 19 and sub-embodiments contained therein, wherein R 9 and R 13 For hydrogen.
[0270] 21. In embodiment 21, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 19 and sub-embodiments contained therein, wherein R 9 and R 13 It is amino.
[0271] 21A. In embodiment 21A, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 19 and sub-embodiments contained therein, wherein R 9 and R 13 It is methyl.
[0272] 21B. In embodiment 21B, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 19 and sub-embodiments contained therein, wherein R 9 and R 13 are independently hydrogen, alkyl or amino.
[0273] 22. In embodiment 22, a compound or pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 21B and subembodiments contained therein, wherein L is S.
[0274] 23. In embodiment 23, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 21B and subembodiments contained therein, wherein L is S(O) or S(O)2.
[0275] 24. In embodiment 24, a compound or pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 21B and subembodiments contained therein, wherein L is a bond.
[0276] 25. In embodiment 25, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 24 and the sub-embodiments contained therein, wherein L is CR 7 R 8 , where R 5 and R 6 is independently hydrogen or alkyl. In one subembodiment of Embodiment 10, L is CH2. In another subembodiment of Embodiment 10, L is C(CH3)2.
[0277] 26. In embodiment 26, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 3, 6-8 and 10 to 25 and sub-embodiments contained therein, wherein R 10 In a first sub-embodiment of embodiment 11, R 10 It is hydroxymethyl.
[0278] 27. In embodiment 27, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 3, 6-8 and 10 to 25 and sub-embodiments contained therein, wherein R 10 In a first sub-embodiment of Embodiment 27, R 2 It is methylsulfonyl or ethylsulfonyl.
[0279] 27A. In embodiment 27A, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 3, 6-8 and 10 to 25 and sub-embodiments contained therein, wherein R 10 For hydrogen.
[0280] 28. In embodiment 28, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 11 to 25 and sub-embodiments contained therein, wherein R 14 For hydrogen.
[0281] 29. In embodiment 29, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 11 to 25 and sub-embodiments contained therein, wherein R 14 In a first sub-embodiment, R 14 It is methyl.
[0282] 30. In embodiment 30, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 29 and sub-embodiments contained therein, wherein:
[0283] R 11 and R 15 is selected from amino and aminoalkyl; and R 12 and R 16 is selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy and cyano. In a subembodiment of embodiment 30, R 11 and R 15 is aminomethyl, and R 12 and R 16 It is methyl.
[0284] 31. In embodiment 31, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 29 and sub-embodiments contained therein, wherein: R 11 and R 12 and R 15 and R 16 Together with the carbon atom to which they are attached, they form a ring of formula (c):
[0285]
[0286] In a first sub-embodiment of Embodiment 31, ring (c) is:
[0287]
[0288] In a second sub-embodiment of Embodiment 31, ring (c) is
[0289] 32. In embodiment 32, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 29 and sub-embodiments contained therein, wherein R 11 and R 12 and R 15 and R 16 Together with the carbon atom to which they are attached, they form a ring of formula (c):
[0290]
[0291] In a first embodiment of embodiment 32, ring (c) is:
[0292]
[0293] 33. In embodiment 33, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 32 and sub-embodiments contained therein, wherein R 1 , R 2 , R 3 and R 4 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano or hydroxy, amino. 1 , R 2 , R 3 and R 4 One of them is hydrogen, and R 1 , R 2 , R 3 and R 4 The remaining three of R are independently selected from hydrogen, methyl, fluoro, methoxy, hydroxyl or amino. In a second sub-embodiment 33, R 1 , R 2 , R 3 and R 4 Two or three of them are hydrogen, and R 1 , R 2 , R 3 and R 4 The remaining one or two of R are independently selected from hydrogen, methyl, fluoro, methoxy, hydroxyl or amino. 1 , R 2 , R 3 and R 4 For hydrogen.
[0294] 34. In embodiment 34, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 32 and sub-embodiments contained therein, wherein R 5 is hydrogen, alkyl, halo or amino, and R 6 is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy or cyano.
[0295] 35. In embodiment 35, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 32 and sub-embodiments contained therein, wherein R 5 is hydrogen, chloro, methyl or amino, and R 6 is hydrogen, methyl, chloro, trifluoromethyl, trifluoromethoxy or methoxy.
[0296] 36. In embodiment 34, the compound or pharmaceutically acceptable salt thereof as described in any one of embodiments 1 to 32 and sub-embodiments contained therein, R 5 and R 6 For hydrogen.
[0297] It should be understood that the above-described embodiments include all combinations of the embodiments and sub-embodiments listed herein. For example, the ring of formula (c) listed in embodiment 31 and the first and second sub-embodiments of embodiment 31 can be independently combined with one or more of embodiments 1-30 and 32-36 and / or the sub-embodiments contained therein.
[0298] Additional embodiments include the following embodiments 37-65:
[0299] 37. A compound of formula (I') or a pharmaceutically acceptable salt thereof:
[0300]
[0301] in:
[0302] A is R a , R b and / or R c Replaced Where R a and R b are independently selected from hydrogen, alkyl, amino, cycloalkyl, olefinic, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, alkoxyalkyl, cyano, aminoalkyl, carboxyl, and alkoxycarbonyl, and R cwherein R is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -S(O)R, S(O)2R, -C(O)R, -OR', -NR'C(O)R, -NR'S02R, -OC(O)NR'R", -C(O)NR'R", -S(O)2NR'R", -NR'R", or -NR'C(O)C(O)R, wherein R is alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, any wherein R′ and R″ are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl, or R′ and R″ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclyl; or when R c and R a When attached to the same carbon of a cycloalkyl or fused heteroaryl ring, then R c and R a together with the carbon atom to which they are attached, form a cycloalkylene or heterocyclylene group;
[0303] Or A has structure (d):
[0304]
[0305] in:
[0306] t is 0, 1, or 2;
[0307] Ring E is a 4- to 7-membered heterocyclic ring containing 1 or 2 heteroatoms independently selected from O, N, S and SO2, wherein the remaining atoms are carbon; and W is O, CH2 or N; the above structure is replaced by R a , R b and / or R c Substitution, where R a and R b are independently selected from hydrogen, amino, alkyl, olefinic, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxyl, and alkoxycarbonyl, and R c is hydrogen, alkyl, halo, hydroxy or alkoxy; or when R a and R c When attached to the same carbon atom, R a and R c Together with the carbon atom to which they are attached, they form a cycloalkylene or heterocyclylene group,
[0308] Q 1 N or CR 1 , where R1 is hydrogen or deuterium;
[0309] Q 2 N or CH or CD;
[0310] R 2 is alkyl, halo, hydroxy, hydroxyalkyl, -CD2OH, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, aminocarbonyl, carboxyl, cyano or alkoxycarbonyl;
[0311] L is a bond, O, S, S(O), S(O)2 or CR 5 R 6 , where R 5 and R 6 are independently hydrogen or alkyl; and
[0312] is a ring of formula (a) or (b):
[0313]
[0314] in:
[0315] m is 0, 1 or 2;
[0316] n is 0, 1 or 2, wherein when n is 2, one of the CH2 can be replaced by O, S or SO2; provided that m+n is 1, 2 or 3;
[0317] k is 0, 1, or 2;
[0318] z is 0, 1, or 2;
[0319] Each R d are independently hydrogen, alkyl or halogen;
[0320] R e and R e1 are independently hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano or oxo; or
[0321] When R e and R e1 When attached to the same carbon atom, R e and R e1 together with the carbon atom to which they are attached, form a cycloalkylene or heterocyclylene group;
[0322] R f and R g are independently hydrogen, alkyl or haloalkyl;
[0323] Each R h are independently alkyl, halo, haloalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxy, cyano or oxo; or
[0324] When an R h connected to carbon 2 or 3 of the piperidine (b) ring and the second R h When the nitrogen atom is at position 1 and connected to carbon 5 or 6 of the piperidine (b) ring, the first and second R h Combine to form an alkylene chain;
[0325] Ring D is phenyl or a 5- or 6-membered heteroaryl ring comprising X and X 1 contains one to three heteroatoms independently selected from N, O and S, and ring D may be optionally substituted with one or two groups independently selected from alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxyl, cycloalkyl, heterocyclyl, heteroaryl and acylamino;
[0326] X and X 1 are independently N or C, provided that X and X 1 Only one of can be N;
[0327] R 3 is amino or aminoalkyl;
[0328] R 4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heterocyclylalkyl, cycloalkylalkyl, heterocyclylalkyl, 5- or 6-membered heteroaryl, or 4- to 6-membered heterocyclyl, wherein the heteroaryl or heterocyclyl itself or as part of the arylalkyl or heteroarylalkyl is replaced by R i and / or R j Replacement, R i and R j is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, amino, aminoalkyl, alkylsulfoxide or alkylsulfonyl; or
[0329] R 3 and R 4 Together with the carbon atom to which they are attached, they form a ring of formula (c):
[0330]
[0331] in:
[0332] m1 is 0, 1 or 2;
[0333] n1 is 0, 1 or 2; the condition is that m1+n1 is 1, 2 or 3;
[0334] R k and R mis independently hydrogen, alkyl or haloalkyl; one of Y and Z is CH2, O, S, S(O), S(O)2 or NH; and the other of X and Y is CH2; and wherein ring (c) is R n and / or R o Replacement, R n and R o is independently selected from hydrogen, alkyl, olefinic, alkenyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, heterocyclyl, and heteroaryl; or
[0335] When R n and R o When attached to the same carbon atom, R n and R o Together with the carbon atom to which they are attached they form a cycloalkylene or heterocyclylene.
[0336] 38. The compound according to embodiment 37 or a pharmaceutically acceptable salt thereof, wherein the compound has the structure of formula (I'A):
[0337]
[0338] in:
[0339] A is R a , R b and / or R c Replaced Where R a and R b are independently selected from hydrogen, alkyl, amino, cycloalkyl, olefinic, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxyl, and alkoxycarbonyl, and R c is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -S(O)R, S(O)2R, -C(O)R, -NR'C(O)R, -NR'S02R, -C(O)NR'R", -S(O)2NR'R", -NR'R", or -NR'C(O)C(O)R, wherein R is alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl , optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl, and R′ and R″ are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl, or R′ and R″ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclyl; or when R cand R a When attached to the same carbon of a cycloalkyl or fused heteroaryl ring, then R c and R a together with the carbon atom to which they are attached, form a cycloalkylene or heterocyclylene group;
[0340] A has the structure (d):
[0341]
[0342]
[0343] in:
[0344] t is 0, 1, or 2;
[0345] Ring E is a 4- to 7-membered heterocyclic ring containing 1 or 2 heteroatoms independently selected from O, N, S and SO2, wherein the remaining atoms are carbon; and W is O, CH2 or N; the above structure is optionally replaced by R a , R b and / or R c Substitution, where R a and R b are independently selected from hydrogen, amino, alkyl, olefinic, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxyl, and alkoxycarbonyl, and R c is hydrogen, alkyl, halo, hydroxy or alkoxy; or when R a and R c When attached to the same carbon atom, R a and R c together with the carbon atom to which they are attached, form a cycloalkylene or heterocyclylene group;
[0346] Q 1 N or CR 1 , where R 1 is hydrogen or deuterium;
[0347] Q 2 N or CH or CD;
[0348] R 2 is alkyl, halo, hydroxy, hydroxyalkyl, -CD2OH, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, aminocarbonyl, carboxyl, cyano or alkoxycarbonyl;
[0349] L is a bond, O, S, S(O), S(O)2 or CR 5 R 6 , where R 5 and R 6 are independently hydrogen or alkyl; and
[0350] is a ring of formula (a) or (b):
[0351]
[0352] in:
[0353] m is 0, 1 or 2;
[0354] n is 0, 1 or 2; provided that m+n is 1, 2 or 3;
[0355] k is 0, 1, or 2;
[0356] z is 0, 1, or 2;
[0357] Each R d are independently hydrogen, alkyl or halogen;
[0358] R e is hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano or oxo;
[0359] R f and R g are independently hydrogen, alkyl or haloalkyl;
[0360] Each R h are independently alkyl, halo, haloalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxy, cyano or oxo; or
[0361] When an R h connected to carbon 2 or 3 of the piperidine (b) ring and the second R h When the nitrogen atom is at position 1 and connected to carbon 5 or 6 of the piperidine (b) ring, the first and second R h Combine to form an alkylene chain;
[0362] Ring D is phenyl or a 5- or 6-membered heteroaryl ring comprising X and X 1 contains one to three heteroatoms independently selected from N, O and S, and ring D may be optionally substituted by one or two groups independently selected from alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxyl, cycloalkyl, heterocyclyl, heteroaryl and acylamino;
[0363] X and X 1 are independently N or C, provided that X and X 1 Only one of can be N;
[0364] R 3 is amino or aminoalkyl;
[0365] R 4is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heterocyclylalkyl, cycloalkylalkyl, heterocyclylalkyl, 5- or 6-membered heteroaryl, or 4- to 6-membered heterocyclyl, wherein the heteroaryl or heterocyclyl itself or as part of the aralkyl or heteroaralkyl group is replaced by R i and / or R j Replacement, R i and R j is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, amino, aminoalkyl, alkylsulfoxide or alkylsulfonyl; or
[0366] R 3 and R 4 Together with the carbon atom to which they are attached, they form a ring of formula (c):
[0367]
[0368] in:
[0369] m1 is 0, 1 or 2;
[0370] n1 is 0, 1 or 2; the condition is that m1+n1 is 1, 2 or 3;
[0371] R k and R m are independently hydrogen, alkyl or haloalkyl;
[0372] One of Y and Z is CH2, O, S, S(O), S(O)2 or NH; and the other of X and Y is CH2; and wherein ring (c) is R n and / or R o Replacement, R n and R o Independently selected from hydrogen, alkyl, olefinic, alkenyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, heterocyclyl, and heteroaryl.
[0373] 39. A compound of formula (I'B) or a pharmaceutically acceptable salt thereof:
[0374]
[0375] in:
[0376] A is R a , R b and / or R c Replaced Where R a and R bare independently selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxyl and alkoxycarbonyl, and R c wherein R is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -S(O)R, S(O)2R, -C(O)R, -NR'C(O)R, -NR'S02R, -C(O)NR'R", -S(O)2NR'R", -NR'R", or -NR'C(O)C(O)R, wherein R is alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl wherein R′ and R″ are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl, or R′ and R″ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclyl;
[0377] Q 1 N or CR 1 , where R 1 is hydrogen or deuterium;
[0378] Q 2 N or CH or CD;
[0379] R 2 is alkyl, halo, hydroxy, hydroxyalkyl, -CD2OH, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, aminocarbonyl, carboxyl, cyano or alkoxycarbonyl;
[0380] L is a bond, O, S, S(O), S(O)2 or CR 5 R 6 , where R 5 and R 6 are independently hydrogen or alkyl; and
[0381] is a ring of formula (a) or (b):
[0382]
[0383] in:
[0384] m is 0, 1 or 2;
[0385] n is 0, 1 or 2; provided that m+n is 1, 2 or 3;
[0386] k is 0, 1, or 2;
[0387] z is 0, 1, or 2;
[0388] Each R d are independently hydrogen, alkyl or halogen;
[0389] R e is hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano or oxo;
[0390] R f and R g are independently hydrogen, alkyl or haloalkyl;
[0391] Each R h are independently alkyl, halo, haloalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxy, cyano or oxo; or
[0392] When an R h connected to carbon 2 or 3 of the piperidine (b) ring and the second R h When the nitrogen atom is at position 1 and connected to carbon 5 or 6 of the piperidine (b) ring, the first and second R h Combine to form an alkylene chain;
[0393] Ring D is phenyl or a 5- or 6-membered heteroaryl ring comprising X and X 1 contains one to three heteroatoms independently selected from N, O and S, and ring D may be optionally substituted by one or two groups independently selected from alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxyl, cycloalkyl, heterocyclyl, heteroaryl and acylamino;
[0394] X and X 1 are independently N or C, provided that X and X 1 Only one of can be N;
[0395] R 3 is amino or aminoalkyl;
[0396] R 4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heterocyclylalkyl, cycloalkylalkyl, heterocyclylalkyl, 5- or 6-membered heteroaryl, or 4- to 6-membered heterocyclyl, wherein the heteroaryl or heterocyclyl itself or as part of the aralkyl or heteroaralkyl group is replaced by R i and / or R j Replacement, R i and R j is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, amino, aminoalkyl, alkylsulfoxide or alkylsulfonyl; or
[0397] R 3 and R 4 Together with the carbon atom to which they are attached, they form a ring of formula (c):
[0398]
[0399] in:
[0400] m1 is 0, 1 or 2;
[0401] n1 is 0, 1 or 2; the condition is that m1+n1 is 1, 2 or 3;
[0402] R k and R m are independently hydrogen, alkyl or haloalkyl;
[0403] One of Y and Z is CH2, O, S, S(O), S(O)2 or NH; and the other of X and Y is CH2; and wherein ring (c) is R n and / or R o Replacement, R n and R o are independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, heterocyclyl, and heteroaryl.
[0404] 40. A compound of formula (I'C) or a pharmaceutically acceptable salt thereof:
[0405]
[0406] in:
[0407] A is R a , R b and / or R c Replaced Where R a and R b are independently selected from hydrogen, alkyl, amino, cycloalkyl, olefinic, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxyl, and alkoxycarbonyl, and R c is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -NHCOR or -NR'R", wherein R is alkyl, cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heteroaralkyl, and R' and R" are independently hydrogen or alkyl, or R' and R" together with the nitrogen atom to which they are attached form an optionally substituted heterocyclyl; or when R c and R aWhen attached to the same carbon of a cycloalkyl or fused heteroaryl ring, then R c and R a together with the carbon atom to which they are attached, form a cycloalkylene or heterocyclylene group;
[0408] A has the structure (d):
[0409]
[0410] in:
[0411] t is 0, 1, or 2;
[0412] Ring E is a 4- to 7-membered heterocyclic ring containing 1 or 2 heteroatoms independently selected from O, N, S and SO2, wherein the remaining atoms are carbon; and W is O, CH2 or N; the above structure is optionally replaced by R a , R b and / or R c Substitution, where R a and R b are independently selected from hydrogen, amino, alkyl, olefinic, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxyl, and alkoxycarbonyl, and R c is hydrogen, alkyl, halo, hydroxy or alkoxy; or when R a and R c When attached to the same carbon atom, R a and R c Together with the carbon atom to which they are attached they form a cycloalkylene or heterocyclylene.
[0413] Q 1 N or CR 1 , where R 1 is hydrogen or deuterium;
[0414] Q 2 N, CH or CD;
[0415] R 2 is alkyl, halo, hydroxy, hydroxyalkyl, -CD2OH, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, aminocarbonyl, carboxyl, cyano or alkoxycarbonyl;
[0416] L is a bond, O, S, SO, SO2 or CR 5 R 6 , where R 5 and R 6 are independently hydrogen or alkyl; and
[0417] is a ring of formula (a) or (b):
[0418]
[0419] in:
[0420] m is 0, 1 or 2;
[0421] n is 0, 1 or 2; provided that m+n is 1, 2 or 3;
[0422] R d is hydrogen or alkyl;
[0423] R e is hydrogen, alkyl, halo or oxo;
[0424] R h are independently alkyl, halo, haloalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxy, cyano or oxo;
[0425] Ring D is phenyl or a 5- or 6-membered heteroaryl ring comprising X and X 1 contains one to three heteroatoms independently selected from N, O or S, and ring D may be optionally substituted with alkyl;
[0426] X and X 1 are independently N or C, provided that X and X 1 Only one of can be N;
[0427] R 3 is amino or aminoalkyl;
[0428] R 4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, 5- or 6-membered heteroaryl or 4- to 6-membered heterocyclic group, wherein the heteroaryl or heterocyclic group is replaced by R i and / or R j Replacement, R i and R j is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide or alkylsulfonyl; or
[0429] R 3 and R 4 Together with the carbon atom to which they are attached, they form a ring of formula (c):
[0430]
[0431] in:
[0432] m1 is 0, 1 or 2;
[0433] n1 is 0, 1 or 2; the condition is that m1+n1 is 1, 2 or 3;
[0434] One of Y and Z is CH2, O, S, SO, SO2 or NH; and the other of X and Y is CH2; and wherein ring (c) is R n and / or R o Replacement, R n and R o Independently selected from hydrogen, alkyl, olefinic, alkenyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl or oxo.
[0435] 41. A compound of formula (I'D) or a pharmaceutically acceptable salt thereof:
[0436]
[0437] in:
[0438] A is R a , R b and / or R c Replaced Where R a and R b are independently selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxyl and alkoxycarbonyl, and R c is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -NHCOR, or -NR'R", wherein R is alkyl, cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl, and R' and R" are independently hydrogen or alkyl, or R' and R" together with the nitrogen atom to which they are attached form an optionally substituted heterocyclyl;
[0439] Q 1 N or CR 1 , where R 1 is hydrogen or deuterium;
[0440] Q 2 N, CH or CD;
[0441] R 2 is alkyl, halo, hydroxy, hydroxyalkyl, -CD2OH, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, aminocarbonyl, carboxyl, cyano or alkoxycarbonyl;
[0442] L is a bond, O, S, SO, SO2 or CR 5 R 6 , where R 5 and R 6 are independently hydrogen or alkyl; and
[0443] is a ring of formula (a) or (b):
[0444]
[0445] in:
[0446] m is 0, 1 or 2;
[0447] n is 0, 1 or 2; provided that m+n is 1, 2 or 3;
[0448] R d is hydrogen or alkyl;
[0449] R e is hydrogen, alkyl, halo or oxo;
[0450] R h are independently alkyl, halo, haloalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxy, cyano or oxo;
[0451] Ring D is phenyl or a 5- or 6-membered heteroaryl ring comprising X and X 1 contains one to three heteroatoms independently selected from N, O or S, and ring D may be optionally substituted with alkyl;
[0452] X and X 1 are independently N or C, provided that X and X 1 Only one of can be N;
[0453] R 3 is amino or aminoalkyl;
[0454] R 4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, 5- or 6-membered heteroaryl or 4- to 6-membered heterocyclic group, wherein the heteroaryl or heterocyclic group is replaced by R i and / or R j Replacement, R i and R j is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide or alkylsulfonyl; or
[0455] R 3 and R 4 Together with the carbon atom to which they are attached, they form a ring of formula (c):
[0456]
[0457] in:
[0458] m1 is 0, 1 or 2;
[0459] n1 is 0, 1 or 2; the condition is that m1+n1 is 1, 2 or 3;
[0460] One of Y and Z is CH2, O, S, SO, SO2 or NH; and the other of X and Y is CH2; and wherein ring (c) is R n and / or R o Replacement, R n and R o are independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl or oxo.
[0461] 42. In embodiment 42, the compound of any one of embodiments 37 to 41 or a pharmaceutically acceptable salt thereof has a structure of formula (III'):
[0462]
[0463] 43. In embodiment 43, the compound of any one of embodiments 37 to 41 or a pharmaceutically acceptable salt thereof has the structure of formula (IV'):
[0464]
[0465] 44. In embodiment 44, the compound or pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 41 has the structure of formula (V') or (VI'):
[0466]
[0467] In one sub-embodiment of Embodiment 4, the compound or a pharmaceutically acceptable salt thereof has structure (V). In another sub-embodiment of Embodiment 4, the compound or a pharmaceutically acceptable salt thereof has structure (VI).
[0468] 45. In embodiment 45, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 43 and sub-embodiments contained therein, wherein R 1 For hydrogen.
[0469] 46. In embodiment 46, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 43 and sub-embodiments contained therein, wherein R 1 For deuterium.
[0470] 47. In embodiment 7, a compound or pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 46 and sub-embodiments contained therein, wherein L is S.
[0471] 48. In embodiment 8, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 46 and sub-embodiments contained therein, wherein L is S(O) or S(O)2.
[0472] 49. In embodiment 49, a compound or pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 46 and subembodiments contained therein, wherein L is a bond.
[0473] 50. In embodiment 50, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 46 and the sub-embodiments contained therein, wherein L is CR 5 R 6 , where R 5 and R 6 is independently hydrogen or alkyl. In one subembodiment of Embodiment 50, L is CH2. In another subembodiment of Embodiment 50, L is C(CH3)2.
[0474] 51. In embodiment 11, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 50 and sub-embodiments contained therein, wherein R 2 In a first sub-embodiment of Embodiment 51, R 2 It is hydroxymethyl.
[0475] 52. In embodiment 52, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 50 and sub-embodiments contained therein, wherein R 2 In a first sub-embodiment of Embodiment 52, R 2 It is methylsulfonyl or ethylsulfonyl.
[0476] 53. In embodiment 53, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 50 and sub-embodiments contained therein, wherein R 2 In a first sub-embodiment of Embodiment 53, R 2 is methylsulfoxide, ethylsulfoxide or isopropylsulfoxide. In a second sub-embodiment of embodiment 53, R 2 It is a methyl sulfoxide group.
[0477] 54. In embodiment 54, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 50 and sub-embodiments contained therein, wherein R 2 It is -CD2OH.
[0478] 55. In embodiment 55, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 50 and sub-embodiments contained therein, wherein R 2 is alkoxycarbonyl, aminosulfonyl or aminocarbonyl. In a first sub-embodiment of embodiment 55, R 2 is -S(O)2NH2. In a second sub-embodiment of Embodiment 55, R 2 In a third sub-embodiment of Embodiment 55, R 2 It is –C(O)CH3.
[0479] 56. In embodiment 16, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 50 and sub-embodiments contained therein, wherein R 2 It is hydroxyl.
[0480] 57. In embodiment 57, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 50 and sub-embodiments contained therein, wherein R 2 In a sub-embodiment of embodiment 17, R 2 For chlorination.
[0481] 58. In embodiment 58, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 57 and sub-embodiments contained therein, wherein:
[0482] is a ring of formula (a):
[0483]
[0484] in:
[0485] m is 0, 1 or 2;
[0486] n is 0, 1 or 2, wherein when n is 2, one of the CH2 can be replaced by O, S or SO2; provided that m+n is 1, 2 or 3;
[0487] k is 0, 1, or 2;
[0488] z is 0, 1, or 2;
[0489] Each R d are independently hydrogen, alkyl or halogen;
[0490] R e and R e1 are independently hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano or oxo; or
[0491] When Re and R e1 When attached to the same carbon atom, R e and R e1 Together with the carbon atom to which they are attached they form a cycloalkylene or heterocyclylene.
[0492] In a first embodiment of embodiment 58,
[0493] is a ring with the formula:
[0494]
[0495] 59. In embodiment 59, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 57 and sub-embodiments contained therein, wherein:
[0496] is a ring of formula (a):
[0497]
[0498] In a first sub-embodiment of embodiment 59, for:
[0499]
[0500] In a second sub-embodiment of embodiment 59, for:
[0501]
[0502] In a third sub-embodiment of embodiment 59, for
[0503] 60. In embodiment 60, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 57 and sub-embodiments contained therein, wherein for:
[0504] Preferably, wherein z is 1, and
[0505] Where R 3 is amino or aminoalkyl;
[0506] R 4 is alkyl, cycloalkylalkyl, halo, hydroxy, amino, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, 5- or 6-membered heteroaryl or 4- to 6-membered heterocyclic group, wherein the heteroaryl or heterocyclic group is replaced by R i and / or R j Replacement, Ri and R j is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide or alkylsulfonyl. In a sub-embodiment of embodiment 20, z is 0, R 3 is aminomethyl, and R 4 It is methyl.
[0507] 61. In embodiment 61, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 57 and sub-embodiments contained therein, wherein for
[0508] Preferably, wherein z is 1, and
[0509] Where R 3 and R 4 Together with the carbon atom to which they are attached, they form a ring of formula (c):
[0510]
[0511] in:
[0512] m1 is 0, 1 or 2;
[0513] n1 is 0, 1 or 2; the condition is that m1+n1 is 1, 2 or 3;
[0514] R k and R m are independently hydrogen, alkyl or haloalkyl;
[0515] One of Y and Z is CH2, O, S, S(O), S(O)2 or NH; and the other of X and Y is CH2; and wherein ring (c) is R n and / or R o Replacement, R n and R o is independently selected from hydrogen, alkyl, olefinic, alkenyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, heterocyclyl, and heteroaryl; or
[0516] When R n and R o When attached to the same carbon atom, R n and R o together with the carbon atom to which they are attached, form a cycloalkylene or heterocyclylene group;
[0517] In a first sub-embodiment of embodiment 61, for
[0518]
[0519] 62. In embodiment 62, a compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 57 and sub-embodiments contained therein, wherein for
[0520] Preferably, wherein z is 1, and
[0521] Where R 3 and R 4 Together with the carbon atom to which they are attached, they form a ring of formula (c):
[0522]
[0523] in:
[0524] m1 is 0, 1 or 2;
[0525] n1 is 0, 1 or 2; the condition is that m1+n1 is 1, 2 or 3;
[0526] R k and R m are independently hydrogen, alkyl or haloalkyl;
[0527] One of Y and Z is CH2, O, S, S(O), S(O)2 or NH; and the other of X and Y is CH2; and wherein ring (c) is R n and / or R o Replacement, R n and R o Independently selected from hydrogen, alkyl, olefinic, alkenyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, heterocyclyl, and heteroaryl.
[0528] In a first sub-embodiment of embodiment 62, for:
[0529]
[0530] In a second sub-embodiment of embodiment 62, for:
[0531]
[0532] In a third sub-embodiment of embodiment 62, for:
[0533]
[0534] In a fourth sub-embodiment of embodiment 62, for
[0535] 65. In embodiment 65, the compound or pharmaceutically acceptable salt thereof as described in any one of embodiments 37 to 60 and the sub-embodiments contained therein, R a and R b are independently selected from hydrogen, alkyl, amino, cycloalkyl, olefinic, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxyl, and alkoxycarbonyl, and R c wherein R is hydrogen, alkyl, halo, hydroxy, alkoxy, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -S(O)R, S(O)2R, -C(O)R, -NR'C(O)R, -NR'S02R, -C(O)NR'R", -S(O)2NR'R", -NR'R", or -NR'C(O)C(O)R, wherein R is alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl wherein R′ and R″ are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl, or R′ and R″ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclyl; or
[0536] When R c and R a When attached to the same carbon of a cycloalkyl or fused heteroaryl ring, then R c and R a Together with the carbon atom to which they are attached they form a cycloalkylene or heterocyclylene.
[0537] In a first sub-embodiment of embodiment 65, R a and R b are independently selected from hydrogen, alkyl, amino, cycloalkyl, olefinic, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxyl and cyano, and R c is hydrogen or -NR'R", wherein R' and R" are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl or optionally substituted heterocyclyl.
[0538] In a second sub-embodiment of embodiment 65, R a and R b are independently selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxyl and cyano, and R cis hydrogen or -NR'R", wherein R' and R" are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl or optionally substituted heterocyclyl.
[0539] In a third sub-embodiment of embodiment 65, R a and R b are independently selected from hydrogen, alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxyl and cyano, and R c is hydrogen or -NR'R", wherein R' and R" are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl or optionally substituted heterocyclyl.
[0540] In a fourth sub-embodiment of embodiment 65, R a and R b are independently selected from hydrogen, methyl, ethyl, methoxy, ethoxy, chloro, fluoro, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, hydroxyl or cyano, and R c For hydrogen.
[0541] In a fifth sub-embodiment of Embodiment 65, and in the first sub-embodiment therein, Ring A has structure (d):
[0542]
[0543] in:
[0544] t is 0, 1, or 2;
[0545] Ring E is a 4- to 7-membered heterocyclic ring containing 1 or 2 heteroatoms independently selected from O, N, S and SO2, wherein the remaining atoms are carbon; and W is O, CH2 or N; the above structure is replaced by R a , R b and / or R c Substitution, where R a and R b are independently selected from hydrogen, amino, alkyl, olefinic, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, aminoalkyl, carboxyl, and alkoxycarbonyl, and R c is hydrogen, alkyl, halo, hydroxy or alkoxy; or
[0546] When R a and R c When attached to the same carbon atom, R a and R c Together with the carbon atom to which they are attached they form a cycloalkylene or heterocyclylene.
[0547] In a first embodiment of the fifth subembodiment, Ring A is In a second embodiment of the fourth subembodiment, Ring A is:
[0548]
[0549] In a second embodiment of the fifth subembodiment, Ring A is:
[0550]
[0551] In a sixth subembodiment of embodiment 65, Ring A is:
[0552]
[0553]
[0554] It should be understood that the above-described embodiments 37 to 65 include all combinations of the embodiments and sub-embodiments listed herein. For example, the ring A listed in the fifth sub-embodiment of embodiment 65 can be independently combined with one or more of embodiments 35 to 64 and / or the sub-embodiments contained therein.
[0555] Additional embodiments include Embodiments 66 to 112 below.
[0556] 66. A compound of formula (I) or a pharmaceutically acceptable salt thereof:
[0557]
[0558] in:
[0559] A and E are independently selected from a bond, CH2, O, NH, S and S(O)2;
[0560] Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl and heteroaryl are optionally substituted with one to three halo), -O(alk) y R a 、-O(alk)OR b 、-S(O)R c 、-S(O)2R d 、-NR e C(O)R f 、-NR g S02R h 、-OC(O)NR i R j 、-C(O)NR k R m 、-S(O)2NR n R o 、-NR p R q 、-NR rC(O)C(O)R s or -YM (wherein Y is a bond, O or SO2, and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl or heteroaryl, wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are replaced by -O(alk) y R a 、-O(alk)OR b 、-S(O)R c 、-S(O)2R d 、-NR e C(O)R f 、-NR g S02R h 、-OC(O)NR i R j 、-C(O)NR k R m 、-S(O)2NR n R o 、-NR p R q or -NR r C(O)C(O)R s substituted, and cycloalkyl, heterocyclyl and heteroaryl are optionally further substituted by 1 to 3 halo); wherein each y is 0 or 1, each alk is alkylene, and each R c , R d , R f , R h and R s is independently alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; and each R a , R b , R e , R g , R i , Rj, R k , R m , R n , R o , R p , R q , R r and R s R is independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; or, independently of one another, each R i and R j , R k and R m , Rn and R o and R p and R q together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl;
[0561] R 1 , R 2 , R 3 and R 4 independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, hydroxyalkyl, amino, and aminoalkyl;
[0562] Or, R 1 and R 2 and R 3 and R 4 of which, when attached to the same carbon, combine to form an oxo group, an olefinic group, a 3- to 6-membered cycloalkylene group, or a 4- to 6-membered optionally substituted heterocyclylene group;
[0563] R 5 and R 6 are independently selected from hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxyalkyl, amino and aminoalkyl, or wherein R 5 and R 6 is an optionally substituted heterocyclic group, and R 5 and R 6 the other of which is selected from the group consisting of hydrogen, alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, hydroxyalkyl, amino, and aminoalkyl;
[0564] L is a bond, O, S, S(O), S(O)2 or CR 7 R 8 , where R 7 and R 8 are independently hydrogen or alkyl;
[0565] Z 1 A group of formula (a) or (b):
[0566]
[0567] in:
[0568] R 9 is hydrogen, alkyl, halo, hydroxy, amino or haloalkyl;
[0569] R 10 is hydrogen, alkyl, halo, hydroxy, hydroxyalkyl, -CD2OH, alkylsulfoxide, alkylsulfonyl, amino, aminoalkyl, aminosulfonyl, aminocarbonyl, carboxyl, cyano or alkoxycarbonyl;
[0570] R 13 is hydrogen, alkyl, halo, hydroxy, amino or haloalkyl;
[0571] R 14 is hydrogen, alkyl or haloalkyl;
[0572] R 11 and R 15 Selected from amino and aminoalkyl;
[0573] R 12 and R 16 is selected from the group consisting of hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl, and heteroaryl, wherein alkyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of alkyl, halo, haloalkyl, haloalkoxy, alkoxy, and cyano;
[0574] Or, R 11 and R 12 and R 15 and R 16 Together with the carbon atom to which they are attached, they form a ring of formula (c):
[0575]
[0576] in:
[0577] e is 0, 1, or 2;
[0578] k is 0, 1 or 2, provided that e+k is 1, 2 or 3;
[0579] q is 0, 1, 2 or 3;
[0580] R 17 and R 18 independently selected from hydrogen, alkyl, cycloalkyl and haloalkyl;
[0581] Each R 19 is independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, cyano, alkylsulfoxide, alkylsulfonyl, oxo, cycloalkyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or
[0582] When two R 19 When the groups are attached to the same carbon atom, the two R 19 The groups, together with the carbon atom to which they are attached, form a cycloalkylene or heterocyclylene group.
[0583] Ring D is absent or present; wherein:
[0584] (i) when ring D is absent, then one of Q and W is CH2, O, S, S(O), S(O)2 or NH; and the other of Q and W is CH2; and
[0585] (ii) when ring D is present, then Q and W are independently N or C, provided that only one of Q and W is N; and ring D is phenyl or a 5- or 6-membered heteroaryl ring containing from one to three heteroatoms independently selected from N, O and S, including Q and W, and ring D is optionally substituted with one or two substituents independently selected from alkyl, cycloalkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, carboxy and optionally substituted heterocyclyl.
[0586] 67. The compound or pharmaceutically acceptable salt thereof as described in Embodiment 66, wherein the compound has the structure of Formula (II):
[0587]
[0588]
[0589] 68. A compound or a pharmaceutically acceptable salt thereof as described in Embodiment 67 or 68, wherein the compound has the structure of Formula (IIA):
[0590]
[0591] 69. The compound or pharmaceutically acceptable salt thereof as described in Embodiment 66, wherein the compound has the structure of Formula (III):
[0592]
[0593] 70. The compound or pharmaceutically acceptable salt thereof according to embodiment 66 or 69, wherein the compound has the structure of formula (IIIA):
[0594]
[0595] 71. A compound as described in any one of embodiments 66 to 70, or a pharmaceutically acceptable salt thereof, wherein E is O and A is CH2 or a bond.
[0596] 72. A compound as described in any one of embodiments 66 to 70, or a pharmaceutically acceptable salt thereof, wherein E is O and A is a bond.
[0597] 73. The compound according to embodiment 68 or a pharmaceutically acceptable salt thereof, which has the structure of formula (IIB):
[0598]
[0599]
[0600] 74. The compound according to embodiment 70 or a pharmaceutically acceptable salt thereof, which has the structure of formula (IIIB):
[0601]
[0602] 75. A compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 66 to 74, wherein Z is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, cycloalkyl, heterocyclyl, heteroaryl (wherein cycloalkyl, heterocyclyl and heteroaryl are optionally substituted with one to three halo), -O(alk) y R a 、-O(alk)OR b 、-S(O)2R d 、-OC(O)NR i R j 、-S(O)2NR n R o 、-NR p R q or -YM (wherein Y is a bond, O or SO2, and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl or heteroaryl, wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are replaced by -O(alk) y R a 、-O(alk)OR b 、-S(O)2R d or -NR p R q substituted, and the cycloalkyl, heterocyclyl and heteroaryl are optionally further substituted with 1 to 3 halo).
[0603] 76. A compound as described in any one of embodiments 66 to 74, or a pharmaceutically acceptable salt thereof, wherein Z is -YM (wherein Y is a bond or O, and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl, or heteroaryl, wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl, and heteroaryl are replaced by -O(alk)OR b 、-S(O)2R d 、-NR e C(O)R f 、-NR g S02R h 、-OC(O)NR i R j 、-C(O)NR k R m or -S(O)2NR n R o replace.
[0604] 77. A compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 66 to 74, wherein Z is -YM (wherein Y is a bond and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl or heteroaryl, wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are replaced by -OR a Substitution, where R a is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl or optionally substituted heteroaryl.
[0605] 78. A compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 66 to 74, wherein Z is -YM (wherein Y is a bond and M is alkyl, haloalkyl, cycloalkyl, heterocyclyl or heteroaryl, wherein alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl are replaced by -O(alk)OR a Substitution, where R a is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl or optionally substituted heteroaryl.
[0606] 79. A compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 66 to 74, wherein Z is -OR a , where R a is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl or optionally substituted heteroaryl.
[0607] 80. A compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 66 to 74, wherein Z is -O(alk)OR b , where R b is alkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl or optionally substituted heteroaryl.
[0608] 81. A compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 66 to 74, wherein Z is hydrogen, fluoro, cyano, methoxy, hydroxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, oxetan-3-yloxy, methoxymethoxy, methoxyethoxy, methylsulfonyl, aminocarbonyloxy, pyrazol-1-yl, hydroxymethyl, methoxymethyl, ethoxymethyl, methoxymethoxymethyl, ethoxymethoxymethyl, methoxyethoxymethyl, cyclopropylmethoxy or oxetan-3-ylmethoxymethyl.
[0609] 82. A compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 66 to 74, wherein Z is methoxymethoxy, methoxyethoxy, methoxymethyl, methoxymethoxymethyl, ethoxymethoxymethyl, methoxyethoxymethyl, cyclopropylmethoxy or oxetan-3-ylmethoxymethyl.
[0610] 83. A compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 66 to 74, wherein Z is methoxymethyl, methoxymethoxymethyl, ethoxymethoxymethyl, methoxyethoxymethyl, cyclopropylmethoxymethyl or oxetan-3-ylmethoxymethyl.
[0611] 84. A compound as described in any one of embodiments 66 to 74, or a pharmaceutically acceptable salt thereof, wherein Z is fluoro.
[0612] 85. A compound as described in any one of embodiments 66 to 84, or a pharmaceutically acceptable salt thereof, wherein R 9 and R 13 For hydrogen.
[0613] 86. A compound as described in any one of embodiments 66 to 84, or a pharmaceutically acceptable salt thereof, wherein R 9 and R 13 It is amino.
[0614] 87. A compound as described in any one of embodiments 66 to 84, or a pharmaceutically acceptable salt thereof, wherein R 9 and R 13 It is amino.
[0615] 88. A compound as described in any one of embodiments 66 to 84, or a pharmaceutically acceptable salt thereof, wherein R 9 and R 13 It is methyl.
[0616] 89. A compound as described in any one of embodiments 66 to 84, or a pharmaceutically acceptable salt thereof, wherein R 9 and R 13 are independently hydrogen, alkyl or amino.
[0617] 90. A compound as described in any one of embodiments 66 to 89, or a pharmaceutically acceptable salt thereof, wherein L is S.
[0618] 91. A compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 66 to 89, wherein L is S(O) or S(O)2.
[0619] 92. A compound as described in any one of embodiments 66 to 89, or a pharmaceutically acceptable salt thereof, wherein L is a bond.
[0620] 93. A compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 66 to 89, wherein L is CR 7 R 8 , where R 5 and R 6 are independently hydrogen or alkyl.
[0621] 94. A compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 66 to 68, 71 to 73 and 75 to 93, wherein R 10 It is a hydroxyalkyl group.
[0622] 95. A compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 66 to 68, 71 to 73 and 75 to 93, wherein R 10 It is hydroxymethyl.
[0623] 96. A compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 66, 69 to 72, 74 to 93, wherein R 14 It is hydrogen or methyl.
[0624] 97. The compound of any one of embodiments 66 to 96, or a pharmaceutically acceptable salt thereof, wherein:
[0625] R 11 and R 15 is selected from amino and aminoalkyl; and R 12 and R 16 independently selected from hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkoxy and cyano.
[0626] 98. The compound or pharmaceutically acceptable salt thereof as described in embodiment 97, wherein R 11 and R 15 is aminomethyl, and R 12 and R 16 It is methyl.
[0627] 99. A compound or a pharmaceutically acceptable salt thereof as described in any one of embodiments 66 to 96, wherein R 11 and R 12 and R 15 and R 16 Together with the carbon atom to which they are attached, they form a ring of formula (c):
[0628]
[0629] 100. The compound of embodiment 97 or a pharmaceutically acceptable salt thereof, wherein the ring of formula (c) is:
[0630]
[0631] 101. A compound as described in any one of embodiments 66 to 96, or a pharmaceutically acceptable salt thereof, wherein R 11 and R 12 and R 15 and R 16 Together with the carbon atom to which they are attached, they form a ring of formula (c):
[0632]
[0633] 102. The compound of embodiment 101 or a pharmaceutically acceptable salt thereof, wherein ring (c) is:
[0634]
[0635] 103. A compound as described in any one of embodiments 66 to 102, or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 and R 4 Independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, cyano and hydroxy, amino.
[0636] 104. The compound or pharmaceutically acceptable salt thereof as described in embodiment 103, wherein R 1 , R 2 , R 3 and R 4 is hydrogen, and R 1 , R 2 , R 3 and R 4 The remaining three of are independently selected from hydrogen, methyl, fluoro, methoxy, hydroxy and amino.
[0637] 105. The compound or pharmaceutically acceptable salt thereof as described in embodiment 103, wherein R 1 , R 2 , R 3 and R 4 For hydrogen.
[0638] 106. A compound as described in any one of embodiments 66 to 105, or a pharmaceutically acceptable salt thereof, wherein R 5 is hydrogen, alkyl, halo or amino, and R 6 is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy or cyano.
[0639] 107. The compound or pharmaceutically acceptable salt thereof as described in embodiment 106, wherein R 5 and R 6 For hydrogen.
[0640] 108. A pharmaceutical composition comprising a compound as described in any one of embodiments 66 to 107 and a pharmaceutically acceptable excipient.
[0641] 109. A method for treating a disease treatable by inhibiting SHP2 in a patient, the method comprising administering to the patient, preferably a patient in need of such treatment, a therapeutically effective amount of a compound as described in any one of claims 66 to 107, or a pharmaceutically acceptable salt thereof, or the method comprising administering to the patient, preferably a patient in need of such treatment, a pharmaceutical composition comprising a compound as described in any one of embodiments 66 to 107, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0642] 110. The method of embodiment 109, wherein the disease is cancer.
[0643] 111. The method of embodiment 109, wherein the cancer is selected from lung cancer, gastric cancer, liver cancer, colon cancer, kidney cancer, breast cancer, pancreatic cancer, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, and acute myeloid leukemia.
[0644] 112. The method of embodiment 109, wherein the disease is selected from Noonan syndrome and Leopard syndrome.
[0645] General synthetic scheme
[0646] The compounds of the present disclosure can be prepared by the methods depicted in the reaction schemes shown below.
[0647] The starting materials and reagents used to prepare these compounds are available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Bachem (Torrance, Calif.) or Sigma (St. Louis, Mo.), or are prepared by methods known to those skilled in the art according to the methods described in the following references, such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplements (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry (John Wiley and Sons, Fourth Edition) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrations of some methods by which the disclosed compounds can be synthesized, and various modifications can be made to these schemes, and those skilled in the art will be inspired when reading this disclosure. If necessary, the starting materials and intermediates of the reaction and the final products can be separated and purified using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography, etc. Such materials can be characterized using conventional means, including physical constants and spectral data.
[0648] Unless otherwise specified, the reactions described herein occur at atmospheric pressure, in a temperature range from about -78°C to about 150°C, such as from about 0°C to about 125°C, and further such as about room temperature (or ambient temperature), for example about 20°C.
[0649] General synthetic scheme
[0650] Compounds of formula (I), (IA), (IB) or (IC) wherein L is S and the other groups are as defined in the Summary of the Invention can be prepared as illustrated and described in Scheme 1 below.
[0651] Solution 1
[0652]
[0653] In the presence of a transition metal catalyst (such as Pd2(dba)3) and xantphos, under standard coupling conditions, a compound of formula 1-a (wherein X 1 is a halogen, where Z, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 As defined in the Summary of the Invention or as a precursor thereof, and E and A are as defined in the Summary of the Invention) and a compound of Formula 1-d (wherein M 1 The compound of formula (I) is produced by coupling with a metal such as sodium or potassium. If the compound of formula 1-a is substituted with an amino group, a suitable protecting group (such as tert-butyl carbamate) can be used to protect the amino group before the coupling reaction. The amino protecting group is removed by methods well known in the art to provide a compound of formula (I), (IA), (IB) or (IC).
[0654] Alternatively, compounds of formula (I), (IA), (IB) or (IC) can be prepared by reacting a compound of formula 1-a with 3-mercaptopropionic acid ester under standard coupling conditions in the presence of a transition metal catalyst (such as Pd2(dba)3) and xantphos to provide a compound of formula 1-b, wherein R' is an alkyl group (such as 3-methylheptane). Treatment of the compound of formula 1-b with a base (such as potassium tert-butoxide, sodium tert-butoxide, sodium methoxide, etc.) provides a compound of formula 1-c (as a thiosalt), wherein M + is a metal ion, such as potassium or sodium. 2 or X 3 is halogen) provides compounds of formula (I), (IA), (IB) or (IC) wherein Z1 is a group of formula (a) or (b), respectively.
[0655] The compound of formula 1-a (wherein X 1 is halogen, E is O, and A, E, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 as defined in the Summary of the Invention or a precursor group thereof) can be prepared as illustrated and described in Methods 1 and 2 below.
[0656] Method (1):
[0657]
[0658] Under Mitsunobu conditions, for example, using diethyl azodicarboxylate and triphenylphosphine, a compound of formula 2-b (wherein R 5 and R 6 As defined in the Summary of the Invention or a precursor thereof) is coupled with an alcohol of Formula 2-a (wherein PG is a suitable amino protecting group, such as Boc) to provide a compound of Formula 2-c. Compounds of Formula 2-b are commercially available or they can be prepared by methods well known in the art. For example, 2-fluoropyridine-3-ol is commercially available. Compounds of Formula 2-a are commercially available or they can be prepared by methods well known in the art. For example, (S)-2-(hydroxymethyl)pyrrolidine-1-carboxylic acid tert-butyl ester, (R)-2-(hydroxymethyl)pyrrolidine-1-carboxylic acid tert-butyl ester, (2S,4S)-4-fluoro-2-(hydroxymethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester, (2S,4R)-4-fluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylic acid tert-butyl ester, (S)-4,4-difluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylic acid tert-butyl ester, (2S,4R)-2-(hydroxymethyl)-4-methoxypyrrolidine-1-carboxylic acid tert-butyl ester. tert-Butyl (2S,4S)-2-(hydroxymethyl)-4-methoxypyrrolidine-1-carboxylate, tert-butyl (S)-6-(hydroxymethyl)-5-azaspiro[2.4]heptane-5-carboxylate, tert-butyl (R)-3-(hydroxymethyl)morpholine-4-carboxylate, tert-butyl (S)-3-(hydroxymethyl)morpholine-4-carboxylate, tert-butyl (R)-2-(hydroxymethyl)azetidine-1-carboxylate, and tert-butyl (S)-2-(hydroxymethyl)azetidine-1-carboxylate are commercially available.
[0659] Removal of the amino protecting group provides a compound of formula 2-d. For example, the Boc group can be cleaved under acidic conditions (such as HCl in dioxane). Cyclization of compound 2-d with a base (such as K2CO3, sodium carbonate, etc.) provides a compound of formula 2-e. Lithiation of compound 2-e using an alkyl lithium (such as n-BuLi) followed by capture with iodine provides a compound of formula 1-a.
[0660] Method (2)
[0661]
[0662] Alternatively, a compound of formula 3-a (wherein X 1 is halogen, R 5 and R 6As defined in the Summary of the Invention) is coupled with an alcohol of Formula 2-a (wherein PG is an amino protecting group, such as Boc) to provide a compound of Formula 3-b. Compounds of Formula 3-a are commercially available or they can be prepared by methods well known in the art. For example, 2-fluoro-4-iodopyridin-3-ol is commercially available. Compound 3-c is converted to a compound of Formula 1-a as described in Scheme 1 above.
[0663] utility
[0664] Src homology-2 phosphatase (SHP2) is a protein tyrosine phosphatase encoded by the PTPN11 gene that contributes to a variety of cellular functions, including proliferation, differentiation, cell cycle maintenance, and migration. SHP2 is involved in signal transduction via the Ras-mitogen activated protein kinase, JAK-STAT, or phosphoinositide 3-kinase-AKT pathways. SHP2 mediates the activation of Erk1 and Erk2 (Erk1 / 2, Erk) MAP kinases through receptor tyrosine kinases such as ErbB1, ErbB2, and c-Met.
[0665] SHP2 has two N-terminal Src homology 2 domains (N-SH2 and C-SH2), a catalytic domain (PTP), and a C-terminal tail. The two SH2 domains control the subcellular localization and functional regulation of SHP2. The molecule exists in an inactive conformation and inhibits its own activity through a binding network involving residues from both the N-SH2 and PTP domains. In response to growth factor stimulation, SHP2 binds to specific tyrosine-phosphorylation sites on docking proteins (such as Gabl and Gab2) through its SH2 domain. This induces conformational changes, leading to SHP2 activation.
[0666] Mutations in PTPN11 have been identified in several human diseases, such as Noonan syndrome, Leopard syndrome, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, acute myeloid leukemia, and breast, lung, and colon cancers. SHP2 is an important downstream signaling molecule for a variety of receptor tyrosine kinases, including the receptor for platelet-derived growth factor (PDGF-R), the receptor for fibroblast growth factor (FGF-R), and the receptor for epidermal growth factor (EGF-R). SHP2 is also an important downstream signaling molecule for the activation of the mitogen-activated protein (MAP) kinase pathway, which can lead to cell transformation, a prerequisite for cancer development. Knockdown of SHP2 significantly inhibits cell growth in lung cancer cell lines with SHP2 mutations or EML4 / ALK translocations, as well as breast and esophageal cancers with EGFR amplification. SHP2 is also activated downstream of oncogenes in gastric cancer, anaplastic large cell lymphoma, and glioblastoma.
[0667] Noonan syndrome (NS) and Leopard syndrome (LS): Mutations in PTPN11 cause LS (multiple lentigenes), ECG conduction abnormalities, hypertelorism, pulmonary stenosis, genital anomalies, growth retardation, sensorineural hearing loss) and NS (congenital anomalies including heart defects, craniofacial malformations, and short stature). Both disorders are part of a family of autosomal dominant syndromes caused by germline mutations in components of the RASRAF / MEK / ERK mitogen-activated protein kinase pathway required for normal cell growth and differentiation. Dysregulation of this pathway has a profound impact, particularly on cardiac development, leading to a variety of abnormalities including valvuloseptal defects and / or hypertrophic cardiomyopathy (HCM). Perturbations in the MAPK signaling pathway have been shown to be critical for these disorders, and several candidate genes along this pathway have been identified in humans, including mutations in KRAS, NRAS, SOS1, RAF1, BRAF, MEK1, MEK2, SHOC2, and CBL. The most commonly mutated gene in NS and LS is PTPN11. Germline mutations in PTPN11 (SHP2) are found in -50% of NS cases and in almost all patients with LS who have some features of NS. For NS, Y62D and Y63C substitutions in the protein are essentially invariant and are among the most common mutations. Both mutations affect the catalytically inactive conformation of SHP2 without interfering with the binding of the phosphatase to its phosphorylation signaling partner.
[0668] Juvenile myelomonocytic leukemia (JMML):-Somatic mutations in PTPN11 (SHP2) occur in approximately 35% of patients with JMML, a childhood myeloproliferative disorder (MPD). These gain-of-function mutations are usually point mutations in the N-SH2 domain or the phosphatase domain, which prevent autoinhibition between the catalytic domain and the N-SH2 domain, resulting in SHP2 activity.
[0669] Acute Myeloid Leukemia: PTPN11 mutations have been identified in: -10% of pediatric acute leukemias, such as myelodysplastic syndrome (MDS); -7% of B-cell acute lymphoblastic leukemia (B-ALL); and -4% of acute myeloid leukemia (AML).
[0670] NS and leukemic mutations cause changes in amino acids located at the interface formed by N-SH2 and the PTP domain in the autoinhibitory SHP2 conformation, disrupting the inhibitory intramolecular interaction and leading to hypersensitivity of the catalytic domain.
[0671] SHP2 acts as a positive regulator in receptor tyrosine kinase (RTK) signaling. Cancers containing RTK alterations (EGFR amplified, Her2 amplified, FGFR amplified, Met 31"15, translocated / activated RTKs, i.e. ALK, BCR / ABL) include esophageal cancer, breast cancer, lung cancer, colon cancer, gastric cancer, glioma, head and neck cancer.
[0672] Esophageal cancer (or esophageal cancer) is a malignant tumor of the esophagus. There are multiple subtypes, mainly squamous cell carcinoma (<50%) and adenocarcinoma. There is a high rate of RTK expression in esophageal adenocarcinoma and squamous cell carcinoma. Therefore, the SHP2 inhibitor of the present invention can be used for innovative treatment strategies.
[0673] Breast cancer is the main type of cancer and the leading cause of death in women, with patients becoming resistant to existing drugs. There are four major subtypes of breast cancer, including luminal A, luminal B, Her2, and triple negative / basal. Triple negative breast cancer (TNBC) is an aggressive breast cancer lacking specific targeted therapies. Epidermal growth factor receptor I (EGFR) was found to be a promising target in TNBC. Inhibition of Her2 and EGFR by SHP2 may be a promising therapy for breast cancer.
[0674] Lung cancer - NSCLC is currently the leading cause of cancer-related mortality, accounting for approximately 85% of lung cancers (mainly adenocarcinomas and squamous cell carcinomas). Although cytotoxic chemotherapy remains an important part of treatment, patients are more likely to benefit from targeted therapies based on genetic alterations in tumors (such as EGFR and ALK).
[0675] Colon cancer - Approximately 30% to 50% of colorectal tumors are known to have mutated (abnormal) KRAS, and BRAF mutations occur in 10% to 15% of colorectal cancers. For a subset of patients whose colorectal tumors have been shown to overexpress EGFR, these patients show good clinical responses to anti-EGFR therapy.
[0676] Gastric cancer is one of the most common types of cancer. Abnormal expression of tyrosine kinases, as reflected by abnormal tyrosine phosphorylation in gastric cancer cells, is known in the art. Three receptor-tyrosine kinases: c-met (HGF receptor), FGF receptor 2, and erbB2 / neu are often amplified in gastric cancer. Therefore, disruption of different signaling pathways may promote the development of different types of gastric cancer.
[0677] Neuroblastoma is a pediatric tumor of the developing sympathetic nervous system, accounting for approximately 8% of childhood cancers. Genomic alterations in the anaplastic lymphoma kinase (ALK) gene have been hypothesized to contribute to the pathogenesis of neuroblastoma.
[0678] Squamous cell carcinoma of the head and neck (SCCHN). High levels of EGFR expression are associated with poor prognosis and resistance to radiotherapy in a variety of cancers, primarily in squamous cell carcinoma of the head and neck (SCCHN). Blockade of EGFR signaling leads to inhibition of receptor stimulation, cell proliferation, and reduced invasiveness and metastasis. Therefore, in SCCHN, EGFR is a major target for new anticancer therapies.
[0679] The present invention relates to compounds capable of inhibiting SHP2 activity. The present invention further provides methods for preparing compounds of the present invention and pharmaceutical formulations comprising such compounds. Another aspect of the present invention relates to a method for treating SHP2-mediated disorders, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of formula I as defined in the Summary of the Invention.
[0680] In certain embodiments, the present invention relates to the above-mentioned method, wherein the SHP2-mediated disorder is a cancer selected from the group consisting of but not limited to: JMML; AML; MDS; B-ALL; neuroblastoma; esophageal cancer; breast cancer; lung cancer; colon cancer; gastric cancer, head and neck cancer.
[0681] The compounds of the present invention may also be used to treat other diseases or conditions associated with abnormal activity of SHP2. Thus, as another aspect, the present invention relates to a method of treating a disorder selected from the group consisting of: NS; LS; JMML; AML; MDS; B-ALL; neuroblastoma; esophageal cancer; breast cancer; lung cancer; colon cancer; gastric cancer; head and neck cancer.
[0682] The SHP2 inhibitors of the present invention can be used in combination with another pharmacologically active compound or with two or more other pharmacologically active compounds, particularly in the treatment of cancer. For example, the compounds of the present invention as defined above, or pharmaceutically acceptable salts thereof, can be administered simultaneously, sequentially or separately in combination with one or more selected from the following agents: chemotherapeutic agents, such as mitotic inhibitors, such as taxanes, vinca alkaloids, paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine or vinflunine, and other anticancer agents, such as cisplatin, 5-fluorouracil or 5-fluoro-2-4 (1H, 3H) -pyrimidinedione (5FU), flutamide or gemcitabine. Such combinations can provide significant advantages in therapy, including synergistic activity.
[0683] In certain embodiments, the present invention relates to the aforementioned method, wherein said compound is administered parenterally.
[0684] In certain embodiments, the present invention relates to the aforementioned method, wherein said compound is administered intramuscularly, intravenously, subcutaneously, orally, pulmonary, intrathecally, topically or intranasally.
[0685] In certain embodiments, the present invention relates to the aforementioned method, wherein said compound is administered systemically.
[0686] In certain embodiments, the present invention relates to the aforementioned method, wherein the patient is a mammal.
[0687] In certain embodiments, the present invention relates to the aforementioned method, wherein the patient is a primate.
[0688] In certain embodiments, the present invention relates to the aforementioned method, wherein the patient is a human.
[0689] In another aspect, the present invention relates to a method of treating a SHP2-mediated disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount of a chemotherapeutic agent in combination with a therapeutically effective amount of a compound of formula I as defined in the Summary of the Invention. In addition to human cancers, inhibition of SHP2 also has therapeutic potential for the treatment of systemic lupus erythematosus, rheumatoid arthritis and fibrosis.
[0690] test
[0691] The compounds of Formula (I), (IA), (IB) and (IC) can be tested for SHP2 inhibitory activity using the in vitro assay described in Biological Example 1 below.
[0692] Pharmaceutical composition
[0693] In general, the compounds of the present disclosure will be administered in a therapeutically effective amount by any accepted mode of administration for medicaments of similar utility. The therapeutically effective amount of the disclosed compounds may be about 0.01 to about 500 mg / kg of patient body weight per day, which can be administered in a single dose or multiple doses. Suitable dosage levels may be about 0.1 to about 250 mg / kg per day; about 0.5 to about 100 mg / kg per day. Suitable dosage levels may be about 0.01 to about 250 mg / kg per day, about 0.05 to about 100 mg / kg per day, or about 0.1 to about 50 mg / kg per day. Within this range, the dosage may be about 0.05 to about 0.5 mg / kg per day, about 0.5 to about 5 mg / kg, or about 5 to about 50 mg / kg per day. For oral administration, these compositions can be provided in tablet form containing from about 1.0 mg to about 1000 mg of active ingredient, particularly about 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900 and 1000 mg of active ingredient. The actual amount of the compound of the present disclosure (i.e., active ingredient) will depend on a variety of factors, such as the severity of the disease to be treated, the age and relative health of the patient, the potency of the compound used, the route and form of administration, and other factors.
[0694] In general, the compounds of the present disclosure will be administered as pharmaceutical compositions by any of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository) or parenteral (e.g., intramuscular, intravenous or subcutaneous). The preferred mode of administration is oral using a convenient daily dosage regimen, which can be adjusted according to the degree of illness. The composition can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols or any other suitable composition.
[0695] The choice of formulation depends on factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules are preferred, including enteric-coated or sustained-release tablets, pills or capsules) and the bioavailability of the drug.
[0696] These compositions generally comprise a combination of a compound of the present disclosure and at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, facilitate administration, and do not adversely affect the therapeutic benefits of the compounds of the present disclosure. Such excipients may be any solid, liquid, semisolid, or in the case of aerosol compositions, a gaseous excipient commonly available to those skilled in the art.
[0697] Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glyceryl monostearate, sodium chloride, skimmed milk powder, etc. Liquid and semisolid excipients can be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers (particularly for injectable solutions) include water, saline, aqueous dextrose and ethylene glycol.
[0698] The compound can be formulated for parenteral administration by injection (e.g., by push injection or continuous infusion). The preparation for injection can be present in unit dosage form, for example, in an ampoule added with a preservative or in a multi-dose container. These compositions can take such forms, such as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain preparatons, such as suspending agents, stabilizers and / or dispersants. The preparation can be provided in unit dose or multi-dose containers (e.g., sealed ampoules and vials), and can be stored in powder form or under freeze drying (lyophilization), and only sterile liquid carriers (e.g., saline or sterile pyrogen-free water) need to be added before use. Temporary injection solutions and suspensions can be prepared by sterile powders, granules and tablets of previously described types.
[0699] Preparations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compound, which may include antioxidants, buffers, bacteriostats, and solutes that make the preparation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions, which may include suspending agents and thickening agents. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil or synthetic fatty acid esters such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may also contain a suitable stabilizer or an agent that increases the solubility of the compound to allow the preparation of a high concentration solution.
[0700] In addition to the aforementioned preparations, the compound can also be formulated as a long-acting preparation. Such long-acting preparations can be used by implantation (for example, subcutaneous or intramuscular) or by intramuscular injection. Therefore, for example, these compounds can be prepared together with suitable polymers or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or are formulated into slightly soluble (spraingly soluble) derivatives, for example, are formulated into slightly soluble salts.
[0701] For buccal or sublingual administration, these compositions may take the form of tablets, lozenges, pastilles or gels formulated in conventional manner.Such compositions may comprise the active ingredient in a flavored base such as sucrose and acacia or tragacanth.
[0702] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, eg, containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
[0703] Certain compounds disclosed herein can be administered topically, i.e., by non-systemic administration. This includes external application of a compound disclosed herein to the epidermis or oral cavity and dripping the compound into the ears, eyes, and nose, so that the compound does not enter the bloodstream in large quantities. In contrast, systemic administration refers to oral, intravenous, intraperitoneal, and intramuscular administration.
[0704] Preparations suitable for topical application include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation, such as gels, wipes, lotions, creams, ointments or pastes, and drops suitable for application to eyes, ears or noses. The active ingredient for topical application may account for, for example, 0.001% to 10% w / w (by weight) of the preparation. In certain embodiments, the active ingredient may account for up to 10% w / w. In other embodiments, it may account for less than 5% w / w. In certain embodiments, the active ingredient may account for 2% w / w to 5% w / w. In other embodiments, it may account for 0.1% to 1% w / w of the preparation.
[0705] For administration by inhalation, the compound can be conveniently delivered from an insufflator, a nebulizer pressurized package or other convenient means of delivering an aerosol spray. The pressurized package may contain a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve for delivering a metered amount. Alternatively, for administration by inhalation or insufflation, the compound according to the present disclosure may take the form of a dry powder composition, such as a powder mixture of a compound and a suitable powder matrix such as lactose or starch. The powder composition may be present in, for example, a capsule, cartridge, gelatin or blister package in unit dosage form, from which the powder may be administered by means of an insufflator or insufflator. Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by EW Martin, (Mack Publishing Company, 20th edition, 2000).
[0706] The level of the compound in the formulation can vary within the full range used by those skilled in the art. Typically, the formulation will contain about 0.01-99.99 wt.% of the compound of the present disclosure based on weight percentage (wt.%), with the balance being one or more suitable pharmaceutical excipients. For example, the compound is present at a level of about 1-80 wt%.
[0707] Combination and combination therapies
[0708] The compounds of the present disclosure can be used in combination with one or more other drugs to treat diseases or conditions to which the compounds of the present disclosure or other drugs may have effectiveness. Such one or more other drugs can be administered simultaneously or sequentially with the compound of formula (I) by a certain route and in its commonly used amount. When the compounds of the present disclosure are used simultaneously with one or more other drugs, a pharmaceutical composition in a unit dosage form containing such other drugs and the compound of formula (I) is preferred. However, combination therapy can also include the therapy of the compounds of the present disclosure and one or more other drugs administered with different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds of formula (I) and other active ingredients can be used at a lower dosage than when each is used alone.
[0709] Therefore, pharmaceutical compositions of formula (I) also include those containing one or more other drugs in addition to the compounds of formula (I).
[0710] The above combination includes not only a combination of a compound of the present disclosure and a kind of other drug, but also a combination with two or more other active drugs. Similarly, the compound of the present disclosure can be used in combination with other drugs for preventing, treating, controlling, improving the disease or condition in which the compound of the present disclosure is useful or reducing the risk of the disease or condition in which the compound of the present disclosure is useful. Such other drugs can be administered simultaneously or sequentially with the compound of formula (I) by a certain route and in its commonly used amount. When the compound of the present disclosure is used simultaneously with one or more other drugs, a pharmaceutical composition containing other drugs in addition to the compound of the present disclosure can be used. Therefore, the pharmaceutical composition of formula (I) also includes those containing one or more other active ingredients in addition to the compound of the present disclosure. The weight ratio of the compound of the present disclosure to the second active ingredient can vary and will depend on the effective dose of each component. Usually, respective effective doses will be used.
[0711] When a subject in need thereof suffers from cancer or is at risk of developing cancer, the subject may be treated with any combination of the disclosed compounds and one or more other anticancer agents, including but not limited to:
[0712] MAP kinase pathway (RAS / RAF / MEK / ERK) inhibitors, including but not limited to: Vemurafanib (PLX4032), Dabrafenib, Encorafenib (LGX818), TQ-B3233, XL-518 (Cas No.: 1029872-29-4, available from ACC Corp); trametinib, selumetinib (AZD6244), TQ-B3234, PD184352, PD325901, TAK-733, pimasertinib, binimetinib, refametinib, cobimetinib (GDC-0973), AZD8330, BVD-523, LTT462, Ulixertinib, AMG510, ARS853 and disclosed in patents WO 2016049565, WO 2016164675, WO 2016168540, WO 2017015562, WO 2017058728, WO 2017058768, WO Any RAS inhibitor in WO 2017058792, WO 2017058805, WO 2017058807, WO 2017058902, WO 2017058915, WO 2017070256, WO 2017087528, WO 2017100546, WO2017172979, WO 2017201161, WO 2018064510, WO 2018068017, WO 2018119183.
[0713] CSF1R inhibitors (PLX3397, LY3022855, etc.) and CSF1R antibodies (IMC-054, RG7155) TGFβ receptor kinase inhibitors, such as LY2157299.
[0714] BTK inhibitors, such as ibrutinib; BCR-ABL inhibitors: imatinib Nilotinib Hydrochloride; Nilotinib Dasatinib (BMS-345825); Bosutinib (SKI-606); Ponatinib (AP24534); Bafetinib (INNO406); Bafetinib (PHA-739358), AT9283 (CAS1133385-83-7); Saracatinib (AZD0530); and A / -[2-[(15,4R)-6-[[4-(cyclobutylamino)-5-(trifluoromethyl)-2-pyrimidinyl]amino]-l,2,3,4-tetrahydronaphthalene-l,4-imino-9-yl]-2-oxoethyl]-acetamide (PF-03814735, CAS 942487-16-3).
[0715] ALK inhibitor: PF-2341066 ( crizotinib); 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine; GSK1838705 A; CH5424802; ZYKADIA; TQ-B3139, TQ-B3101 PI3K inhibitor: 4-[2-(1H-indazol-4-yl)-6-[[4-(methylsulfonyl)piperazin-1-yl]methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine (also known as GDC 0941 and described in PCT Publication Nos. WO 09 / 036082 and WO 09 / 055730), 2-methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile (also known as BEZ 235 or NVP-BEZ 235 and described in PCT Publication No. WO 06 / 122806).
[0716] Vascular endothelial growth factor (VEGF) receptor inhibitors: Bevacizumab (developed by Genentech / Roche under the trademark AG013736, and described in PCT Publication No. WO 01 / 002369), Brivanib ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1 f][1,2,4]triazin-6-yloxy)propan-2-yl) 2-aminopropanoate, also known as BMS-582664), motesanib (N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridylmethyl)amino]-3-pyridinecarboxamide, and described in PCT Publication No. WO 02 / 066470), pasireotide (also known as SOM230, and described in PCT Publication No. WO 02 / 010192), sorafenib (trade name sold); AL-2846MET inhibitors, such as foretinib, carbozantinib or crizotinib.
[0717] FLT3 inhibitor - sunitinib malate (sold by Pfizer under the trade name sold); PKC412 (midostaurin); tanutinib, sorafenib, lestaurtinib, KW-2449, quizartinib (AC220), and crenolanib.
[0718] Epidermal growth factor receptor (EGFR) inhibitors: Gefitinib (trade name Sold by Boehringer Ingelheim under the trade name Sold by Bristol-Myers Squibb under the trade name Panitumumab (sold by Amgen under the trade name sell).
[0719] HER2 receptor inhibitors: Trastuzumab (trastuzumab) (manufactured by Genentech / Roche under the trademark ), neratinib (also known as HKI-272, (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide, and described in PCT Publication No. WO 05 / 028443), lapatinib or lapatinib ditosylate (marketed by GlaxoSmithKline under the trademark Trastuzumab emtansine (trastuzumab emtansine, trade name Kadcyla in the United States) - antibody-drug conjugate, which consists of the monoclonal antibody trastuzumab (Herceptin) linked to the cytotoxic agent maytansine (DM1);
[0720] HER dimerization inhibitor: Pertuzumab (developed by Genentech under the trademark sell).
[0721] CD20 antibody: Rituximab (developed by Genentech / Roche under the trademark and tositumomab (sold by GlaxoSmithKline under the trademark ofatumumab (sold by GlaxoSmithKline under the trademark sell).
[0722] Tyrosine kinase inhibitors: Erlotinib hydrochloride (available from Genentech / Roche under the trademark ), Linifanib (N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N'-(2-fluoro-5-methylphenyl)urea, also known as ABT869, available from Genentech), Sunitinib malate (available from Pfizer under the trade name ), bosutinib (4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile, also known as SKI-606 and described in U.S. Pat. No. 6,780,996), dasatinib (sold by Bristol-Myers Squibb under the trade name sold by GlaxoSmithKline), armala (also known as pazopanib, marketed by GlaxoSmithKline under the trade name ), imatinib, and imatinib mesylate (sold by Novartis under the trade name and sell).
[0723] DNA synthesis inhibitors: Capecitabine (available from Roche under the trademark Gemcitabine hydrochloride (sold under the trademark Nelarabine ((2R,3S,4R,5R)-2-(2-amino-6-methoxy-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, marketed by GlaxoSmithKline under the trade name and sell).
[0724] Antineoplastic agent: Oxaliplatin (sold by Sanofi-Aventis under the trade name Sold by and described in U.S. Pat. No. 4,169,846).
[0725] Human granulocyte colony stimulating factor (G-CSF) regulator: Filgrastim (available from Amgen under the trade name sell).
[0726] Immunomodulators: Afutuzumab (can be Pegfilgrastim (available from Amgen under the trade name Sold under the trade name Sold under the trade name thalidomide (sold under the tradename );
[0727] CD40 inhibitor: Dacetuzumab (also known as SGN-40 or huS2C6, available from Seattle Genetics, Inc); Pro-apoptotic receptor agonist (PARA): Dulanermin (also known as AMG-951, available from Amgen / Genentech).
[0728] Hedgehog antagonist: 2-chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)-benzamide (also known as GDC-0449 and described in PCT Publication No. WO 06 / 028958);
[0729] Phospholipase A2 inhibitors: Anagrelide (trade name sell);
[0730] BCL-2 inhibitor: 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide (also known as ABT-263 and described in PCT Publication No. WO 09 / 155386);
[0731] MCl-1 inhibitors: MIK665, S64315, AMG 397, and AZD5991;
[0732] Aromatase inhibitors: Exemestane (marketed by Pfizer under the trade name Sold by Novartis), letrozole (sold by Novartis under the trade name Sold under the trade name sell);
[0733] Topoisomerase I inhibitors: Irinotecan (marketed by Pfizer under the trademark Sold), topotecan hydrochloride (sold by GlaxoSmithKline under the trade name sell);
[0734] Topoisomerase II inhibitors: Etoposide (also known as VP-16 and etoposide phosphate, sold under the trade name and Teniposide (also known as VM-26, sold under the trade name sell);
[0735] mTOR inhibitors: Temsirolimus (sold by Pfizer under the trade name for sale), ridaforolimus (formally known as deferolimus, (lR,2R,4S)-4-[(2R)-2[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28Z,30S,32S,35R)-l,18-dihydroxy-19,30-dimethoxy-1 5,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04'9]hexatriacont-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphite, also known as AP23573 and MK8669, and described in PCT Publication No. WO 03 / 064383), everolimus (available from Novartis under the trade name sell);
[0736] Proteasome inhibitors, such as carfilzomib, MLN9708, delanzomib, or bortezomib;
[0737] BET inhibitors, such as INCB054329, OTX015, and CPI-0610; LSD1 inhibitors, such as GSK2979552 and INCB059872; HIF-2α inhibitors, such as PT2977 and PT2385;
[0738] Osteoclast bone resorption inhibitor: l-Hydroxy-2-imidazol-l-yl-phosphorylethyl)phosphonic acid monohydrate (sold by Novartis under the trade name CD33 antibody-drug conjugate: Gemtuzumab ozogamicin (sold by Pfizer / Wyeth under the trade name sell);
[0739] CD22 antibody drug conjugate: Inotuzumab ozogamicin (also known as CMC-544 and WAY-207294, available from Hangzhou Sage Chemical Co., Ltd.);
[0740] CD20 antibody-drug conjugate: Ibritumomab tiuxetan (trade name sell);
[0741] Somatostatin analogs: octreotide (also known as octreotide acetate, sold under the trade name and Sandostatin sell);
[0742] Synthetic interleukin-11 (IL-11): oprelvekin (marketed by Pfizer / Wyeth under the trade name sell);
[0743] Synthetic erythropoietin: Darbepoetin alfa (available from Amgen under the trade name sell);
[0744] Receptor activator of nuclear factor kappa B (RANK) inhibitor: Denosumab (sold by Amgen under the trade name sell);
[0745] Thrombopoietin mimetic peptide: Romiplostim (sold by Amgen under the trade name sell);
[0746] Cell growth stimulator: Palifermin (sold by Amgen under the trade name sell);
[0747] Anti-insulin-like growth factor-1 receptor (IGF-1R) antibodies: Figitumumab (also known as CP-751,871, available from ACC Corp), robatumumab (CAS No. 934235-44-6);
[0748] Anti-CS1 antibody: Elotuzumab (HuLuc63, CAS No. 915296-00-3);
[0749] CD52 antibody: Alemtuzumab (trade name sell);
[0750] Histone deacetylase inhibitors (HDIs): Vorinostat (marketed by Merck under the trade name sell);
[0751] Alkylating agent: Temozolomide (available from Schering-Plough / Merck under the trade name and dactinomycin (also known as actinomycin-D and sold under the trade name Sold under the trade names of Sold), hexamethylmelamine (also known as hexamethylmelamine (HMM), sold under the trade name Carmustine (sold under the trade name Bendamustine (sold under the trade name Sold under the trade name and Carboplatin (sold under the trade name Lomustine (also known as CCNU, sold under the trade name Cisplatin (also known as CDDP, sold under the trade name and -AQ), chlorambucil (sold under the trade name Sold under the trade name and ), dacarbazine (also known as DTIC, DIC and imidazole carboxamide, sold under the trade name Sold), hexamethylmelamine (also known as hexamethylmelamine (HMM), sold under the trade name Ifosfamide (sold under the trade name Sold under the trade name Sold under the trade name mechloroethamine, also known as nitrogen mustard, mustine, and mechloroethamine hydrochloride Sold under the trade name Sold under the trade names thiotepa (also known as thiophosphoramide, TESPA and TSPA, sold under the trade names Bacillus Calmette-Guerin (sold under the trade name and BCG), denileukin diftitox (sold under the trade name sell);
[0752] Anti-tumor antibiotics: doxorubicin (trade name and Sold under the trade name daunorubicin (also known as daunorubicin hydrochloride, daunomycin and daunorubicin hydrochloride, sold under the trade name Sold), daunorubicin liposomes (daunorubicin citrate liposomes, sold under the trade name ), mitoxantrone (also known as DHAD, sold under the trade name Sold), epirubicin (sold under the trade name Ellence TM Idarubicin (sold under the trade name Idamycin Sold), mitomycin C (trade name sell);
[0753] Antimicrotubule agents: Estramustine (trade name sell);
[0754] Cathepsin K inhibitor: Odanacatib (also known as MK-0822, N-(l-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-l-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide, available from Lanzhou Chon Chemicals, ACC Corp. and ChemieTek, and described in PCT Publication No. WO 03 / 075836); Epothilone B analog: Ixabepilone (available from Bristol-Myers Squibb under the trade name sell);
[0755] Heat shock protein (HSP) inhibitors: Tanespimycin (17-allylamino-17-demethoxygeldanamycin, also known as KOS-953 and 17-AAG, available from SIGMA and described in U.S. Pat. No. 4,261,989), NVP-HSP990, AUY922, AT13387, STA-9090, Debio 0932, KW-2478, XL888, CNF2024, TAS-116;
[0756] TpoR agonists: Eltrombopag (marketed by GlaxoSmithKline under the trade name and sell);
[0757] Anti-mitotic agents: Docetaxel (available from Sanofi-Aventis under the trade name Adrenal steroid inhibitors: aminoglutethimide (sold under the trade name sell);
[0758] Anti-androgen: Nilutamide (trade name and bicalutamide (sold under the trade name Flutamide (sold under the trade name Fulexin TM sell);
[0759] Androgens: Fluoxymesterone (trade name sell);
[0760] Proteasome inhibitors: Bortezomib (trade name sell);
[0761] CDK (CDK1, CDK2, CDK3, CDK5, CDK7, CDK8 or CDK9) inhibitors, including but not limited to Alvocidib (a pan-CDK inhibitor also known as flavopirdol or HMR-1275, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4-chromenone, and described in U.S. Pat. No. 5,621,002);
[0762] CDK4 / 6 inhibitors: pabociclib, ribociclib, abemaciclib, and trilaciclib; CDK9 inhibitors: AZD 4573, P276-00, AT7519M, and TP-1287;
[0763] Gonadotropin-releasing hormone (GnRH) receptor agonists: Leuprolide or leuprolide acetate (marketed by Bayer AG under the trade name For sale by Sanofi-Aventis Sold and sold by AbbottLab sell);
[0764] Taxane anti-tumor agents: Cabazitaxel (l-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytaxanthin-l l-ene-2a,4,13a-triyl-4-acetate-2-benzoate-13-[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropionate), larotaxel ((2α,3ξ,4α,5β,7α,10β,13α)-4,10-bis(acetoxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropionyl}oxy)-l-hydroxy-9-oxo-5,20-epoxy-7,19-cyclotaxanthin-l l-ene-2-yl benzoate);
[0765] 5HT1a receptor agonist: Xaliproden (also known as SR57746, 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine, and described in U.S. Pat. No. 5,266,573); HPC vaccine: sold by GlaxoSmithKline Sold by Merck Iron chelator: Deferasirox (available from Novartis under the trade name sell);
[0766] Anti-metabolite: Claribine (2-chlorodeoxyadenosine, sold under the trade name Sold under the trade name Sold), 6-thioguanine (trade name Pemetrexed (sold under the trade name arabinoside (also known as cytosine arabinoside (Ara-C), sold under the trade name cytarabine liposomes (also known as liposome Ara-C, sold under the trade name DepoCyt TM Sold under the trade name Sold under the trade name Droxia TM and Mylocel TM Sold under the trade name Sold under the trade name Cladribine (also known as 2-chlorodeoxyadenosine (2-CdA), sold under the trade name Leustatin TMSold by and Trexall TM Sold), pentostatin (trade name sell);
[0767] Bisphosphonates: Pamidronate (trade name Sold under the trade name Demethylating agent: 5-azacitidine (trade name Sold under the trade name sell);
[0768] Plant alkaloids: protein-bound paclitaxel (trade name ), vinblastine (also known as vinblastine sulfate, vinblastine, and VLB, sold under the trade name and Sold under the trade names of and Vincasar Sold), Vinorelbine (trade name Taxol and Onxal TM sell);
[0769] Retinoic acid: Ali tretinoin (trade name Retinoic acid (all-trans retinoic acid, also known as ATRA, sold under the trade name isotretinoin (13-cis-vitamin A acid, sold under the trade name and Bexarotene (sold under the trade name sell);
[0770] Glucocorticoids: Hydrocortisone (also known as cortisone, hydrocortisone sodium succinate, hydrocortisone sodium phosphate, and under the trade name Hydrocortisone phosphate, Solu- Hydrocort and Dexamethasone ((8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-3-one), prednisolone (trade name and Sold under the trade name and methylprednisolone (also known as 6-methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, and and sell);
[0771] Cytokines: Interleukin-2 (also known as aldesleukin and IL-2, and sold under the trade name Sold), interleukin-11 (also known as oprevelkin, sold under the trade name Sold under the trade name Interferon-α (also known as IFN-α A and
[00209] Estrogen receptor down-regulator: Fulvestrant (Fulvestrant) (trade name sell);
[0772] Anti-estrogen: tamoxifen (trade name toremifene (sold under the trade name sell);
[0773] Selective estrogen receptor modulators (SERMs): Raloxifene (trade name sell);
[0774] Luteinizing hormone-releasing hormone (LHRH) agonists: Goserelin (trade name Progesterone: megestrol acetate (also known as megestrol acetate, sold under the trade name sell);
[0775] Other cytotoxic agents: Arsenic trioxide (trade name Asparaginase (also known as L-asparaginase, Erwinia L-asparaginase, sold under the trade name and sell);
[0776] One or more additional immune checkpoint inhibitors can be used in combination with compounds as described herein to treat diseases, disorders or conditions associated with SHP2. Exemplary immune checkpoint inhibitors include inhibitors (Smac molecules or biologics) for immune checkpoint molecules such as CD27, CD28, CD40, CD122, CD96, CD73, CD39, CD47, OX40, GITR, CSF1R, JAK, PI3Kδ, PI3Kγ, TAM kinases, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, A2BR, HIF-2α, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, CD96, TIGIT, PD-1, PD-L1 and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from the following: CD27, CD28, CD40, ICOS, OX40, GITR, CD137 and STING. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from the following: B7-H3, B7-H4, BTLA, CTLA-4, IDO, TDO, arginase, KIR, LAG3, PD-1, TIM3, CD96, TIGIT and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from the following: KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFRβ inhibitors.
[0777] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of PD-1, such as an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001 or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab or PDR001. In some embodiments, the anti-PD1 antibody is pembrolizumab.
[0778] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of PD-L1, such as an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A (atezolizumab) or MEDI4736 (durvalumab).
[0779] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of CTLA-4, such as an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab or tremelimumab. In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of LAG3, such as an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016 or LAG525. In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of GITR, such as an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518 or MK-4166, INCAGN01876 or MK-1248. In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of OX40, such as an anti-OX40 antibody or an OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562 or INCAGN01949, GSK2831781, GSK-3174998, MOXR-0916, PF-04518600, or LAG525. In some embodiments, the OX40L fusion protein is MEDI6383.
[0780] The compounds of the invention may also be used to increase or enhance immune responses, including increasing immune responses to antigens; to improve immune effects, including increasing vaccine efficacy; and to increase inflammation. In some embodiments, the compounds of the invention may be used to enhance immune responses to vaccines, including but not limited to Listeria vaccines, oncolytic virus vaccines, and cancer vaccines, such as (Tumor cell vaccines transfected with granulocyte-macrophage colony stimulating factor (GM-CF) gene). Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses. Other immunomodulators also include those that block the migration of immune cells, such as antagonists of chemokine receptors (including CCR2 and CCR4); Sting agonists and Toll receptor agonists.
[0781] Other anticancer agents also include those that enhance the immune system, such as helper or adoptive T cell transfer. The compounds of the present application may be effective as boosters for T cell activation in combination with CAR (chimeric antigen receptor) T cell therapy.
[0782] The compounds of the present invention may also be used in combination with the following adjunctive therapies:
[0783] Anti-nausea drugs: NK-1 receptor antagonist: casopitant (marketed by GlaxoSmithKline under the trade name and sale); and
[0784] Cytoprotectant: Amifostine (trade name sold), leucovorin (also known as folinic acid, citrovorum factor, and folinic acid). Example
[0785] The preparation of the intermediate (reference) compounds of the following formula (I) compounds is provided so that those skilled in the art can more clearly understand and implement the present disclosure. They should not be considered as limiting the scope of the present disclosure, but only as its description and representation.
[0786] Reference 1
[0787] Synthesis of (5S)-5,6-dihydrospiro[piperidin-4,4-pyrrolo[1,2-b]pyrazole]-5-amine dihydrochloride
[0788]
[0789] Step 1: 1-[1-[(tert-Butoxy)(hydroxy)methyl]-4-[hydroxy(methoxy)methyl]piperidin-4-yl]ethan-1-ol
[0790]
[0791] To a solution of [1-[(tert-butoxy)(hydroxy)methyl]piperidin-4-yl](methoxy)methanol (20 g, 80.86 mmol, 1.0 eq) in THF (200 mL) was added LDA (48.52 mL, 97.03 mmol, 1.2 eq) dropwise at -78°C under nitrogen atmosphere. After stirring at -78°C to -60°C for 1.5 hours, acetaldehyde (5.34 g, 121.29 mmol, 1.5 eq) was added dropwise at -78°C for 5 minutes to the mixture, and the resulting mixture was stirred at -78°C to -40°C for another 2 hours. The reaction mixture was then poured into a saturated aqueous NH4Cl solution and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (EtOAc / PE, 0-50%) to give 12 g (50.9% yield) of the title compound as a light yellow oil.
[0792] Step 2: 1-tert-Butyl 4-methyl 4-[1-(trifluoromethanesulfonyloxy)ethyl]piperidine-1,4-dicarboxylate
[0793]
[0794] To a solution of 1-tert-butyl 4-methyl 4-(1-hydroxyethyl)piperidine-1,4-dicarboxylate (9.5 g, 33.06 mmol, 1 eq.) in DCM (100 mL) was added pyridine (10.4 g, 131.48 mmol, 4.0 eq.) and (trifluoromethane)sulfonyl trifluoromethanesulfonate (18.7 g, 66.27 mmol, 2.0 eq.) dropwise at 0°C under nitrogen atmosphere. After stirring at 0°C for 2 hours, the reaction mixture was quenched with water at 0°C. The resulting mixture was extracted with CH2Cl2. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to give 20 g (crude) of the title compound. The crude product was used directly in the next step without further purification.
[0795] Step 3: 1-tert-Butyl 4-methyl 4-vinylpiperidine-1,4-dicarboxylate
[0796]
[0797] To a stirred solution of 1-tert-butyl 4-methyl 4-[1-(trifluoromethanesulfonyloxy)-ethyl]piperidine-1,4-dicarboxylate (20 g, crude) in DCM (300 mL) was added DBU (28.50 mL, 187.18 mmol) at room temperature under nitrogen atmosphere. After stirring at room temperature for 4 hours, the reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (EtOAc / PE, 6%) to give the title compound (4.5 g, 55.2% yield, two steps) as a light yellow oil.
[0798] Step 4: 1-[(tert-Butyloxy)carbonyl]-4-vinylpiperidine-4-carboxylic acid
[0799]
[0800] To a solution of 1-tert-butyl 4-methyl 4-vinylpiperidine-1,4-dicarboxylate (4.8 g, 17.82 mmol, 1.0 equiv) in MeOH (40 mL) was added water (10 mL) and LiOH (2.35 g, 98.01 mmol, 5.5 equiv) at room temperature. After stirring at room temperature for 16 hours, the mixture was acidified to pH = 5 with 0.5 M aqueous HCl. The reaction mixture was then extracted with CH2Cl2. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated to give the title compound (4.5 g, 98.9% yield) as a light yellow oil, which was used in the next step without further purification.
[0801] Step 5: tert-Butyl 4-vinyl-4-[methoxy(methyl)carbamoyl]piperidine-1-carboxylate
[0802]
[0803] To a solution of 1-[(tert-butoxy)carbonyl]-4-vinylpiperidine-4-carboxylic acid (4.5 g, 17.62 mmol, 1.0 equiv) and methoxy(methyl)amine (1.61 g, 26.43 mmol, 1.5 equiv) in DCM (70 mL) was added HATU (13.40 g, 35.25 mmol, 2.0 equiv) and Et3N (5.35 g, 52.86 mmol, 3.0 equiv) at room temperature under nitrogen atmosphere. After stirring at room temperature for 12 hours, the reaction mixture was quenched with water at room temperature and extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (EtOAc / PE, 5%) to give the title compound (5 g, 95% yield) as a white solid.
[0804] Step 6: tert-Butyl 4-acetyl-4-vinylpiperidine-1-carboxylate
[0805]
[0806] Under nitrogen atmosphere, 2.5M CH3MgBr (16.76mL, 41.89mmol, 2.50equiv) was added dropwise to a solution of tert-butyl 4-vinyl-4-[methoxy(methyl)carbamoyl]piperidine-1-carboxylate (5g, 16.75mmol, 1.0equiv) in THF (60mL) at 0°C. After stirring at room temperature for 12 hours, the reaction was quenched with saturated aqueous NH4Cl at 0°C, and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (EtOAc / PE, 1 / 3) to give the title compound (3.5g, 82.4% yield) as a light yellow oil.
[0807] Step 7: tert-Butyl 4-[(2Z)-3-(dimethylamino)prop-2-enoyl]-4-vinylpiperidine-1-carboxylate
[0808]
[0809] A solution of tert-butyl 4-acetyl-4-vinylpiperidine-1-carboxylate (2.2 g, 8.68 mmol, 1.0 equiv) in [(tert-butoxy)(dimethylamino)methyl]dimethylamine (2 mL, 9.69 mmol, 1.1 equiv) was stirred at 100°C for 4 hours under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give the title compound (1.6 g, 59.7% yield) as a light yellow oil.
[0810] Step 8: tert-Butyl 4-vinyl-4-(1H-pyrazol-5-yl)piperidine-1-carboxylate
[0811]
[0812] To a stirred solution of tert-butyl 4-[(2Z)-3-(dimethylamino)prop-2-enoyl]-4-vinylpiperidine-1-carboxylate (2.2 g, 7.13 mmol, 1.0 equiv) in EtOH (50 mL) was added hydrazine monohydrate (0.54 g, 10.78 mmol, 1.5 equiv) under nitrogen atmosphere at 25°C. After stirring at 25°C for 16 hours, the reaction was quenched with water and the resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (30%-60%) to give the title compound (1.6 g, 80.8% yield) as a white solid.
[0813] Step 9: tert-Butyl 4-(oxirane-2-yl)-4-(1H-pyrazol-5-yl)piperidine-1-carboxylate
[0814]
[0815] To a stirred mixture of tert-butyl 4-vinyl-4-(1H-pyrazol-5-yl)piperidine-1-carboxylate (2 g, 7.2 mmol, 1.0 equiv) and methyltrioxorhenium(VII) (179.72 mg, 0.72 mmol, 0.1 equiv) in DCM (30 mL) at room temperature was added pyridine (228.14 mg, 2.88 mmol, 0.4 equiv) and H2O2 (30%) (1.23 g, 10.85 mmol, 1.5 equiv). After stirring at room temperature for 16 h, the reaction was quenched with water and extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (30%-60%) to give the title compound (0.8 g, 37.82%) as a white solid.
[0816] Step 10: tert-Butyl 5-hydroxy-5,6-dihydrospiro[piperidin-4,4-pyrrolo[1,2-b]pyrazole]-1-carboxylate
[0817]
[0818] To a stirred solution of tert-butyl 4-(oxirane-2-yl)-4-(1H-pyrazol-5-yl)piperidine-1-carboxylate (0.7 g, 2.38 mmol, 1.0 equiv) in THF (10 mL) at room temperature were added LiBr (0.62 g, 7.15 mmol, 3.0 equiv) and CH3COOH (0.43 g, 7.15 mmol, 3.0 equiv). After stirring at room temperature for 16 hours, the reaction mixture was stirred at 45°C for 8 hours. After cooling to room temperature, the reaction mixture was quenched with saturated aqueous NaHCO3 solution, and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (30%-100%) to give the title compound (0.4 g, 57.1% yield) as a white solid.
[0819] Step 11: tert-Butyl 5-oxo-5,6-dihydrospiro[piperidin-4,4-pyrrolo[1,2-b]pyrazole]-1-carboxylate
[0820]
[0821] To a solution of tert-butyl 5-hydroxy-5,6-dihydrospiro[piperidine-4,4-pyrrolo[1,2-b]pyrazole]-1-carboxylate (0.4 g, 1.36 mmol, 1.0 equiv) in DCM (8 mL) was added Dess-Martin (0.87 g, 2.04 mmol, 1.5 equiv) at room temperature. After stirring at room temperature for 4 h, the reaction mixture was quenched with saturated aqueous NaHCO3 at room temperature and extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (EtOAc / PE, 20%-60%) to give the title compound (0.36 g, 90.62%) as a white solid.
[0822] Step 12: (S)-tert-butyl 5-[(R)-2-methylpropane-2-sulfinyl)amino]-5,6-dihydrospiro[piperidine-4,4-pyrrolo[1,2-b]pyrazole]-1-carboxylate
[0823]
[0824] To a solution of tert-butyl 5-oxo-5,6-dihydrospiro[piperidine-4,4-pyrrolo[1,2-b]pyrazole]-1-carboxylate (0.36 g, 1.23 mmol, 1.0 equiv) in THF (6 mL) was added (R)-2-methylpropane-2-sulfenamide (0.30 g, 2.47 mmol, 2.0 equiv) and Ti(OEt)4 (1.13 g, 4.94 mmol, 4.0 equiv) at room temperature under nitrogen atmosphere. After stirring at 75°C for 4 hours, the reaction mixture was cooled to -20°C. MeOH (1 mL) and LiBH4 (40.38 mg, 1.85 mmol, 1.50 equiv) were added to the above mixture at -20°C. After stirring at 0°C for another 6 hours, the reaction mixture was quenched with saturated aqueous NH4Cl solution at 0°C. The mixture was then filtered and the filter cake was washed with EtOAc. The filtrate was concentrated under reduced pressure, and the residue was dissolved in MeOH (3 mL). LiBH4 (80.75 mg, 3.71 mmol, 3.0 equiv.) was added to the above mixture at room temperature. The resulting mixture was stirred for another 8 hours at 45 ° C. The reaction mixture was quenched with saturated NH4Cl aqueous solution at 0 ° C. The resulting mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with EtOAc / PE (30%-70%) to give the title compound (200 mg, 40.8% yield) as a white solid.
[0825] Step 13: (5S)-5,6-dihydrospiro[piperidin-4,4-pyrrolo[1,2-b]pyrazole]-5-amine dihydrochloride
[0826]
[0827] To a stirred solution of (S)-tert-butyl 5-[(R)-2-methylpropane-2-sulfinyl)amino]-5,6-dihydrospiro[piperidine-4,4-pyrrolo[1,2-b]pyrazole]-1-carboxylate (100 mg, 0.252 mmol, 1.0 equiv) in 1,4-dioxane (0.5 mL) was added dropwise HCl in dioxane (4M, 0.50 mL) at room temperature. After stirring at room temperature for 30 minutes, the reaction mixture was concentrated under reduced pressure. Et2O (1 mL) was added to the residue, and the precipitate was collected by filtration to give the title compound (60 mg, 89.7% yield) as a white solid.
[0828] Example 1
[0829] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0830]
[0831] Step 1: (2S)-tert-butyl 2-[[(2-fluoropyridin-3-yl)oxy]methyl]pyrrolidine-1-carboxylate
[0832]
[0833] To a stirred mixture of 2-fluoropyridin-3-ol (1 g, 8.84 mmol, 1.00 equiv) and (2S)-2-(hydroxymethyl)pyrrolidine-1-carboxylic acid tert-butyl ester (2.14 g, 10.61 mmol, 1.2 equiv) in THF (15 mL) at room temperature under nitrogen was added PPh3 (3.48 g, 13.26 mmol, 1.50 equiv) and DEAD (2.31 g, 13.26 mmol, 1.5 equiv). After stirring at room temperature for 16 h, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (15:1) to give the title compound (2.5 g, 95.4% yield) as a light yellow oil.
[0834] Step 2: 2-Fluoro-3-[[(2S)-pyrrolidin-2-yl]methoxy]pyridine dihydrochloride
[0835]
[0836] To a stirred solution of (2S)-2-[[(2-fluoropyridin-3-yl)oxy]methyl]-pyrrolidine-1-carboxylic acid tert-butyl ester (2500 mg, 8.43 mmol, 1.00 equiv) in DCM (15 mL) was added hydrogen chloride (4M in dioxane) (15 mL) at room temperature. After stirring at room temperature for 4 hours, the reaction mixture was concentrated in vacuo to give the title compound (2.20 g, 96.8% yield) as a white solid.
[0837] Step 3: (S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
[0838]
[0839] To a stirred solution of 2-fluoro-3-[[(2S)-pyrrolidin-2-yl]methoxy]pyridine dihydrochloride (2.20 g, 8.17 mmol, 1.00 equiv) in ethanol (50 mL) was added K2CO3 (5.64 g, 40.87 mmol, 5.00 equiv) at room temperature, and the resulting mixture was stirred at 65°C for 12 hours. The mixture was then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (3:1) to give the title compound (1.34 g, 93% yield) as a colorless oil.
[0840] Step 4: (S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
[0841]
[0842] To a stirred solution of (S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (600 mg, 3.41 mmol, 1.00 equiv) in THF (15 mL) was added n-butyllithium solution (2.5 M in hexane, 3.4 mL, 8.5 mmol, 2.50 equiv) dropwise at -78 °C under N2 atmosphere. The reaction mixture was warmed to 0 °C and stirred for 1.5 hours. To the above mixture was added a solution of I2 (950.60 mg, 3.74 mmol, 1.10 equiv) in THF (2 mL) dropwise at -78 °C. The resulting mixture was warmed to room temperature and stirred at room temperature for 2 hours. The reaction mixture was quenched with saturated aqueous NH4Cl solution and diluted with EtOAc. The organic layer was washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (3:1) to give the title compound (700 mg, 68% yield) as a yellow solid.
[0843] Step 5: 2-Ethylhexyl 3-(((S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)propanoate
[0844]
[0845] To a stirred mixture of (S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (150.00 mg, 0.496 mmol, 1.00 equiv), 2-ethylhexyl 3-thiopropanoate (162.62 mg, 0.745 mmol, 1.50 equiv), Pd2(dba)3 (22.73 mg, 0.025 mmol, 0.05 equiv) and Xantphos (14.36 mg, 0.025 mmol, 0.05 equiv) in 1,4-dioxane (2 mL) was added DIEA (192.51 mg, 1.489 mmol, 3.00 equiv) under nitrogen at room temperature. After stirring at 90°C for 1 hour, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-30%) to give the title compound (160 mg, 82% yield) as a light yellow solid.
[0846] Step 6: Potassium (S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine-4-thiol
[0847]
[0848] To a stirred solution of 2-ethylhexyl 3-(((S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]-pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)propanoate (140.00 mg, 0.357 mmol, 1.0 equiv) in THF (2 mL) at -10°C was added 1.0 M t-BuOK (0.43 mL, 0.43 mmol, 1.20 equiv). After stirring at 0°C for 0.5 h, the reaction mixture was diluted with petroleum ether. The precipitated solid was collected by filtration and washed with ethyl acetate to give the title compound (75 mg, 85% yield) as a light yellow solid.
[0849] Step 7: 6-bromo-3-[(3S,4S)-4-[[(tert-butoxy)carbonyl]amino]-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]pyrazine-2-carboxylic acid methyl ester
[0850]
[0851] A solution of 3,6-dibromopyrazine-2-carboxylic acid methyl ester (500 mg, 1.690 mmol, 1 eq.), (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-amine dihydrochloride (493.05 mg, 2.028 mmol, 1.2 eq.) and DIEA (1091.88 mg, 8.448 mmol, 5.0 eq.) in DMA (10 mL) was stirred at 55 °C for 2 hours. Di-tert-butyl dicarbonate (552.33 mg, 2.531 mmol, 1.5 eq.) was then added and the resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with PE / EtOAc=1:1 to give the title compound (615 mg, 2 steps, 75% yield) as a yellow oil.
[0852] Step 8: tert-Butyl N-[(3S,4S)-8-[5-bromo-3-(hydroxymethyl)pyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl]carbamate
[0853]
[0854] To a stirred solution of methyl 6-bromo-3-[(3S,4S)-4-[[(tert-butoxy)carbonyl]-amino]-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]pyrazine-2-carboxylate (150 mg, 0.309 mmol, 1 eq) in DCM (3.75 mL) was added DIBAL-H (1.0 M in DCM, 1.24 mL, 1.240 mmol, 4.01 eq) dropwise at -78 °C under nitrogen atmosphere. The resulting mixture was stirred at -78 °C for 30 min, warmed to room temperature, and then quenched by the addition of saturated aqueous Rochelle's salt solution. The resulting mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-50%) to give the title compound (65 mg, 46%) as a yellow solid.
[0855] Step 9: tert-Butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl)carbamate
[0856]
[0857] Under nitrogen, at room temperature, tert-butyl N-[(3S,4S)-8-[5-bromo-3-(hydroxymethyl)pyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl]carbamate (25.00 mg, 0.055 mmol, 1.00 equiv), (S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine were added to the stirred solution. To a mixture of potassium-4-thiolate (20.20 mg, 0.082 mmol, 1.50 equiv), Pd2(dba)3 (15.02 mg, 0.0164 mmol, 0.30 equiv) and Xantphos (9.49 mg, 0.0164 mmol, 0.30 equiv) in 1,4-dioxane (1 mL) was added DIEA (21.19 mg, 0.164 mmol, 3.00 equiv). After stirring at 100°C for 1.5 hours, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (50%-100%) to give the title compound (25 mg, 78% yield) as a light yellow solid.
[0858] Step 10: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol formate
[0859]
[0860] To a stirred solution of tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((S)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl)carbamate (20.00 mg, 0.034 mmol, 1.0 equiv) in DCM (1.5 mL) at room temperature was added TFA (0.3 mL). After stirring at room temperature for 5 hours, the reaction mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC to give the title compound (7 mg, 39% yield) as a light yellow solid. MS (ES, m / z): [M+1] + =485.2.
[0861] Example 2
[0862] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((R)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0863]
[0864] Compound 2 was synthesized by the method described in Example 1 using (2R)-2-(hydroxymethyl)pyrrolidine-1-carboxylic acid tert-butyl ester instead of (2S)-2-(hydroxymethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester in step 1. MS (ES, m / z): [M+1] + =485.3.
[0865] Example 3
[0866] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-fluoro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0867]
[0868] Step 1: tert-Butyl (2S,4S)-4-fluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylate
[0869]
[0870] Under nitrogen atmosphere, BH3-Me2S (2.8 mL, 29.5 mmol, 3.0 equiv) was added dropwise to a stirred solution of (2S, 4S)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid (2.33 g, 9.99 mmol, 1.0 equiv) in THF (25 mL) at 0-5°C, and the resulting mixture was stirred overnight at room temperature. The mixture was cooled to 0°C and quenched with MeOH. The resulting mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography, eluting with EtOAc / PE (1 / 1) to give the title compound (2.0 g, 91.3%).
[0871] Step 2: (2S,4S)-tert-butyl 4-fluoro-2-[[(2-fluoro-4-iodopyridin-3-yl)oxy]methyl]pyrrolidine-1-carboxylate
[0872]
[0873] To a stirred solution of 2-fluoro-4-iodopyridin-3-ol (436 mg, 1.82 mmol, 1.0 equiv), (2S,4S)-4-fluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylic acid tert-butyl ester (400 mg, 1.82 mmol, 1.0 equiv) and PPh3 (717 mg, 2.73 mmol, 1.5 equiv) in THF (4.00 mL) was added DEAD (476 mg, 2.73 mmol, 1.5 equiv) dropwise at 0°C under nitrogen atmosphere. The resulting mixture was stirred overnight at room temperature under nitrogen. The reaction mixture was quenched with water and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-50%) to give the title compound (610 mg, 75.5%).
[0874] Step 3: 2-Fluoro-3-(((2S,4S)-4-fluoropyrrolidin-2-yl)methoxy)-4-iodopyridine hydrochloride
[0875]
[0876] To a stirred solution of tert-butyl (2S,4S)-4-fluoro-2-[[(2-fluoro-4-iodopyridin-3-yl)oxy]methyl]pyrrolidine-1-carboxylate (560 mg, 1.272 mmol, 1.0 eq) in 1,4-dioxane (5 mL) was added dropwise 3.3 M HCl in 1,4-dioxane (5 mL, 16.5 mmol, 13 eq) at 0°C. After stirring at room temperature for 1 hour, the reaction mixture was concentrated under reduced pressure and the residue was triturated with Et2O. The solid was collected by filtration and dried under vacuum to give the product as the HCl salt (375 mg, 78.3%).
[0877] Step 4: (6aS,8S)-8-Fluoro-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
[0878]
[0879] A mixture of 2-fluoro-3-(((2S,4S)-4-fluoropyrrolidin-2-yl)methoxy)-4-iodopyridine hydrochloride (370 mg, 0.983 mmol, 1.0 equiv) and K2CO3 (407 mg, 2.95 mmol, 3.0 equiv) in EtOH (4 mL) was stirred at 60 °C for 2 hours. The resulting mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-30%) to give the title compound (245 mg, 77.9%).
[0880] Step 5: 2-Ethylhexyl 3-([5-[(3S,4S)-4-[(tert-butoxycarbonyl)amino]-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-6-(hydroxymethyl)pyrazin-2-yl]thio)propanoate
[0881]
[0882] Under nitrogen atmosphere, a solution of tert-butyl N-[(3S,4S)-8-[5-bromo-3-(hydroxymethyl)pyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl]carbamate (580.0 mg, 1.27 mmol, 1.0 equiv), 2-ethylhexyl 3-mercaptopropanoate (332.29 mg, 1.52 mmol, 1.2 equiv), Pd2(dba)3 (116.1 mg, 0.127 mmol, 0.10 equiv), XantPhos (73.38 mg, 0.127 mmol, 0.10 equiv) and DIEA (491.69 mg, 3.804 mmol, 3.00 equiv) in 1,4-dioxane (12.0 mL) was stirred at 100 °C for 1 hour. The resulting mixture was concentrated in vacuo and the residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-50%) to give the title compound (600 mg, 79.54%).
[0883] Step 6: Sodium 5-((3S,4S)-4-((tert-butoxycarbonyl)amino)-3-methyl-2-oxa-8-azaspiro[4.5]-dec-8-yl)-6-(hydroxymethyl)pyrazine-2-thiolate
[0884]
[0885] To a stirred solution of 2-ethylhexyl 3-([5-[(3S,4S)-4-[(tert-butoxycarbonyl)amino]-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-6-(hydroxymethyl)pyrazin-2-yl]thio)propanoate (680.0 mg, 1.14 mmol, 1.0 equiv) in CHOH (6.80 mL) at 5° C. was added CHONa (247.04 mg, 1.372 mmol, 1.20 equiv, 30% in MeOH) dropwise. After stirring at room temperature for 16 h, the reaction mixture was concentrated in vacuo and the residue was triturated with EtO to give the title compound (390 mg, crude) which was used in the next step without further purification.
[0886] Step 7: tert-Butyl ((3S,4S)-8-(5-(((6aS,8S)-8-fluoro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-3-(hydroxymethyl)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl)carbamate
[0887]
[0888] Under nitrogen atmosphere, (6aS,8S)-8-fluoro-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (30.00 mg, 0.094 mmol, 1.0 equiv), 5-((3S,4S)-4-((tert-butoxycarbonyl)amino)-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(hydroxymethyl)pyrazine were added. A solution of sodium 2-thiolate (48.64 mg, 0.112 mmol, 1.2 equiv), Pd2(dba)3 (25.75 mg, 0.028 mmol, 0.30 equiv), XantPhos (16.27 mg, 0.028 mmol, 0.30 equiv) and DIEA (36.34 mg, 0.281 mmol, 3.00 equiv) in dioxane (0.90 mL) was stirred at 80°C for 1 hour. After cooling to room temperature, the reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water and brine, dried over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography eluting with MeOH / CH2Cl2 (0-10%) to give the title compound (32 mg, 56.4%).
[0889] Step 8: (3-((S)-4-amino-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-fluoro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0890]
[0891] To a solution of tert-butyl ((3S,4S)-8-(5-(((6aS,8S)-8-fluoro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-3-(hydroxymethyl)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl)carbamate (26 mg, 0.043 mmol, 1.00 equiv) in DCM (1.2 mL) at 5°C was added TFA (0.4 mL, 5.23 mmol, 122 equiv) dropwise. After stirring at room temperature for 1 hour, the reaction mixture was concentrated in vacuo and the residue was purified by preparative HPLC to give the title compound (3.1 mg, 14.30%). MS (ES, m / z): [M+1] + =503.2.
[0892] Example 4
[0893] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8R)-8-fluoro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0894]
[0895] The title compound was synthesized by the method described in Example 3 using (2S,4R)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid in step 1. MS (ES, m / z): [M+1] + =503.3.
[0896] Example 5
[0897] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0898]
[0899] Step 1: 1-tert-butyl 2-methyl (2S,4S)-4-[(tert-butyldimethylsilyl)oxy]pyrrolidine-1,2-dicarboxylate
[0900]
[0901] To a stirred solution of (2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-tert-butyl 2-methyl ester (6.0 g, 24.46 mmol, 1.0 equiv) and imidazole (2.5 g, 36.72 mmol, 1.50 equiv) in DCM (60 mL) was added TBS-Cl (5.53 g, 36.69 mmol, 1.50 equiv) in portions at 0-5°C. After stirring overnight at room temperature, the reaction mixture was quenched with MeOH and water, and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-10%) to give the title compound (9.0 g, 102.3%).
[0902] Step 2: tert-Butyl (2S,4S)-4-[(tert-butyldimethylsilyl)oxy]-2-(hydroxymethyl)pyrrolidine-1-carboxylate
[0903]
[0904] Under nitrogen atmosphere, to a stirred mixture of (2S,4S)-4-[(tert-butyldimethylsilyl)oxy]-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl 2-methyl ester (3.0 g, 8.344 mmol, 1.0 equiv) in THF (30 mL) at 0°C, LiAlH4 (475 mg, 12.516 mmol, 1.50 equiv) was added in portions, and the resulting mixture was stirred at room temperature under nitrogen for 2 hours. After cooling to 0°C, the reaction mixture was quenched with saturated aqueous Na2SO4. The resulting mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-100%) to give the title compound (1.6 g, 57.8%).
[0905] Step 3: (2S,4S)-tert-butyl 4-[(tert-butyldimethylsilyl)oxy]-2-[[(2-fluoro-4-iodopyridin-3-yl)oxy]methyl]pyrrolidine-1-carboxylate
[0906]
[0907] To a stirred mixture of 2-fluoro-4-iodopyridin-3-ol (400 mg, 1.674 mmol, 1.0 equiv), (2S,4S)-tert-butyl 4-[(tert-butyldimethylsilyl)oxy]-2-(hydroxymethyl)pyrrolidine-1-carboxylate (555 mg, 1.674 mmol, 1.00 equiv) and PPh3 (658 mg, 2.511 mmol, 1.50 equiv) in THF (4 mL) was added DEAD (437 mg, 2.51 mmol, 1.50 equiv) dropwise under nitrogen at 0°C. The resulting mixture was stirred at room temperature under nitrogen for 2 hours, then quenched with water at 0°C and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-30%) to give the title compound (735 mg, 79.4%).
[0908] Step 4: (3S,5S)-5-[[(2-fluoro-4-iodopyridin-3-yl)oxy]methyl]pyrrolidin-3-ol hydrochloride
[0909]
[0910] To a stirred solution of tert-butyl (2S,4S)-4-[(tert-butyldimethylsilyl)oxy]-2-[[(2-fluoro-4-iodopyridin-3-yl)oxy]methyl]pyrrolidine-1-carboxylate (750 mg, 1.357 mmol, 1.0 eq) was added dropwise 3.0 M HCl in 1,4-dioxane (5 mL, 15 mmol, 11 eq) at 0-5°C. After stirring at room temperature for 1 hour, the reaction mixture was concentrated under reduced pressure and the residue was triturated with Et2O. The precipitate was collected by filtration and dried under reduced pressure to give the title compound (400 mg, 78.7%).
[0911] Step 5: (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol
[0912]
[0913] A mixture of (3S,5S)-5-[[(2-fluoro-4-iodopyridin-3-yl)oxy]methyl]pyrrolidin-3-ol hydrochloride (400 mg, 1.068 mmol, 1.00 equiv) and K2CO3 (443 mg, 3.205 mmol, 3.00 equiv) in EtOH (4 mL) was stirred at 60 °C for 2 hours. After cooling to room temperature, the resulting mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-40%) to give the title compound (300 mg, 88.3%).
[0914] Step 6: (6aS,8S)-4-iodo-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
[0915]
[0916] To a stirred solution of (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol (100.00 mg, 0.314 mmol, 1.0 equiv) and Ag2O (364.23 mg, 1.572 mmol, 5.0 equiv) in DMF (1.00 mL) was added MeI (133.86 mg, 0.943 mmol, 3.00 equiv) dropwise at room temperature, and the resulting mixture was stirred at 50°C for 4 hours. After cooling to room temperature, the reaction mixture was filtered. The filtrate was washed with H2O and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with PE / EA (2 / 1) to give the title compound (89 mg, 85.2%).
[0917] Step 7: tert-Butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((6aS,8S)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl)carbamate
[0918]
[0919] Under N2 atmosphere, (6aS,8S)-4-iodo-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (30.00 mg, 0.090 mmol, 1.0 equiv) and N-[(3S,4S)-8-[3-(hydroxymethyl)-5-thiopyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (30.00 mg, 0.090 mmol, 1.0 equiv) were added to a stirred mixture at room temperature. To a mixture of tert-butyl]dec-4-yl]carbamate (37.08 mg, 0.090 mmol, 1.0 equiv) in dioxane (0.30 mL) were added Pd2(dba)3 (24.81 mg, 0.027 mmol, 0.30 equiv), Xantphos (15.68 mg, 0.027 mmol, 0.30 equiv) and DIEA (35.02 mg, 0.271 mmol, 3.0 equiv). The resulting mixture was stirred at 80 °C for 1 hour under N2 atmosphere. After cooling to room temperature, the reaction mixture was concentrated in vacuo and the residue was purified by silica gel column chromatography eluting with DCM / MeOH (10 / 1) to give the title compound (25 mg, 45.6%).
[0920] Step 8: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol formate
[0921]
[0922] TFA (1.3 mL) was added to a solution of tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((6aS,8S)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl)carbamate (130.0 mg, 0.21 mmol, 1.0 equiv) in DCM (3.0 mL) at room temperature. After stirring at room temperature for 2 hours, the reaction solution was concentrated and the residue was purified by preparative HPLC to give the product (19 mg, 16.1%). MS (ES, m / z): [M+1] + =515.3.
[0923] Example 6
[0924] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8R)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0925]
[0926] Step 1: (6aS,8R)-4-iodo-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
[0927]
[0928] The compound (6aS,8R)-4-iodo-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine was synthesized in step 1 using (2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-(tert-butyl)2-methyl ester.
[0929] Step 2: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8R)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0930]
[0931] (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8R)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol was synthesized by a method similar to that described in Example 5, Steps 7-8. MS (ES, m / z): [M+1] + =515.3.
[0932] Example 7
[0933] Synthesis of (6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol
[0934]
[0935] The title compound was synthesized by the method described in Example 5, Steps 7-8, using (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol in Step 7. MS (ES, m / z): [M+1] + =501.3.
[0936] Example 8
[0937] Synthesis of (6aS,8R)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol
[0938]
[0939] The title compound was synthesized by a method similar to that described in Example 7. MS (ES, m / z): [M+1] + =501.3.
[0940] Example 9
[0941] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aR,8R)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0942]
[0943] The title compound was synthesized by a method similar to that described in Example 5, Steps 2-8, using (2R,4R)-4-methoxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl 2-methyl ester in Step 2. MS (ES, m / z): [M+1] + =515.3.
[0944] Example 10
[0945] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aR,8S)-8-methoxy-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0946]
[0947] The title compound was synthesized by a method similar to that described in Example 5, Steps 2-8, using (2R,4S)-2-(hydroxymethyl)-4-methoxypyrrolidine-1-carboxylic acid tert-butyl ester in Step 2. MS (ES, m / z): [M+1] + =515.2.
[0948] Embodiment 11
[0949] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-(((S)-tetrahydrofuran-3-yl)oxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0950]
[0951] Step 1: (6aS,8S)-4-iodo-8-(((S)-tetrahydrofuran-3-yl)oxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
[0952]
[0953] To a stirred solution of (3R)-4-methylbenzenesulfonic acid oxacyclopentane-3-yl ester (457 mg, 1.886 mmol, 3 eq.) and (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol (200 mg, 0.629 mmol, 1.00 eq.) in DMF (2.00 mL) was added NaH (88 mg, 2.200 mmol, 3.5 eq., 60%) in portions at 0°C under nitrogen atmosphere, and the resulting mixture was stirred overnight at room temperature under nitrogen. After cooling to 0°C, the reaction was quenched with water, and the resulting mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by preparative TLC (EtOAc 100%) to give the title compound (70 mg, 28.7%).
[0954] Step 2: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-(((S)-tetrahydrofuran-3-yl)oxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0955]
[0956] The title compound was synthesized from (6aS,8S)-4-iodo-8-(((S)-tetrahydrofuran-3-yl)oxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine by a method similar to that described in Example 5, Steps 7-8. MS (ES, m / z): [M+1] + =571.3.
[0957] Example 12
[0958] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-(((R)-tetrahydrofuran-3-yl)oxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0959]
[0960] The title compound was synthesized from (3S)-oxolan-3-yl 4-methylbenzenesulfonate by a method similar to that described in Example 11. MS (ES, m / z): [M+1] + =571.3.
[0961] Embodiment 13
[0962] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-(oxetan-3-yloxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0963]
[0964] Step 1: (6aS,8R)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl trifluoromethanesulfonate
[0965]
[0966] To a stirred solution of (6aS,8R)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]-pyrrolo[1,2-d][1,4]oxazin-8-ol (400 mg, 1.257 mmol, 1.00 equiv) and DIEA (244 mg, 1.886 mmol, 1.50 equiv) in DCM (4.00 mL) was added Tf2O (426 mg, 1.509 mmol, 1.20 equiv) dropwise at 5°C. The reaction solution was stirred at 5°C for 30 minutes and then concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-40%) to give the title compound (300 mg, 53.0%) as a white solid.
[0967] Step 2: (6aS,8S)-4-iodo-8-(oxetan-3-yloxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
[0968]
[0969] To a stirred solution of oxetane-3-ol (99 mg, 1.336 mmol, 2.00 equiv) in DMF (3.00 mL) at 5°C was added 60% NaH (67 mg, 1.67 mmol, 2.50 equiv). The mixture was stirred at this temperature for 1 hour. (6aS,8R)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl trifluoromethanesulfonate (300.00 mg, 0.666 mmol, 1.00 equiv) was added at 20°C. The resulting mixture was warmed to 50°C and stirred for 10 minutes. The reaction was quenched with water at 5°C and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-100%) to give the title compound (20 mg, 8.0%) as a white solid.
[0970] Step 3: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-(oxetan-3-yloxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0971]
[0972] The title compound was synthesized by a method similar to that described in Example 5, Steps 7-8, using (6aS,8S)-4-iodo-8-(oxetan-3-yloxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine in Step 7. MS (ES, m / z): [M+1] + =557.3.
[0973] Embodiment 14
[0974] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-(methoxymethoxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0975]
[0976] Step 1: (6aS,8S)-4-iodo-8-(methoxymethoxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
[0977]
[0978] To a stirred solution of (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d]-[1,4]oxazin-8-ol (60 mg, 0.189 mmol, 1.00 equiv) and DIEA (49 mg, 0.377 mmol, 2.00 equiv) in DME (1.00 mL) was added dropwise bromo(methoxy)methane (35.35 mg, 0.283 mmol, 1.50 equiv) under N2 atmosphere at room temperature. The resulting mixture was stirred for 4 hours at room temperature under N2 atmosphere and then quenched with H2O. The resulting mixture was extracted with EA and the combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 1) to give the title compound (50 mg, 73.2%) as a pale yellow solid.
[0979] Step 2: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-(methoxymethoxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0980]
[0981] The title compound was synthesized by a method similar to that described in Example 5, Steps 7-8, using tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((6aS,8S)-8-(methoxymethoxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl)carbamate in Step 7. MS (ES, m / z): [M+1] + =545.2.
[0982] Embodiment 15
[0983] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-(2-methoxyethoxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0984]
[0985] The title compound was synthesized by a method similar to that described in Example 14 using 2-bromoethyl methyl ether in step 1. MS (ES, m / z): [M+1] + =559.3.
[0986] Example 16
[0987] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-(cyclopropylmethoxy)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[0988]
[0989] The title compound was synthesized by a method similar to that described in Example 14 using (bromomethyl)cyclopropane in step 1. MS (ES, m / z): [M+1] + =555.4.
[0990] Embodiment 17
[0991] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((S)-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine]-4'-yl)thio)pyrazin-2-yl)methanol
[0992]
[0993] Step 1: (S)-4'-iodo-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido[3,2-b]pyrrolo[1,2-d]-[1,4]oxazine]
[0994]
[0995] Compound (S)-4'-iodo-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine] was synthesized by a method similar to that described in Example 1, Steps 1-4, using (6S)-5-azaspiro[2.4]heptane-5,6-dicarboxylic acid 5-tert-butyl 6-methyl ester in Step 1.
[0996] Step 2: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((S)-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine]-4'-yl)thio)pyrazin-2-yl)methanol
[0997]
[0998] The title compound was synthesized by a method similar to that described in Example 1, Steps 5-8. MS (ES, m / z): [M+1] + =511.3.
[0999] Examples 18 and 19
[1000] Synthesis of (6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-8-methyl-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]-pyrrolo[1,2-d][1,4]oxazin-8-ol and (6aS,8R)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-8-methyl-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol
[1001]
[1002] Step 1: (S)-4-iodo-6a,7-dihydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8(9H)-one
[1003]
[1004] Under nitrogen atmosphere, DMSO (257.89 mg, 3.301 mmol, 3.0 equiv) in DCM (0.2 mL) was added dropwise to a stirred solution of oxalyl chloride (209.47 mg, 1.650 mmol, 1.5 equiv) in DCM (1.4 mL) at -78°C and stirred for 30 minutes at this temperature. (6aS)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol (350.00 mg, 1.100 mmol, 1.00 equiv) in DCM (2.0 mL) was added to the above solution at -78°C. After stirring at -78°C for 30 minutes, DIEA (853.1 mg, 6.6 mmol, 6.0 equiv) was added dropwise at -78°C. The resulting mixture was stirred at -78°C for another 30 minutes and then warmed to room temperature over 30 minutes. After stirring at room temperature for 10 minutes, the reaction mixture was cooled to 5°C and quenched by adding saturated aqueous NH4Cl at 5°C. The resulting mixture was extracted with EtOAc, and the combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated to give the title compound (250 mg, 71.8%).
[1005] Step 2: 2-Ethylhexyl 3-(((S)-8-oxo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]-oxazin-4-yl)thio)propanoate
[1006]
[1007] Under nitrogen atmosphere, a solution of (S)-4-iodo-6a,7-dihydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8(9H)-one (220.00 mg, 0.696 mmol, 1.00 equiv), 2-ethylhexyl 3-mercaptopropanoate (182.37 mg, 0.835 mmol, 1.20 equiv), Pd2(dba)3 (63.73 mg, 0.070 mmol, 0.10 equiv), XantPhos (40.27 mg, 0.070 mmol, 0.10 equiv) and DIEA (269.85 mg, 2.088 mmol, 3.00 equiv) in dioxane (4.40 mL) was stirred at 100 °C for 1 hour. The resulting mixture was concentrated in vacuo and the residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-50%) to give the title compound (280 mg, 99%).
[1008] Step 3: 2-Ethylhexyl 3-(((6aS)-8-hydroxy-8-methyl-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]-pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)propanoate
[1009]
[1010] To a stirred solution of 2-ethylhexyl 3-(((S)-8-oxo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)propanoate (160 mg, 0.394 mmol, 1.00 equiv) in THF (1.60 mL) was added 2.0 M (methyl)magnesium bromide (0.24 mL, 0.48 mmol, 1.22 equiv) dropwise under nitrogen at 5°C and the resulting mixture was stirred at 5°C for 1 hour. The reaction was quenched by the addition of saturated aqueous NH4Cl at 5°C and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-100%) to give the title compound (90 mg, 54.1%).
[1011] Step 4: (6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-8-methyl-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]-pyrrolo[1,2-d][1,4]oxazine-8 -ol and (6aS,8R)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-8-methyl-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol.
[1012]
[1013] The title compound was synthesized from 2-ethylhexyl 3-(((6aS)-8-hydroxy-8-methyl-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)propanoate by a method similar to that described in Example 1, Steps 6-8. MS (ES, m / z): [M+1] + =515.3,
[1014] Embodiment 20
[1015] Synthesis of (6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine-8-carbonitrile
[1016]
[1017] Step 1: Methanesulfonic acid (6aS,8R)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl ester
[1018]
[1019] To a stirred solution of (6aS,8R)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol (400.00 mg, 1.257 mmol, 1.00 equiv) in DCM (6.00 mL) at room temperature was added TEA (190.86 mg, 1.886 mmol, 1.50 equiv) and MsCl (172.85 mg, 1.509 mmol, 1.20 equiv). After stirring at room temperature for 16 h, the reaction mixture was cooled to 0 °C and quenched with water. The resulting mixture was extracted with EtOAc and the combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-50%) to give the title compound (450 mg, 90.3%).
[1020] Step 2: (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine-8-carbonitrile
[1021]
[1022] To a stirred solution of (6aS,8R)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl methanesulfonate (300.00 mg, 0.757 mmol, 1.00 equiv) in DMF (5.00 mL) at room temperature was added NaCN (55.66 mg, 1.136 mmol, 1.50 equiv). After stirring at 75°C for 16 hours, the reaction mixture was cooled at room temperature and quenched with water. The mixture was then extracted with EtOAc, and the combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-50%) to give the title compound (140 mg, 56.5%).
[1023] Step 3: (6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]-oxazine-8-carbonitrile
[1024]
[1025] This compound was synthesized from (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine-8-carbonitrile by a method similar to that described in Example 5, Steps 7-8. [M+1] + =510.2.
[1026] Embodiment 21
[1027] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-(methylsulfonyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1028]
[1029] Step 1: 1-tert-butyl 2-methyl (2S,4R)-4-(methylsulfonyloxy)pyrrolidine-1,2-dicarboxylate
[1030]
[1031] To a stirred solution of (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-tert-butyl 2-methyl ester (9 g, 36.7 mmol, 1.0 eq) and TEA (7.43 g, 73.4 mmol, 2.0 eq) in DCM (100 mL) was added MsCl (5 g, 43.6 mmol, 1.2 eq) dropwise at 0°C and the resulting mixture was stirred at 0°C for 1 hour. The reaction was quenched with water and extracted with DCM. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-50%) to give the title compound (10.5 g, 88.5%).
[1032] Step 2: (2R,4R)-4-methoxypyrrolidine-1,2-dicarboxylic acid 1-(tert-butyl) 2-methyl ester
[1033]
[1034] To a solution of 1-tert-butyl 2-methyl (2S,4R)-4-(methylsulfonyloxy)pyrrolidine-1,2-dicarboxylate (4.30 g, 13.298 mmol, 1.00 equiv) in dry DMF (20.00 mL) at 30°C was added NaSCH3 (1.07 g, 15.27 mmol, 1.07 equiv). After stirring overnight at room temperature, the reaction mixture was poured into water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 1) to give the title compound (4 g, 109.2%).
[1035] Step 3: tert-Butyl (2S,4S)-2-(hydroxymethyl)-4-(methylthio)pyrrolidine-1-carboxylate
[1036]
[1037] To a stirred mixture of (2S,4S)-4-(methylthio)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl 2-methyl ester (3.70 g, 13.44 mmol, 1.0 eq.) in THF (37.0 mL) was added LiAlH4 (0.76 g, 20.03 mmol, 1.5 eq.) in portions at 0°C. After stirring at room temperature for 2 hours, the reaction mixture was quenched with Na2SO4·10H2O at room temperature. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure to give the title compound (2.6 g, 78.2%).
[1038] Step 4: tert-Butyl (2S,4S)-2-(hydroxymethyl)-4-(methylsulfonyl)pyrrolidine-1-carboxylate
[1039]
[1040] To a stirred solution of (2S,4S)-2-(hydroxymethyl)-4-(methylthio)-pyrrolidine-1-carboxylic acid tert-butyl ester (3.70 g, 14.959 mmol, 1.00 equiv) in DCM (40 mL) was added m-CPBA (77% 12.91 g, 57.60 mmol, 3.85 equiv) in portions at room temperature over 5 hours. The resulting mixture was diluted with DCM and washed with saturated aqueous NaHCO3 and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with DCM / MeOH (20 / 1) to give the title compound (1 g, 23.9%).
[1041] Step 5: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-(methylsulfonyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1042]
[1043] The title compound was synthesized from tert-butyl (2S,4S)-2-(hydroxymethyl)-4-(methylsulfonyl)pyrrolidine-1-carboxylate by the method described in Example 1, Step 2-8. MS (ES, m / z): [M+1] + =563.3.
[1044] Embodiment 22
[1045] Synthesis of (6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d]-[1,4]oxazin-8-yl carbamate
[1046]
[1047] Step 1: (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl carbamate
[1048]
[1049] To a stirred solution of (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol (150.0 mg, 0.472 mmol, 1.0 eq) in DCM (1.80 mL) was added trichloroacetyl isocyanate (222.08 mg, 1.179 mmol, 2.5 eq) dropwise at 5°C and the resulting mixture was stirred at this temperature for about 30 minutes. To the above solution was added K2CO3 (129.88 mg, 0.940 mmol, 2.0 eq) and MeOH (1.80 mL) at room temperature and the resulting mixture was stirred at room temperature for another 6 hours. The mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-100%) to give the title compound (100 mg, 58.7%).
[1050] Step 2: (6aS,8S)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]-oxazin-8-yl carbamate
[1051]
[1052] The title compound was synthesized from tert-butyl (2S,4S)-2-(hydroxymethyl)-4-(methylsulfonyl)pyrrolidine-1-carboxylate by a method similar to that described in Example 5, Steps 7-8. MS (ES, m / z): [M+1] + =544.3.
[1053] Embodiment 23
[1054] Synthesis of (6aS,8R)-4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl carbamate
[1055]
[1056] The title compound was synthesized from ((6aS,8R)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-ol by the method described in Example 22. MS (ES, m / z): [M+1] + =544.2.
[1057] Embodiment 24
[1058] Synthesis of (6-(((6aS,8S)-8-(1H-pyrazol-1-yl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]-pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)pyrazin-2-yl)methanol
[1059]
[1060] Step 1: (6aS,8S)-4-iodo-8-(1H-pyrazol-1-yl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]-pyrrolo[1,2-d][1,4]oxazine
[1061]
[1062] To a stirred solution of pyrazole (17.18 mg, 0.252 mmol, 1.0 equiv) in DMF (0.75 mL) was added NaH (20.19 mg, 0.505 mmol, 2.0 equiv, 60%) in portions at 5°C and the resulting mixture was stirred at 5°C for 1 hour. To the above mixture was added (6aS,8R)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl methanesulfonate (100.00 mg, 0.252 mmol, 1.00 equiv) at room temperature and the resulting mixture was stirred at 50°C. After cooling to 0°C, the reaction was quenched by the addition of water and then extracted with EtOAc. The combined organic layers were washed with water, brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-100%) to give the title compound (60 mg, 64.5%).
[1063] Step 2: (6-(((6aS,8S)-8-(1H-pyrazol-1-yl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)pyrazin-2-yl)methanol
[1064]
[1065] The title compound was synthesized from (6aS,8S)-4-iodo-8-(1H-pyrazol-1-yl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine by a method similar to that described in Example 5, Steps 7-8. MS (ES, m / z): [M+1] + =551.3
[1066] Embodiment 25
[1067] Synthesis of (6-(((6aS,8R)-8-(1H-pyrazol-1-yl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]-pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)pyrazin-2-yl)methanol
[1068]
[1069] The title compound was synthesized from methanesulfonic acid (6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl ester by the method described in Example 24. MS (ES, m / z): [M+1] + =551.3.
[1070] Examples 26 and 27
[1071] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((R)-6a,7,9,10-tetrahydro-6H-[1,4]oxazino[4,3-d]pyrido[3,2-b][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol and (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((S)-6a,7,9,10-tetrahydro-6H-[1,4]oxazino[4,3-d]pyrido[3,2-b][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1072]
[1073] The title compound was synthesized by a method similar to that described in Example 5, Steps 2-8, using tert-butyl 3-(hydroxymethyl)morpholine-4-carboxylate in Step 2. MS (ES, m / z): [M+1] + =501.2.
[1074] Embodiment 28
[1075] Synthesis of 4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(hydroxymethyl)pyrazin-2-yl)thio)-6a,7,9,10-tetrahydro-6H-pyrido[3,2-b][1,4]thiazino[4,3-d][1,4]oxazine 8,8-dioxide
[1076]
[1077] Step 1: 4-(tert-Butyloxycarbonyl)thiomorpholine-3-carboxylic acid
[1078]
[1079] To a stirred solution of thiomorpholine-3-carboxylic acid (3000 mg, 20.382 mmol, 1.00 equiv) and Et3N (4125 mg, 40.764 mmol, 2.00 equiv) in DCM (50.00 mL) was added Boc2O (6672 mg, 30.57 mmol, 1.50 equiv) in portions at room temperature under N2 atmosphere. The resulting mixture was stirred at room temperature for 16 hours under N2 atmosphere, and then diluted with water and extracted with DCM. The combined organic layers were dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with DCM / MeOH (10 / 1) to give the title compound (3.2 g, 63.5%) as a light yellow oil.
[1080] Step 2: tert-Butyl 3-(hydroxymethyl)thiomorpholine-4-carboxylate
[1081]
[1082] To a stirred solution of 4-(tert-butoxycarbonyl)thiomorpholine-3-carboxylic acid (2000 mg, 8.087 mmol, 1.00 equiv) in THF (20 mL) was added 1M BH3-THF (16.18 mL, 16.180 mmol, 2.00 equiv) dropwise under N2 at 0°C. The resulting mixture was stirred at 45°C for 16 hours under N2 atmosphere and then quenched with MeOH at 0°C. The resulting mixture was concentrated in vacuo and the residue was purified by silica gel column chromatography eluting with DCM / MeOH (10 / 1) to give the title compound (1.8 g, 95.4%) as a light yellow oil.
[1083] Step 3: tert-Butyl 3-(hydroxymethyl)thiomorpholine-4-carboxylate 1,1-dioxide
[1084]
[1085] A solution of tert-butyl 3-(hydroxymethyl)thiomorpholine-4-carboxylate (500 mg, 2.143 mmol, 1.00 equiv) and m-CPBA (77%, 851 mg, 3.78 mmol, 1.77 equiv) in DCM (10 mL) was stirred at room temperature for 16 hours under N2 atmosphere. The reaction was quenched with saturated NaHCO3 (5 mL) at room temperature. The resulting mixture was extracted with DCM. The combined organic layers were washed with saturated NaHCO3 and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with DCM / MeOH (10 / 1) to give the title compound (400 mg, 70.4%) as a light yellow oil.
[1086] Step 4: 3-(Hydroxymethyl)thiomorpholine 1,1-dioxide; trifluoroacetic acid
[1087]
[1088] To a stirred solution of tert-butyl 3-(hydroxymethyl)thiomorpholine-4-carboxylate 1,1-dioxide (180 mg, 0.678 mmol, 1.00 equiv) in DCM (5.0 mL) at room temperature was added TFA (3.868 g, 33.921 mmol, 50.00 equiv). The resulting mixture was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure to afford the title compound (170 mg, 89.74%) as a white solid.
[1089] Step 5: 4-iodo-6a,7,9,10-tetrahydro-6H-pyrido[3,2-b][1,4]thiazino[4,3-d][1,4]oxazine 8,8-dioxide
[1090]
[1091] To a stirred solution of 3-(hydroxymethyl)thiomorpholine 1,1-dioxide trifluoroacetic acid (180 mg, 0.645 mmol, 1.00 equiv) and 2-fluoro-4-iodopyridin-3-ol (154 mg, 0.645 mmol, 1.00 equiv) in toluene (3.0 mL) under nitrogen was added PPh3 (254 mg, 0.967 mmol, 1.50 equiv) and DEAD (168 mg, 0.967 mmol, 1.50 equiv) at room temperature. The resulting mixture was stirred at 60 °C for 16 hours under nitrogen atmosphere and then concentrated under reduced pressure. The residue was purified by preparative TLC (PE / EtOAc 5:1) to give the title compound (45 mg, 19.1%) as a light yellow solid.
[1092] Step 6: 4-((5-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(hydroxymethyl)-pyrazin-2-yl)thio)-6a,7,9,10-tetrahydro-6H-pyrido[3,2-b][1,4]thiazino[4,3-d][1,4]oxazine 8,8-dioxide
[1093]
[1094] The title compound was synthesized by a method similar to that described in Example 5, Steps 7-8, using 4-iodo-6a,7,9,10-tetrahydro-6H-pyrido[3,2-b][1,4]thiazino[4,3-d][1,4]oxazine 8,8-dioxide in Step 7. MS (ES, m / z): [M+1] + =549.2.
[1095] Examples 29 and 30
[1096] (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[29] and ( Synthesis of 3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8R)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[30]
[1097]
[1098] Step 1: (S)-1-(tert-butyl)2-methyl 4-(methoxymethylene)pyrrolidine-1,2-dicarboxylate
[1099]
[1100] To a stirred mixture of (S)-4-oxopyrrolidine-1,2-dicarboxylic acid 1-(tert-butyl)-2-methyl ester (4.00 g, 16.443 mmol, 1.00 equiv) and K2CO3 (1.50 g, 10.853 mmol, 0.66 equiv) in MeOH (80.0 mL) at 0°C under nitrogen atmosphere was added dimethyl (1-diazo-2-oxopropyl)phosphonate (9.48 g, 49.330 mmol, 3.00 equiv). After stirring at room temperature for 12 h, the reaction mixture was poured into water and the resulting mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (3:1) to give the title compound (1.45 g, 32.5%) as a light yellow oil.
[1101] Step 2: 1-(tert-butyl)2-methyl(2S)-4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate
[1102]
[1103] Under hydrogen atmosphere, MgO (220 mg, 5.46 mmol, 1.02 equiv) was added to a stirred solution of (S)-4-(methoxymethylene)pyrrolidine-1,2-dicarboxylic acid 1-(tert-butyl) 2-methyl ester (1.45 g, 5.344 mmol, 1.00 equiv) and 10% Pd / C (145 mg) in MeOH (20.0 mL) at room temperature. After stirring at room temperature for 2 hours, the resulting mixture was filtered. The filtrate was concentrated under reduced pressure to give the title compound (1.35 g, 92.42%) as a light yellow oil, which was used directly in the next step without further purification.
[1104] Step 3: tert-Butyl (2S)-2-(hydroxymethyl)-4-(methoxymethyl)pyrrolidine-1-carboxylate
[1105]
[1106] To a stirred solution of (2S)-4-(methoxymethyl)pyrrolidine-1,2-dicarboxylic acid 1-(tert-butyl) 2-methyl ester (180 mg, 0.659 mmol, 1.00 equiv) in THF (4.0 mL) at room temperature was added LiAlH4 (37 mg, 0.975 mmol, 1.50 equiv). After stirring at room temperature for 2 h, the resulting mixture was diluted with DCM and quenched with water at 0°C. After filtration, the filter cake was washed with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give the title compound (90 mg, 55.7%) as a light yellow oil.
[1107] Step 4: (2S)-2-(((2-Fluoro-4-iodopyridin-3-yl)oxy)methyl)-4-(methoxymethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester
[1108]
[1109] To a stirred solution of (2S)-2-(hydroxymethyl)-4-(methoxymethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester (90 mg, 0.367 mmol, 1.00 equiv) and 2-fluoro-4-iodopyridin-3-ol (88 mg, 0.367 mmol, 1.00 equiv) in THF (2.00 mL) under nitrogen at room temperature was added PPh3 (144 mg, 0.550 mmol, 1.50 equiv) and DEAD (96 mg, 0.55 mmol, 1.50 equiv). After stirring at room temperature for 16 hours, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-60%) to give the title compound (115 mg, 67.2%) as a light yellow oil.
[1110] Step 5: 2-Fluoro-4-iodo-3-(((2S)-4-(methoxymethyl)pyrrolidin-2-yl)methoxy)pyridine hydrochloride
[1111]
[1112] To a stirred solution of tert-butyl (2S)-2-(((2-fluoro-4-iodopyridin-3-yl)oxy)methyl)-4-(methoxymethyl)pyrrolidine-1-carboxylate (115 mg, 0.247 mmol, 1.00 equiv) in dioxane (1.0 mL) was added HCl (4.0 M in dioxane, 0.62 mL, 2.48 mmol, 10.00 equiv) at room temperature. After stirring at room temperature for 5 hours, the reaction mixture was concentrated under reduced pressure to give the title compound (110 mg, crude) as a pale yellow solid, which was used in the next step without further purification. MS (ES, m / z): [M+1] + =367.0.
[1113] Step 6: (6aS)-4-iodo-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
[1114]
[1115] To a stirred solution of 2-fluoro-4-iodo-3-(((2S,4S)-4-(methoxymethyl)pyrrolidin-2-yl)-methoxy)pyridine hydrochloride (110 mg, 0.273 mmol, 1.00 equiv) in EtOH (3.0 mL) at room temperature was added K2CO3 (208 mg, 1.50 mmol, 5.51 equiv). After stirring at 60°C for 2 hours, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-60%) to give the title compound (80 mg, 93.5% for 2 steps) as a light yellow oil.
[1116] Step 7: tert-Butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((6aS)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl)carbamate
[1117]
[1118] Under nitrogen, at room temperature, (6aS)-4-iodo-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido-[3,2-b]pyrrolo[1,2-d][1,4]oxazine (80 mg, 0.231 mmol, 1.00 equiv), 5-((3S,4S)-4-((tert-butoxycarbonyl)amino)-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-1,2-d-[1,4]oxazine (50 mg, 0.231 mmol, 1.00 equiv) were added to a stirred solution. To a mixture of sodium 6-(hydroxy-methyl)pyrazine-2-thiolate (100 mg, 0.231 mmol, 1.0 equiv), Pd2(dba)3 (63 mg, 0.069 mmol, 0.30 equiv) and XantPhos (40 mg, 0.069 mmol, 0.30 equiv) in dioxane (1.50 mL) was added DIEA (90 mg, 0.693 mmol, 3.00 equiv). After stirring at 80°C for 1 hour, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with MeOH / DCM (0-10%) to give the title compound (110 mg, 75.7%) as a yellow solid.
[1119] Step 8: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-pyrazin-2-yl)methanol[2 9] and (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8R)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[30]
[1120]
[1121] To a stirred solution of tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl)carbamate (70.00 mg, 0.111 mmol, 1.00 equiv) in DCM (1.0 mL) at room temperature was added TFA (0.20 mL, 2.61 mmol, 23.5 equiv). After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure. The mixture was purified by preparative HPLC to give 50 mg of crude product. The crude product (50 mg) was further purified by chiral-HPLC to give the title compound
[29] (9.9 mg, 16.8%), MS (ES, m / z): [M+1] + =529.3 and
[30] (5.5 mg, 9.4%), MS (ES, m / z): [M+1] + =529.3; white solid.
[1122] Embodiment 31
[1123] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1124]
[1125] Step 1: tert-Butyl (2S,4S)-2-(hydroxymethyl)-4-(methoxymethyl)pyrrolidine-1-carboxylate
[1126]
[1127] To a stirred solution of (2S,4S)-1-(tert-butoxycarbonyl)-4-(methoxymethyl)pyrrolidine-2-carboxylic acid (180 g, 694.171 mmol, 1.00 equiv) in THF (1.8 L) was added dropwise BH3-Me2S (173.00 mL, 1824.073 mmol, 2.63 equiv) under N2 atmosphere at 0°C. The resulting mixture was stirred at room temperature for 16 hours under N2 atmosphere. The reaction was quenched with MeOH (200 mL) at 0°C, and the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 1) to give the title compound (160 g, 94%) as a colorless oil.
[1128] Step 2: (2S,4S)-2-(((2-fluoro-4-iodopyridin-3-yl)oxy)methyl)-4-(methoxymethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester
[1129]
[1130] To a stirred solution of (2S,4S)-2-(hydroxymethyl)-4-(methoxymethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester (7.0 g, 28.534 mmol, 1.00 equiv), 2-fluoro-4-iodopyridin-3-ol (6.8 g, 28.534 mmol, 1.00 equiv) and PPh3 (11.2 g, 42.7 mmol, 1.50 equiv) in THF (140.00 mL) was added DEAD (7.5 g, 43 mmol, 1.5 equiv) dropwise under N2 atmosphere at room temperature, and the resulting mixture was stirred at room temperature for 16 hours. The reaction mixture was then concentrated under reduced pressure, and the residue was purified by silica gel column chromatography eluting with PE / EA (5 / 1) to give the title compound (11.5 g, 86.4%) as a light yellow oil.
[1131] Step 3: 2-Fluoro-4-iodo-3-(((2S,4S)-4-(methoxymethyl)pyrrolidin-2-yl)methoxy)pyridine dihydrochloride
[1132]
[1133] A solution of tert-butyl (2S,4S)-2-(((2-fluoro-4-iodopyridin-3-yl)oxy)methyl)-4-(methoxymethyl)pyrrolidine-1-carboxylate (11.5 g, 24.663 mmol, 1.00 equiv) in 1,4-dioxane (20.0 mL) and 4.0 M HCl in 1,4-dioxane (50.0 mL) were stirred at room temperature for 3 h under N2 atmosphere. The resulting mixture was concentrated under reduced pressure to give the title compound (14 g, crude) as a pale yellow oil which was used in the next step without further purification.
[1134] Step 4: (6aS,8S)-4-iodo-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
[1135]
[1136] A mixture of crude 2-fluoro-4-iodo-3-(((2S,4S)-4-(methoxymethyl)pyrrolidin-2-yl)-methoxy)pyridine dihydrochloride (14.0 g, 31.88 mmol, 1.00 equiv) and K2CO3 (15.9 g, 115 mmol, 3.6 equiv) in EtOH (280.0 mL) was stirred at 60 °C for 3 hours. After cooling at room temperature, the resulting mixture was filtered and the filter cake was washed with EtOAc. The combined filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (2 / 1) to give the title compound (6.6 g, 2 steps, 77%) as a light yellow solid.
[1137] Step 5: ((6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl)-methanol
[1138]
[1139] To a stirred mixture of (6aS,8S)-4-iodo-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (250 mg, 0.722 mmol, 1.00 equiv) and NaI (357 mg, 2.383 mmol, 3.3 equiv) in CH3CN (5.00 mL) was added SiCl4 (405 mg, 2.383 mmol, 3.30 equiv) dropwise under nitrogen at room temperature. The resulting mixture was stirred at 80°C for 2 hours under nitrogen atmosphere. The mixture was cooled to room temperature, diluted with water, and the pH of the solution was adjusted to pH = 8 using saturated aqueous NaHCO3. The resulting mixture was extracted with DCM, and the organic layer was dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give the title compound (200 mg, 83.4%) as a yellow solid.
[1140] Step 6: (6aS,8S)-4-iodo-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
[1141]
[1142] To a stirred solution of ((6aS,8S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-8-yl)methanol (75 mg, 0.226 mmol, 1.00 equiv) and DIEA (88 mg, 0.68 mmol, 3.0 equiv) in DCM (3.75 mL) was added bromo(methoxy)methane (85 mg, 0.68 mmol, 3.0 equiv) dropwise under nitrogen at room temperature. The resulting mixture was stirred at room temperature for 24 h under nitrogen. The reaction solution was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give the title compound (65 mg, 76.5%) as a yellow solid.
[1143] Step 7: tert-Butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl)carbamate
[1144]
[1145] Sodium 5-((3S,4S)-4-((tert-butoxycarbonyl)amino)-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(hydroxymethyl)pyrazine-2-thiolate (55 mg, 0.127 mmol, 1.00 equiv), (6aS,8S)-4-iodo-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyridinium chloride (50 mg, 0.127 mmol, 1.00 equiv) and (6aS,8S)-4-iodo-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyridinium chloride (50 mg, 0.127 mmol, 1.00 equiv) were added to the stirred solution at room temperature under nitrogen. To a mixture of [3,2-b]pyrrolo[1,2-d][1,4]oxazine (48 mg, 0.128 mmol, 1 eq.) and XantPhos (22 mg, 0.038 mmol, 0.30 eq.) in dioxane (2.0 mL) were added DIEA (82 mg, 0.63 mmol, 5 eq.) and Pd2(dba)3 (35 mg, 0.038 mmol, 0.30 eq.) in portions. The resulting mixture was stirred at 80 °C for 1 hour under nitrogen atmosphere, and then diluted with water and extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography eluting with DCM / MeOH (10:1) to give the title compound (45 mg, 53.8%) as a brown solid.
[1146] Step 8: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1147]
[1148] To a stirred solution of tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-(((6aS,8S)-8-((methoxy-methoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl)carbamate (35 mg, 0.053 mmol, 1.00 equiv) in DCM (1.80 mL) at room temperature was added TFA (0.15 mL) dropwise. The resulting mixture was stirred at room temperature for 2 hours and then basified to pH = 8 with aqueous ammonium hydroxide. The organic solvent was removed in vacuo and the residue was purified by preparative HPLC to give the title compound (7 mg, 23.6%) as a white solid. MS (ES, m / z): [M+1] + =559.3.
[1149] Embodiment 32
[1150] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-((2-methoxyethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1151]
[1152] The title compound was synthesized by a method similar to that described in Example 31, Steps 6-8, using 1-bromo-2-methoxyethane in Step 6. MS (ES, m / z): [M+1] + =573.3.
[1153] Embodiment 33
[1154] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-((cyclopropylmethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1155]
[1156] The title compound was synthesized by a procedure similar to that described in Example 31, Steps 6-8, using (bromomethyl)cyclopropane in Step 6. MS (ES, m / z): [M+1] + =569.3
[1157] Embodiment 34
[1158] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-((oxetan-3-ylmethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1159]
[1160] The title compound was synthesized by a method similar to that described in Example 31, Steps 6-8, using 3-(bromomethyl)propylene oxide in Step 6. MS (ES, m / z): [M+1] + =585.3
[1161] Embodiment 35
[1162] Synthesis of formic acid; (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((S)-2-amino-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1163]
[1164] Step 1: 2-Fluoro-4-iodo-6-nitropyridin-3-ol
[1165]
[1166] To a stirred solution of 2-fluoro-4-iodopyridin-3-ol (100 mg, 0.418 mmol, 1.00 equiv) and Bu4NNO3 (191 mg, 0.628 mmol, 1.50 equiv) in DCM (2.0 mL) was added TFAA (0.10 mL, 0.595 mmol, 1.42 equiv) dropwise under nitrogen atmosphere at 0°C, and the resulting mixture was stirred at 0°C for 1 hour. The reaction was quenched with saturated NH4Cl (aq) at 0°C, and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and brine, and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (5:1) to give the title compound (10 mg, 8.4%) as a yellow solid.
[1167] Step 2: (S)-tert-Butyl 2-(((2-fluoro-4-iodo-6-nitropyridin-3-yl)oxy)methyl)pyrrolidine-1-carboxylate
[1168]
[1169] Under nitrogen atmosphere, DIAD (181 mg, 0.9 mmol, 1.5 eq) was added dropwise to a stirred solution of 2-fluoro-4-iodo-6-nitropyridine-3-ol (170 mg, 0.599 mmol, 1.00 eq), (2S)-2-(hydroxymethyl)pyrrolidine-1-carboxylic acid tert-butyl ester (180 mg, 0.898 mmol, 1.50 eq) and PPh3 (235 mg, 0.9 mmol, 1.5 eq) in THF (2 mL) at 0 °C. Under nitrogen atmosphere, the resulting mixture was stirred at 60 °C overnight and then quenched with water at room temperature. The resulting mixture was extracted with EtOAc, and the combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-30%) to give the title compound (50 mg, 17.9%) as a yellow oil.
[1170] Step 3: (S)-2-Fluoro-4-iodo-6-nitro-3-(pyrrolidin-2-ylmethoxy)pyridine hydrochloride
[1171]
[1172] To an 8 mL sealed tube at 0°C was added (S)-tert-butyl 2-(((2-fluoro-4-iodo-6-nitropyridin-3-yl)oxy)methyl)pyrrolidine-1-carboxylate (50 mg, 0.107 mmol, 1.00 equiv) and 4M HCl in 1,4-dioxane (0.50 mL, 2.0 mmol, 18.69 equiv). The reaction solution was stirred at room temperature for 1 hour and then concentrated under reduced pressure. The residue was triturated with EtO to give the crude title product (30 mg) as a yellow oil, which was used in the next step without further purification.
[1173] Step 4: (S)-4-iodo-2-nitro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
[1174]
[1175] To an 8 mL sealed tube was added (S)-2-fluoro-4-iodo-6-nitro-3-(pyrrolidin-2-ylmethoxy)pyridine hydrochloride (30 mg, crude), K2CO3 (34 mg, 0.246 mmol) and EtOH (0.30 mL) at room temperature. The resulting mixture was stirred at 60°C for 2 hours and then cooled to room temperature. The resulting mixture was extracted with EtOAc, and the combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (5:1) to give the title compound (13 mg, 2 steps, 34.6%) as a yellow solid.
[1176] Step 5: (S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-2-amine
[1177]
[1178] A mixture of (S)-4-iodo-2-nitro-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (13 mg, 0.037 mmol, 1.0 equiv), NH4Cl (4 mg, 0.075 mmol, 2.0 equiv) and Fe (4 mg, 0.075 mmol, 2.0 equiv) in EtOH (0.10 mL) and H2O (0.10 mL) was stirred at 60 °C for 2 h. The mixture was cooled to room temperature and filtered. The filter cake was washed with EtOAc, and the filtrate was washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-100%) to give the title compound (9 mg, 75.8%) as a yellow solid.
[1179] Step 6: Formic acid; (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((S)-2-amino-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1180]
[1181] The title compound was synthesized by a method similar to that described in Example 5, Steps 7-8, using (S)-4-iodo-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-2-amine in Step 7. MS (ES, m / z): [M+1] + =500.3.
[1182] Examples 36 and 37
[1183] (3-((S)-5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidin]-1'-yl)-6-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[36] and ( Synthesis of 3-((S)-5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidin]-1'-yl)-6-(((6aS,8R)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[37]
[1184]
[1185] Step 1: 2-Ethylhexyl 3-(((6aS)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)propanoate
[1186]
[1187] To a stirred mixture of (6aS)-4-iodo-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (500 mg, 1.444 mmol, 1.00 equiv), 2-ethylhexyl 3-thiopropanoate (378 mg, 1.733 mmol, 1.20 equiv), Pd2(dba)3 (130 mg, 0.142 mmol, 0.10 equiv) and XantPhos (85 mg, 0.147 mmol, 0.10 equiv) in 1,4-dioxane (7.5 mL) was added DIEA (560 mg, 4.333 mmol, 3.00 equiv) at room temperature under nitrogen and the resulting mixture was stirred at 85° C. for 2 h. After cooling to room temperature, the reaction was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated, and the residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-60%) to give the title compound (500 mg, 79.3%) as a light yellow oil.
[1188] Step 2: Sodium (6aS)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine-4-thiol
[1189]
[1190] To a stirred solution of 2-ethylhexyl 3-(((6aS)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)propanoate (500 mg, 1.145 mmol, 1.00 equiv) in MeOH (10.0 mL) at room temperature was added NaOMe (68 mg, 1.260 mmol, 1.10 equiv). After stirring at room temperature for 5 h, the reaction mixture was concentrated in vacuo and the residue was triturated with Et2O to give the title compound (220 mg, 70%) as a yellow solid.
[1191] Step 3: (3-chloro-6-(((6aS)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1192]
[1193] To a stirred mixture of sodium (6aS)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine-4-thiol (100 mg, 0.365 mmol, 1.00 equiv), (6-bromo-3-chloropyrazin-2-yl)methanol (90 mg, 0.40 mmol, 1.10 equiv), Pd2(dba)3 (33 mg, 0.036 mmol, 0.10 equiv) and XantPhos (21 mg, 0.036 mmol, 0.10 equiv) in 1,4-dioxane (2 mL) was added DIEA (141 mg, 1.09 mmol, 3.0 equiv) at room temperature under nitrogen. After stirring at 85 °C for 2 hours, the reaction mixture was concentrated in vacuo and the residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-60%) to give the title compound (105 mg, 72.9%) as a light yellow oil.
[1194] Step 4: (3-((S)-5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidin]-1'-yl)-6-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl) Methanol and (3-((S)-5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidin]-1'-yl)-6-(((6aS,8R)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1195]
[1196] To a stirred mixture of (3-chloro-6-(((6aS)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol (50 mg, 0.127 mmol, 1.00 equiv) and (S)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidin]-5-amine trihydrochloride (50 mg, 0.159 mmol, 1.25 equiv) in ACN (2.0 mL) at room temperature was added DIEA (82 mg, 0.63 mmol, 5.0 equiv) and the resulting mixture was stirred at 80° C. for 48 h. After cooling to room temperature, the reaction mixture was filtered and the filter cake was washed with MeOH, the combined filtrates were concentrated, and the residue was purified by preparative HPLC to give the title compound. MS (ES, m / z): [M+1] + =562.3.
[1197] Embodiment 38
[1198] Synthesis of (3-((S)-5-amino-13-oxa-9-azabispiro[3.1.56.24]tridec-9-yl)-6-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1199]
[1200] (3-Chloro-6-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol (35 mg, 0.089 mmol, 1.00 equiv), (S)-13-oxa-9-azabispiro[3.1.5 6 .2 4 A solution of tridecane-5-amine dihydrochloride (29 mg, 0.106 mmol, 1.20 equiv) and DIEA (57 mg, 0.443 mmol, 5.00 equiv) in CH3CN (0.56 mL) was stirred at 80°C for 16 hours. The reaction mixture was purified by preparative HPLC to give the title compound (9.8 mg, 18.4%) as a yellow solid. MS (ES, m / z): [M+1] + =555.2.
[1201] Examples 39 and 40
[1202] Synthesis of (3-((S)-5-amino-13-oxa-9-azabispiro[3.1.56.24]tridec-9-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[39]
[1203]
[1204] By a method similar to that described in Examples 36 and 37, (6aS,8S)-4-iodo-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine and (S)-13-oxa-9-azabispiro[3.1.5 6 .2 4 ]Tridecane-5-amine dihydrochloride was used to synthesize the title compound. MS (ES, m / z): [M+1] + =585.3.
[1205] (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-(((methoxymethoxy)methoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[40]
[1206] It is separated as a by-product.
[1207] Embodiment 41
[1208] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-(hydroxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1209]
[1210] Step 1: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-(hydroxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1211]
[1212] During the synthesis of Example 31, compound 42 was also isolated as a by-product. MS (ES, m / z): [M+1] + =515.3.
[1213] Embodiment 42
[1214] Synthesis of (3S,4S)-8-(5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine
[1215]
[1216] Step 1: (6aS,8S)-4-((5-chloropyrazin-2-yl)thio)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
[1217]
[1218] Under nitrogen atmosphere, a mixture of (6aS,8S)-4-iodo-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (90 mg, 0.239 mmol, 1.00 equiv), sodium 5-chloropyrazine-2-thiolate (61 mg, 0.36 mmol, 1.51 equiv) (see WO2016 / 203406), Pd2(dba)3 (22 mg, 0.024 mmol, 0.10 equiv), Xantphos (14 mg, 0.024 mmol, 0.10 equiv) and DIEA (93 mg, 0.72 mmol, 3.0 equiv) in THF (2 mL) was stirred at 60 °C for 0.5 h. The residue was purified by silica gel column chromatography to give the title compound (93 mg, 98.5%) as a brown oil. MS (ES, m / z): [M+1] + =395.2.
[1219] Step 2: (3S,4S)-8-(5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine
[1220]
[1221] A solution of (6aS,8S)-4-((5-chloropyrazin-2-yl)thio)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (40 mg, 0.101 mmol, 1.00 equiv), (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine dihydrochloride (42 mg, 0.173 mmol, 1.70 equiv) and DIEA (65 mg, 0.50 mmol, 5.00 equiv) in CH3CN (0.40 mL) was stirred at 100°C for 16 h. The residue was purified by preparative HPLC to give the title compound (16 mg, 29.9%) as an off-white solid. MS (ES, m / z): [M+1] + =529.3
[1222] Embodiment 43
[1223] Synthesis of (3S,4S)-8-(5-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine
[1224]
[1225] The title compound was synthesized by a method similar to that described in Example 42. MS (ES, m / z): [M+1] + =499.3.
[1226] Embodiment 44
[1227] Synthesis of (3S,4S)-8-(6-amino-5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine
[1228]
[1229] Step 1: 6-Chloro-3-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-amine
[1230]
[1231] Under nitrogen atmosphere, a mixture of (6aS,8S)-4-iodo-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (90.00 mg, 0.239 mmol, 1.00 equiv), sodium 3-amino-5-chloropyrazine-2-thiolate (60 mg, 0.359 mmol, 1.5 equiv) (see WO2015 / 107494), Pd2(dba)3 (22 mg, 0.024 mmol, 0.1 equiv), Xantphos (14 mg, 0.024 mmol, 0.1 equiv) and DIEA (93 mg, 0.72 mmol, 3.0 equiv) in THF (2.00 mL) was stirred at 60 °C for 0.5 h. The residue was purified by silica gel column chromatography to give the title compound (93 mg, 98.9%) as a brown oil.
[1232] Step 2: (3S,4S)-8-(6-amino-5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine
[1233]
[1234] A solution of 6-chloro-3-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-amine (40 mg, 0.1 mmol, 1.00 equiv), (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine dihydrochloride (42 mg, 0.17 mmol, 1.76 equiv) and DIEA (65 mg, 0.5 mmol, 5.1 equiv) in CH3CN (0.40 mL) was stirred at 100°C for 16 h. The residue was purified by preparative HPLC to give the title compound (16 mg, 30%) as an off-white solid. MS (ES, m / z): [M+1] + =544.3.
[1235] Embodiment 45
[1236] Synthesis of (3S,4S)-8-(6-amino-5-(((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine
[1237]
[1238] The title compound was synthesized by a method similar to that described in Example 44. MS (ES, m / z): [M+1] + =514.3
[1239] Embodiment 46
[1240] Synthesis of (S)-1'-(5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidin]-5-amine
[1241]
[1242] A solution of (6aS,8S)-4-((5-chloropyrazin-2-yl)thio)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (40 mg, 0.10 mmol, 1.0 equiv), (S)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidin]-5-amine trihydrochloride (48 mg, 0.15 mmol, 1.5 equiv) and DIEA (65 mg, 0.50 mmol, 5.00 equiv) in CH3CN (0.40 mL) was stirred at 100°C for 16 h. The reaction solution was purified by preparative HPLC to give the title compound (12.0 mg, 21.2%) as an off-white solid. MS (ES, m / z): [M+1] + =562.3.
[1243] Embodiment 47
[1244] Synthesis of (S)-1'-(6-amino-5-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidin]-5-amine
[1245]
[1246] A solution of 6-chloro-3-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-amine (40 mg, 0.098 mmol, 1.00 equiv), (S)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidin]-5-amine trihydrochloride (46 mg, 0.147 mmol, 1.50 equiv) and DIEA (63 mg, 0.487 mmol, 5.0 equiv) in CH3CN (0.40 mL) was stirred at 100°C for 16 hours. The reaction solution was purified by preparative HPLC to give the title compound (16.0 mg, 28.4%) as an off-white solid. MS (ES, m / z): [M+1] + =577.3.
[1247] Embodiment 48
[1248] Synthesis of (3-((S)-5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidin]-1'-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo-[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1249]
[1250] To a stirred solution of (S)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidin]-5-amine trihydrochloride (28 mg, 0.09 mmol, 1.53 equiv) and DIEA (38 mg, 0.294 mmol, 5.0 equiv) in ACN (0.5 mL) was added (3-chloro-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol (25 mg, 0.059 mmol, 1.00 equiv) at room temperature under nitrogen. The resulting mixture was stirred at 100 °C overnight, and the mixture was cooled to room temperature. The crude product was purified by preparative HPLC to give the title compound (6.5 mg, 18.67%) as a white solid. MS (ES, m / z): [M+1] + =592.3.
[1251] Embodiment 49
[1252] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)-5-methylpyrazin-2-yl)methanol
[1253]
[1254] The title compound was synthesized by a method similar to that described in Example 31. MS (ES, m / z): [M+1] + =573.3.
[1255] Embodiment 50
[1256] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8R)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1257]
[1258] Step 1: (3-Chloro-6-(((6aS)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido-[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1259]
[1260] To a mixture of (6aS)-4-iodo-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (1.00 g, 2.658 mmol, 1.00 equiv) and sodium 5-chloro-6-(hydroxymethyl)pyrazine-2-thiolate (0.78 g, 3.93 mmol, 1.48 equiv) in THF (10.00 mL) at room temperature were added XantPhos (0.15 g, 0.26 mmol, 0.10 equiv) and DIEA (1.02 g, 7.892 mmol, 2.97 equiv). Then Pd2(dba)3 (0.12 g, 0.13 mmol, 0.05 eq) was added to the solution under nitrogen atmosphere, and the resulting mixture was stirred at 60°C for 1 hour under nitrogen atmosphere. The resulting mixture was cooled to room temperature and filtered, and the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography, eluting with PE / EA (0-100%) to obtain the product (790 mg, 69.9%).
[1261] Step 2: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aS,8R)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1262]
[1263] To a mixture of (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-amine dihydrochloride (730 mg, 3.002 mmol, 1.72 equiv) and DIEA (1.30 g, 10.06 mmol, 5.77 equiv) in ACN (5 mL) was added (3-chloro-6-(((6aS)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol (740 mg, 1.742 mmol, 1.00 equiv) at room temperature. The resulting mixture was stirred at 60 °C for 16 hours under nitrogen atmosphere and then purified by preparative HPLC and chiral HPLC to give the product. MS (ES, m / z): [M+1] + =559.3.
[1264] Examples 51 and 52
[1265] (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aR,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol and ( Synthesis of 3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aR,8R)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1266]
[1267] Step 1: (6aR)-4-iodo-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine
[1268]
[1269] The title compound was synthesized by a procedure analogous to that described in Examples 29-30, Steps 1-6.
[1270] Step 2: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-(((6aR,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methyl alcohol and (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro-[4.5]dec-8-yl)-6-(((6aR,8R)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)thio)pyrazin-2-yl)methanol
[1271]
[1272] A mixture of the title compounds was synthesized by a method similar to that described in Example 31, Steps 5-8. The material was then purified by HPLC to give Compounds 51 and 52. Compound 51: MS (ES, m / z): [M+1] + =559.3. Compound 52: MS (ES, m / z): [M+1] + =559.3.
[1273] Embodiment 53
[1274] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)pyrazin-2-yl)methanol
[1275]
[1276] Step 1: ((6aS,8S)-8-(Methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d]-[1,4]oxazin-4-yl)boronic acid
[1277]
[1278] To a stirred solution of (6aS,8S)-4-iodo-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazine (100 mg, 0.289 mmol, 1.00 equiv), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) (110 mg, 0.433 mmol, 1.5 equiv), AcOK (57 mg, 0.581 mmol, 2.0 equiv) in toluene (2 mL) was added Pd(dppf)Cl (12 mg, 0.0164 mmol, 0.057 equiv) at room temperature under N2 atmosphere. The resulting mixture was stirred at 100°C for 16 h under N2 atmosphere and used in the next step without further purification.
[1279] Step 2: tert-Butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl)carbamate
[1280]
[1281] To a mixture of ((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)boronic acid in toluene from the last step was added KCO (120 mg, 0.87 mmol, 3.00 equiv), tert-butyl ((3S,4S)-8-(5-bromo-3-(hydroxymethyl)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl)carbamate (132 mg, 0.290 mmol, 1.00 equiv), Pd(dppf)Cl (12.00 mg, 0.064 mmol, 0.057 equiv) and H0 (0.2 mL) under N2. After stirring at 100°C for 3 h, the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EA to give the title compound (70 mg, 40.7%, 2 steps) as a pale yellow oil. MS (ES, m / z): [M+1]=597.3.
[1282] Step 3: (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)pyrazin-2-yl)methanol
[1283]
[1284] A mixture of tert-butyl ((3S,4S)-8-(3-(hydroxymethyl)-5-((6aS,8S)-8-(methoxymethyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]dec-4-yl)carbamate (70 mg, 0.117 mmol, 1.00 equiv) in DCM (3 mL) and TFA (1 mL) was stirred at room temperature for 3 hours. The resulting mixture was concentrated and purified by preparative HPLC to give the title compound (17 mg, 29.3%). MS (ES, m / z): [M+H] + =497.3.
[1285] Embodiment 54
[1286] Synthesis of (3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl)-6-((6aS,8S)-8-((methoxymethoxy)methyl)-6a,7,8,9-tetrahydro-6H-pyrido[3,2-b]pyrrolo[1,2-d][1,4]oxazin-4-yl)pyrazin-2-yl)methanol
[1287]
[1288] The title compound was synthesized by a method similar to that described in Example 54. MS (ES, m / z): [M+H] + =527.3.
[1289] Bioassay
[1290] SHP2 allosteric inhibition assay
[1291] SHP2 has two N-terminal Src homology 2 (SH2) domains, a central protein-tyrosine phosphatase (PTP) domain, and a C-terminal tail. In the basal state, SHP2 is auto-inhibited, and the intermolecular interactions between the SH2 domain and the PTP domain block the access between the substrate and the catalytic site. When a di-tyrosyl-phosphorylated peptide binds to the SH2 domain of SHP2, the PTP domain becomes available for substrate recognition and reaction catalysis, and SHP2 is allosterically activated. The fluorescent artificial substrate DiFMUP can be used to measure SHP2 catalytic activity.
[1292] Phosphatase reactions were performed at room temperature in 384-well black polystyrene plates (Greiner Bio-One, catalog #784076) using assay buffer containing 60 mM HEPES, pH 7.2, 75 mM NaCl, 75 mM KCl, 1 mM EDTA, 0.05% P-20 and 5 mM DTT.
[1293] 0.33 nM SHP2 was incubated with 0.5 μM bisphos-IRS1 peptide (sequence: H2N-LN(pY)IDLDLV(dPEG8)LST(pY)ASINFQK-amide) and different concentrations of compounds for 30-60 minutes at room temperature. The reaction was then initiated by adding the alternative substrate DiFMUP (Invitrogen, catalog # D6567, final 100 μM).
[1294] The real-time conversion of DiFMUP to DiFMU (6,8-difluoro-7-hydroxy-4-methyl-coumarin) was measured every 5 min for a total of 30 min using a microplate reader (CLARIOstar, BMG Labtech) with excitation and emission wavelengths of 340 nm and 450 nm, respectively. The initial reaction rate was determined by linear fitting of the data and the normalized IC fitted with a control-based normalization was used. 50 The dose-response curves of the inhibitors were analyzed by regression analysis.
[1295] IC of the compounds numbered in Table 1 above 50 The values are given below in Table 4 below.
[1296] Table 4
[1297]
[1298]
[1299]
[1300]
[1301]
[1302]
[1303]
[1304]
[1305] p-ERK cell assay
[1306] Detroit562 cells were seeded in 96-well plates and cultured overnight (30,000 cells per well, total volume 200ul). The next morning, cells were treated with compounds of the present disclosure, starting at 10uM and diluted to 1nM by 1 / 2log, and the treatment lasted for 2 hours at 37°C. DMSO treatment was used as a control. Ultra TM p-ERK 1 / 2 (Thr202 / Tyr204) detection kit (PerkinElmer, ALSU-PERK-A500) was used to measure p-ERK according to the instructions. Briefly, the culture medium was removed and 50ul of 1X lysis buffer was added, followed by incubation on a plate shaker at room temperature for 10 minutes. 10ul of the lysate was then transferred to a white 384-well plate and 5ul of the acceptor mix and 5ul of the donor mix (both prepared according to the manufacturer's instructions) were added. The plate was wrapped in foil, shaken on a plate reader for 1-2 minutes and incubated for >2 hours. Then on The signal was measured on a plate reader. The percentage of inhibition was calculated based on DMSO treatment as 100% signal, and the IC was calculated by Graphpad Prism 7. 50 .
[1307] Formulation Examples
[1308] The following are representative pharmaceutical formulations containing compounds of formula (I).
[1309] Tablet formulation
[1310] The following ingredients are intimately mixed and compressed into single scored tablets.
[1311]
[1312] Capsule preparation
[1313] The following ingredients are mixed intimately and filled into hard shell gelatin capsules.
[1314]
[1315] Injectable preparations
[1316] Compounds of the present disclosure (e.g., Compound 1) in 2% HPMC, 1% Tween 80 in DI water, pH 2.2 (with MSA), made up to at least 20 mg / mL
[1317] Inhalation composition
[1318] To prepare a pharmaceutical composition for inhalation delivery, 20 mg of a compound disclosed herein is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture is incorporated into an inhalation delivery unit (eg, a nebulizer) suitable for inhalation administration.
[1319] Topical gel composition
[1320] To prepare a pharmaceutical topical gel composition, 100 mg of a compound disclosed herein is mixed with 1.75 g of hydroxypropylcellulose, 10 mL of propylene glycol, 10 mL of isopropyl myristate, and 100 mL of purified alcohol USP. The resulting gel mixture is then incorporated into a container (such as a tube) suitable for topical administration.
[1321] Ophthalmic solution composition
[1322] To prepare a pharmaceutical ophthalmic solution composition, 100 mg of a compound disclosed herein is mixed with 0.9 g NaCl in 100 mL of purified water and filtered using a 0.2 micron filter. The resulting isotonic solution is then incorporated into an ophthalmic delivery unit (such as an eye drop container) suitable for ophthalmic administration.
[1323] Nasal spray solution
[1324] To prepare a pharmaceutical nasal spray solution, 10 g of a compound disclosed herein is mixed with 30 mL of 0.05 M phosphate buffer solution (pH 4.4). The solution is placed in a nasal applicator designed to deliver 100 ul of spray per application.
Claims
1. Compound of formula (IIB): or a pharmaceutically acceptable salt thereof; in: (a) Z is -YM, wherein Y is a bond and M is -O(alkylene)OR a Substituted alkyl, wherein R a is an alkyl group; or (b) Z is -YM, where Y is a bond and M is -OR a Substituted alkyl, wherein R a is alkyl, cycloalkylalkyl or heterocyclylalkyl; or (c) Z is -OR a , where R a is alkyl, cycloalkylalkyl or heterocyclyl; or (d) Z is -O(alkylene)OR b , where R b is an alkyl group; R 1 , R 2 , R 3 and R 4 It is hydrogen; R 5 and R 6 It is hydrogen; L is S; R 9 is hydrogen, alkyl or amino; R 10 is hydrogen or hydroxyalkyl; R 11 and R 12 Together with the carbon atoms to which they are attached, they form a ring which is in: "Alkylene" refers to a straight-chain saturated divalent hydrocarbon group having 1 to 6 carbon atoms or a branched-chain saturated divalent hydrocarbon group having 3 to 6 carbon atoms; "Cycloalkyl" refers to a monocyclic saturated monovalent hydrocarbon radical having three to ten carbon atoms; "Cycloalkylalkyl" refers to an -(alkylene)-R group where R is cycloalkyl; "Haloalkyl" refers to an alkyl group substituted with one or more halogen atoms; "Heterocyclyl" refers to a saturated or unsaturated monovalent monocyclic or bicyclic ring having 4 to 10 ring atoms, one of which is a heteroatom which is O and the remaining ring atoms are C; "Heterocyclylalkyl" refers to an -(alkylene)-R group where R is heterocyclyl; "Hydroxyalkyl" means a straight chain monovalent hydrocarbon radical having 1 to 6 carbon atoms or a branched monovalent hydrocarbon radical having 3 to 6 carbon atoms substituted with one or two hydroxy radicals, provided that if two hydroxy radicals are present, they are not on the same carbon atom; and The "alkyl group" refers to a straight-chain saturated monovalent hydrocarbon group having 1 to 6 carbon atoms or a branched-chain saturated monovalent hydrocarbon group having 3 to 6 carbon atoms.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Z is -YM, wherein Y is a bond, and M is -O(alkylene)OR a Substituted alkyl, wherein R a It is an alkyl group.
3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Z is -YM, wherein Y is a bond, and M is -OR a Substituted alkyl, wherein R a It is an alkyl group.
4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Z is -OR a , where R a is alkyl or cycloalkylalkyl.
5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Z is -O(alkylene)OR b , where R b It is an alkyl group.
6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Z is methoxymethoxymethyl, ethoxymethoxymethyl, methoxyethoxymethyl, cyclopropylmethoxymethyl or oxetan-3-ylmethoxymethyl.
7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Z is methoxymethoxy, methoxyethoxy, methoxymethyl, methoxymethoxymethyl, ethoxymethoxymethyl, methoxyethoxymethyl, cyclopropylmethoxy or oxetan-3-ylmethoxymethyl.
8. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R 9 For hydrogen.
9. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R 9 It is amino.
10. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R 9 It is methyl.
11. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R 9 is hydrogen, alkyl or amino.
12. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R 10 For hydrogen.
13. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R 10 It is a hydroxyalkyl group.
14. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R 10 It is hydroxymethyl.
15. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R 10 It is hydrogen or hydroxymethyl.
16. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:
17. The compound according to claim 16 or a pharmaceutically acceptable salt thereof, wherein the compound is 18. The compound of claim 16 or a pharmaceutically acceptable salt thereof, wherein the compound is 19. The compound of claim 16 or a pharmaceutically acceptable salt thereof, wherein the compound is 20. The compound of claim 16 or a pharmaceutically acceptable salt thereof, wherein the compound is 21. The compound of claim 16 or a pharmaceutically acceptable salt thereof, wherein the compound is 22. The compound of claim 16 or a pharmaceutically acceptable salt thereof, wherein the compound is 23. The compound of claim 16 or a pharmaceutically acceptable salt thereof, wherein the compound is 24. The compound of claim 16 or a pharmaceutically acceptable salt thereof, wherein the compound is 25. A pharmaceutical composition comprising a compound according to any one of claims 1 to 24 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
26. Use of a compound according to any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament useful in the treatment of a disease treatable by inhibition of SHP2 in a patient.
27. The use of claim 26, wherein the disease is selected from cancer, Noonan syndrome and Leopard syndrome.
28. The use of claim 27, wherein the cancer is selected from the group consisting of lung cancer, stomach cancer, liver cancer, colon cancer, kidney cancer, breast cancer, pancreatic cancer, juvenile myelomonocytic leukemia, neuroblastoma, melanoma and acute myeloid leukemia.
29. Use of the pharmaceutical composition of claim 25 in the preparation of a medicament suitable for treating a disease treatable by inhibiting SHP2 in a patient.
30. The use of claim 29, wherein the disease is selected from the group consisting of cancer, Noonan syndrome and Leopard syndrome.
31. The use of claim 30, wherein the cancer is selected from the group consisting of lung cancer, stomach cancer, liver cancer, colon cancer, kidney cancer, breast cancer, pancreatic cancer, juvenile myelomonocytic leukemia, neuroblastoma, melanoma and acute myeloid leukemia.
